England and Wales | 4911 | Not Applicable | ||||
(State or Other Jurisdiction of Incorporation or Organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) | ||||
† | The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. |
• | up to 4,910,451 ordinary shares, par value $0.02288 per share (“Ordinary Shares”), of newcleo plc (“newcleo” or the “Company”) issued to NewHold Industrial Technology III, LLC (the “Sponsor”), BTIG, LLC (“BTIG”) and certain directors of NewHold Investment Corp III, a Cayman Islands exempted company (“SPAC”), in exchange for SPAC Ordinary Shares (as defined herein). These Ordinary Shares are subject to lock-up restrictions under the Sponsor Support Agreement (as defined herein) and are entitled to resale registration under the Registration Rights Agreement (as defined herein); |
• | up to 5,410,058 Ordinary Shares issued to Pre-PIPE Investors (as defined herein) and Post-PIPE Investors (as defined herein) in connection with certain capital raises carried out by the Company in March, April and July 2026; |
• | up to 21,600,000 Ordinary Shares issued to the PIPE Investors (as defined herein) pursuant to the PIPE Subscription Agreements (as defined herein) at a purchase price of $10.00 per share; |
• | up to 168,237,194 Ordinary Shares held by the RRA Shareholders (as defined herein). Certain of these shares are subject to lock-up restrictions under the Lock-up Arrangements (as defined herein) and are entitled to resale registration under the Registration Rights Agreement. |
• | up to 17,677,233 Ordinary Shares issuable upon the conversion of Class B Shares (as defined herein) held by certain Selling Securityholders. The Class B Shares will convert into Ordinary Shares only if the applicable volume weighted average price vesting conditions are satisfied (as described in Certain Relationships and Related Person Transactions—Transactions Related to the Business Combination—Business Combination Agreement—Earnout Arrangements”). None of those conditions has been satisfied as of the date of this prospectus and they may never be satisfied, in which case no Ordinary Shares will be issued in respect of the Class B Shares. |
Page | |||
• | We have not yet constructed any LFR plants or MOX fuel manufacturing plants or entered into any binding contract with any customer to operate an LFR or MOX fuel manufacturing plant, and there is no guarantee that we will be able to do so in the future. This limited commercial operating history makes it difficult to evaluate our prospects, the risks and challenges we may encounter and our total potential addressable market. |
• | We have a limited commercial operating history in a rapidly evolving industry. As a result, it is difficult for us to evaluate and prepare for all the risks and challenges we may encounter. |
• | We have no operating history as a company that builds, operates or maintains commercial nuclear power plants, or that licenses technology for customers to do so, and our limited institutional experience in executing such a business model may adversely affect our business. |
• | Our LFR technology is subject to significant technical development and validation risks, including risks relating to lead corrosion and materials degradation, which could adversely affect the performance, cost, licensing and commercial viability of our LFR technology. |
• | We are an early-stage company with a history of financial losses (e.g., negative cash flows), and we expect to incur significant expenses and continuing financial losses at least until our LFR and MOX fuel manufacturing plants become commercially viable, which may never occur. |
• | Incidents involving nuclear energy facilities in the United States or globally, including accidents, terrorist acts or other high profile events involving radioactive materials, could materially and adversely affect the public perception of the safety of nuclear energy, our customers and the markets in which we operate, and such adverse effects could potentially decrease demand for nuclear energy, increase regulatory requirements and costs or result in liability or claims that could materially and adversely affect our business. |
• | The advanced nuclear industry in which we operate is nascent, characterized by limited commercial precedent, long development timelines, substantial capital requirements and significant execution uncertainty, which makes our commercialization pathway difficult to predict. |
• | Our construction and delivery timeline estimates for our plants, facilities, and other equipment may increase due to a number of factors, including the degree of pre-fabrication, standardization, licensing regulation, on-site construction, long-lead procurement, contractor performance, plant pre-operational and startup testing and other site-specific considerations. |
• | Changes in the availability and cost of oil, natural gas, nuclear fuel cycle inputs and other forms of energy, as well as our ability to access plutonium and other reprocessed nuclear materials on acceptable terms, are subject to volatile market, regulatory and geopolitical conditions that could adversely affect our business, prospects, financial condition, results of operations and cash flows. |
• | Building a new LFR plant or MOX fuel manufacturing plant is challenging as a result of many factors, including regulatory and construction complexity, and may take longer or cost more than we expect. |
• | Uncertain global macroeconomic, trade and political conditions could materially and adversely affect our business prospects, financial condition, results of operations and cash flows. |
• | The occurrence of adverse events, cancellations of significant projects, delays in project timelines, adjustments in cost structures, and other negative developments announced by competitors could have an impact on our operations, financial performance, and future prospects. |
• | The cost of electricity generated from our reactors may not be cost competitive with other sources of electricity or other low-carbon energy solutions in some markets, which could materially and adversely affect our business. |
• | Our operations involve hazardous materials and highly technical processes, requiring strict compliance with safety procedures, guidelines, and regulatory requirements. Any failure of the measures we have implemented to address potential issues related to our operations could adversely affect our business. |
• | Our operations and business plans could be significantly impacted by changes in federal, state, and local government policies and priorities. |
• | We may become involved in litigation that may materially adversely affect us. |
• | We will seek to cover gaps in nuclear liability coverage in our contracts, but such coverage may not always be possible, and such liability could materially and adversely affect our business, results of operations and financial condition. |
• | The amount of time and funding needed to develop our LFRs, LFR plants and MOX fuel manufacturing plants may significantly exceed our expectations, and we may need to make significant adjustments to our business plan or significantly delay, scale back or discontinue the deployment, construction or operation of our LFRs, LFR plants, MOX fuel manufacturing plants and/or some or all of our research and development programs, or need to seek additional capital. |
• | In order to fulfill our business plan, we will require additional funding, which may be dilutive to our investors, may result in a decline in the market price of our shares, and no assurances can be provided as to the availability or terms of any such funding. |
• | Our actual operating results may differ significantly from our guidance. Any failure to successfully implement our operating strategy or the occurrence of any of the events or circumstances set forth in this “Risk Factors” section could result in our actual operating results being different from our guidance, and the differences may be adverse and material. |
• | The public market performance and transaction outcomes of other advanced nuclear, clean energy and other capital-intensive development-stage companies may adversely affect investor perceptions of our business, the market price of our securities and our ability to raise capital. |
• | As a foreign private issuer, we are not subject to U.S. proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company. |
• | Future resales of the Ordinary Shares issued in connection with the Business Combination may cause the market price of the Ordinary Shares to drop significantly, even if our business is doing well. |
• | The exercise of Company Warrants for our Ordinary Shares would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders. |
• | We may redeem your unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making your Warrants worthless. |
• | The market price of our equity securities may be volatile, and your investment could suffer or decline in value. |
• | We may issue additional Ordinary Shares or other equity securities without seeking approval of our shareholders, which would dilute your ownership interests and may depress the market price of the Ordinary Shares. |
For the Six Months Ended June 30, | For the Year Ended December 31, | |||||||||||
2026 | 2025 | 2025 | 2024 | |||||||||
(in thousands of €, except share and per share data) | ||||||||||||
Consolidated Statements of Operations Data: | ||||||||||||
Revenue from products and services | €19,429 | €13,347 | €32,769 | €46,743 | ||||||||
Cost of sales | (13,299) | (9,193) | (24,953) | (34,999) | ||||||||
Gross profit | 6,130 | 4,154 | 7,816 | 11,744 | ||||||||
Other income | 6,554 | 4,763 | 19,347 | 17,746 | ||||||||
Research and development expenses | (34,629) | (35,450) | (68,544) | (58,473) | ||||||||
Selling, general and administrative expenses | (59,170) | (48,932) | (98,547) | (86,815) | ||||||||
Operating loss | (81,115) | (75,465) | (139,928) | (115,798) | ||||||||
Other income (expense): | ||||||||||||
(Loss) gain on disposal of assets | (9) | (3) | (1,630) | 180 | ||||||||
Finance income | 353 | 1,581 | 1,937 | 5,232 | ||||||||
Change in fair value of financial assets measured at fair value through profit or loss | — | — | — | 1,798 | ||||||||
Finance costs | (1,448) | (991) | (2,120) | (1,977) | ||||||||
Share of loss of associates | (83) | — | (48) | — | ||||||||
Loss before income tax | (82,302) | (74,878) | (141,789) | (110,565) | ||||||||
Income tax benefit | 321 | 585 | 1,824 | 402 | ||||||||
Net loss | €(81,981) | €(74,293) | €(139,965) | €(110,163) | ||||||||
Net loss per share attributable to ordinary shareholders, basic and diluted | €(0.16) | €(0.16) | €(0.30) | €(0.25) | ||||||||
Weighted-average ordinary shares outstanding, basic and diluted | 497,532,570 | 462,052,416 | 462,252,560 | 436,276,314 | ||||||||
As of June 30, 2026 | As of December 31, 2025 | |||||
(in thousands of €) | ||||||
Consolidated Balance Sheet Data: | ||||||
Cash and cash equivalents | €66,540 | €105,270 | ||||
Working capital(1) | €85,011 | €85,105 | ||||
Total assets | €434,750 | €436,317 | ||||
Total liabilities | €114,527 | €139,389 | ||||
Total equity | €320,223 | €296,928 | ||||
(1) | We define working capital as current assets less current liabilities. |
Pro Forma | ||||||
For the Six Months Ended June 30, 2026 | For the Year Ended December 31, 2025 | |||||
Actual Redemption | ||||||
(in thousands of €, except share and per share amounts) | ||||||
Combined Statement of Operations data: | ||||||
Revenue | €19,429 | €32,769 | ||||
Total gross profit | €6,130 | €7,816 | ||||
Operating loss | €(87,231) | €(270,295) | ||||
Net loss | €(88,097) | €(270,332) | ||||
Basic and diluted net loss per ordinary share | €(0.32) | €(1.04) | ||||
Weighted average ordinary shares outstanding, basic and diluted | 276,452,480 | 259,493,379 | ||||
Pro Forma | |||
As of June 30, 2026 | |||
Actual Redemption | |||
(in thousands of €) | |||
Combined Balance Sheet data: | |||
Cash and cash equivalents | €253,007 | ||
Total assets | €623,407 | ||
Total liabilities | €121,587 | ||
Total equity | €501,820 | ||
Pro Forma Combined(1) | |||||||||
Newcleo (IFRS Historical) | NewHold (U.S. GAAP Historical) | Actual Redemption into Cash (IFRS) | |||||||
For the Six Months Ended June 30, 2026 | (in thousands of €, except share and per share amounts) | ||||||||
Net loss | €(81,981) | €(2,264) | €(88,097) | ||||||
Shareholders’ equity(2) | €320,223 | €174,843 | €501,820 | ||||||
Shareholders’ equity per share(3) | €0.63 | €6.33 | €1.79 | ||||||
Ending shares subject to redemption(4) | — | 20,125,000 | — | ||||||
Ending shares | 504,560,981 | 7,487,763 | 279,830,526 | ||||||
Ending shares (including shares subject to redemption) | 504,560,981 | 27,612,763 | 279,830,526 | ||||||
Cash dividends | €— | €— | €— | ||||||
Weighted average Class A Ordinary Shares outstanding – basic and diluted | N/A | 20,905,100 | N/A | ||||||
Class A Ordinary Shares – Basic and diluted net loss per share | N/A | €(0.08) | N/A | ||||||
Weighted average Class B Ordinary Shares outstanding – basic and diluted | N/A | 6,707,663 | N/A | ||||||
Class B Ordinary Shares – Basic and diluted net loss per share | N/A | €(0.08) | N/A | ||||||
Weighted average ordinary shares outstanding − basic and diluted | 497,532,570 | N/A | 276,452,480 | ||||||
Net loss per ordinary share - basic and diluted | €(0.16) | N/A | €(0.32) | ||||||
(1) | Refer to “Unaudited Pro Forma Condensed Combined Financial Information” for more information. |
(2) | Stockholders’ equity includes capital amounts subject to possible redemption. |
(3) | Calculated based on total stockholders’ equity including shares subject to possible redemption. |
(4) | Excludes the impact of the Non-Redemption Agreements on historical financial information. |
Pro Forma Combined(1) | |||||||||
Newcleo (IFRS Historical) | NewHold (U.S. GAAP Historical) | Actual Redemption into Cash (IFRS) | |||||||
For the Year Ended December 31, 2025 | (in thousands of €, except share and per share amounts) | ||||||||
Net income (loss) | €(139,965) | €4,349 | €(270,332) | ||||||
Ending shares subject to redemption(2) | — | 20,125,000 | — | ||||||
Ending shares | 473,910,109 | 7,487,763 | 279,830,526 | ||||||
Ending shares (including shares subject to redemption) | 473,910,109 | 27,612,763 | 279,830,526 | ||||||
Cash dividends | €— | €— | €— | ||||||
Weighted average Class A Ordinary Shares outstanding – basic and diluted | N/A | 17,354,000 | N/A | ||||||
Class A Ordinary Shares – Basic and diluted net income per share | N/A | €0.18 | N/A | ||||||
Weighted average Class B Ordinary Shares outstanding – basic and diluted | N/A | 6,707,663 | N/A | ||||||
Class B Ordinary Shares – Basic and diluted net income per share | N/A | €0.18 | N/A | ||||||
Weighted average ordinary shares outstanding − basic and diluted | 462,252,560 | N/A | 259,493,379 | ||||||
Net loss per ordinary share - basic and diluted | €(0.30) | N/A | €(1.04) | ||||||
(1) | Refer to “Unaudited Pro Forma Condensed Combined Financial Information” for more information. |
(2) | Excludes the impact of the Non-Redemption Agreements on historical financial information. |
• | our limited commercial operating history and the fact that it has not yet constructed any commercial LFR plants or MOX fuel manufacturing plants and has limited or no binding commercial operating experience with respect to the planned business model; |
• | the fact that we have not yet entered into binding customer contracts for the construction, operation or long-term commercial deployment of our planned LFR plants or MOX fuel manufacturing plants and may not do so on the anticipated timeline or at all; |
• | our history of losses and negative cash flows and our need for significant additional capital to fund its business plan; |
• | the risk that construction, delivery, licensing, commissioning, startup testing and operation of our planned plants, facilities and equipment take longer, cost more or perform differently than expected; |
• | the risk that our LFRs, LFR plants, MOX fuel manufacturing plants, fuel recycling activities or related technologies may not operate as planned or may not be successfully commercialized; |
• | risks relating to the availability, industrialization, handling, transport, fabrication, economics and regulatory treatment of MOX fuel and related nuclear materials; |
• | the reliance on a limited number of suppliers, contractors and other third parties, including for highly specialized, first-of-a-kind, long-lead or sole-source materials and components, and the risk that such suppliers or contractors may not perform as expected or that supply chains may not scale as anticipated; |
• | the risk that our supply base may not be able to scale to the production levels necessary to meet projected deployment plans or anticipated customer demand; |
• | the risk that increased demand across the nuclear sector, including from new-build, life-extension, refurbishment, SMR, advanced reactor and fuel-cycle projects, could constrain access to nuclear-grade components, qualified suppliers, contractors, specialized labor and regulatory resources, resulting in longer lead times, increased costs or delays in our development and deployment timelines; |
• | the risk that our technologies, designs or business model may not attract customers as quickly as expected, or at all; |
• | risks relating to competition from existing or future competitors and from other energy generation technologies or solutions, including renewables, carbon capture solutions, fusion, geothermal and other alternative carbon-free technologies; |
• | the risk that our products or technologies may not achieve or maintain cost competitiveness, including levelized cost of electricity or fuel economics, relative to competing sources of energy; |
• | changes in domestic and foreign business, market, financial, political, tax, trade, legal and regulatory conditions, including tariffs, trade restrictions, import or export controls, sanctions and other governmental actions; |
• | geopolitical instability, including Russia’s invasion of Ukraine, heightened tensions or conflicts involving major economies or strategic regions, including in the Middle East (such as in the Suez Canal or the Strait of Hormuz) or the Taiwan Strait, related sanctions, resulting supply chain disruptions, commodity price volatility and broader disruptions in global energy markets; |
• | negative public or political perception of nuclear energy, radioactive materials, spent fuel recycling, MOX fuel, plutonium handling or the nuclear industry generally, including as a result of incidents at unrelated nuclear facilities anywhere in the world; |
• | the risk that adverse events involving the nuclear energy industry generally, or delays, cost overruns, cancellations or other negative developments affecting peers or competitors, could adversely affect demand for our technologies, financing conditions, investor sentiment or the market price of our securities; |
• | the risk that applicable laws, regulations, mandates, governmental policies, funding levels, budgets, staffing or enforcement priorities change in ways that adversely affect our business, licensing strategy, approvals, construction timelines or cost structure; |
• | our ability and our commercial partners’ ability to obtain and maintain all necessary permits, licenses, approvals, authorizations and regulatory clearances in the jurisdictions in which they operate or intend to operate; |
• | changes in the availability or terms of government support, tax credits, grants, awards, subsidies or other incentives on which elements of our business plan may depend; |
• | our ability to maintain, protect and enforce its intellectual property and proprietary rights, as well as risks of infringement claims, ownership disputes and challenges to its patents or other intellectual property; |
• | our ability to attract, retain and motivate senior management, technical personnel and other highly skilled employees and contractors; |
• | the ability of our management team to operate a public company and to comply with the additional laws, rules, regulations and reporting requirements applicable to a public company; |
• | the ability to design, implement and maintain effective disclosure controls and procedures and internal control over financial reporting following the business combination; |
• | risks relating to cybersecurity, information technology failures, data protection, insider threats, third-party access vulnerabilities, operational technology risks and cyberattacks, including those involving sensitive or classified information; |
• | the outcome of any legal proceedings, governmental investigations, enforcement actions or other disputes that may be instituted against us; |
• | fluctuations in inflation, interest rates, commodity prices, labor costs, shipping costs, energy costs, exchange rates and broader macroeconomic conditions; |
• | the exposure of our results of operations and cash flows to foreign currency exchange rate fluctuations, including euro/U.S. dollar fluctuations; |
• | changes in tax laws or interpretation thereof, tax rates, or tax audits and the risk that tax attributes may not be available as expected; |
• | the risk that actual results differ materially from any forecasts, projections, illustrative revenue streams, market estimates, cost estimates, timing expectations or other forward-looking metrics included in this prospectus; and |
• | the other risks and uncertainties set forth in the section entitled “Risk Factors” and elsewhere in this prospectus. |
• | hiring and training new personnel with requisite skill and expertise; |
• | completing the designs, licensing, construction, and commissioning of our plants; |
• | optimizing applications of our LFRs and LFR plants to serve a variety of customers, including state-owned utility and nuclear operators and private industrial and infrastructure energy users; |
• | developing the supply chain necessary to supply components, equipment and materials for our LFRs, LFR plants and MOX fuel manufacturing plants; |
• | protecting our technical innovations, know-how and proprietary processes, including through patent filings, trade secret protection and contractual safeguards, in jurisdictions relevant to our development, manufacturing and commercialization activities; |
• | developing the processes and technologies to transport radiological and other hazardous materials; |
• | developing the operational capabilities and functions necessary to operate our plants; |
• | controlling expenses and investments in anticipation of expanded operations; |
• | managing construction timelines, performance and budgets of our third-party contracts; |
• | upgrading the existing operational management and financial reporting systems and team to comply with requirements as a public company; and |
• | implementing and enhancing administrative infrastructure, systems, and processes. |
• | market acceptance of nuclear power, especially in light of potential incidents at power plants; |
• | cost competitiveness, reliability and performance of our LFRs and plants compared to conventional and renewable energy sources and products; |
• | availability and amount of government subsidies and incentives to support the development and deployment of our LFRs and plants; |
• | the extent to which the nuclear power industry and broader energy industries are deregulated to permit broader adoption of nuclear electricity generation; |
• | the cost and availability of key materials and components used in the production of our LFRs and plants; |
• | prices of traditional utility-provided energy sources; and |
• | the emergence, continuance, or success of, or increased government support for, other alternative energy generation technologies and products. |
• | targeted cyberattacks due to the strategic and sensitive nature of nuclear-related information; |
• | state-sponsored and criminal threat actors; |
• | catastrophic events impacting IT infrastructure, including power outages and physical damage; |
• | insider threats, whether malicious or inadvertent; |
• | human error; and |
• | supply chain and third-party access vulnerabilities. |
• | causing operational disruptions that impair our ability to conduct core business activities; |
• | compromising classified or sensitive nuclear design and technical information; |
• | resulting in the loss or theft of intellectual property and proprietary data, thus adversely affecting our competitive advantage; |
• | leading to regulatory non-compliance and potential legal, contractual, or financial penalties; |
• | exposing third party classified or sensitive information, negatively impacting future business opportunities; |
• | causing reputational damage and loss of stakeholder confidence; and |
• | creating potential national security implications. |
• | ongoing development and enhancement of our information and cybersecurity architecture; |
• | dedicated investments for specific tools and technology adoption; |
• | access controls and role-based permissions; |
• | network segregation and secure environments for sensitive and classified data; |
• | continuous monitoring, logging, and incident detection and response capabilities; |
• | cybersecurity awareness and training programs; |
• | supplier assurance processes and third-party security requirements with regular audits; and |
• | compliance with applicable cyber security and nuclear regulatory standards. |
• | Negative news or events associated with industry peers may lead to decreased investor confidence in the sector, which could impact the broader stock market performance of companies operating within the industry, including newcleo. This could result in fluctuations or declines in our stock price irrespective of our internal performance. |
• | Adverse events in competitor firms may alter the competitive landscape, affecting market share dynamics, pricing strategies, and overall positioning within the industry. This could impact our ability to retain or expand our market presence. |
• | Changes in market dynamics influenced by competitors’ actions, such as inflated cost adjustments or potential cancellations, could have ripple effects on our financial stability and profitability, influencing our financial metrics and potentially impacting investor perceptions. |
• | the U.S. government could reduce or delay its spending on, reprioritize its spending away from, or decline to provide funding for the government programs in which we participate, or fail to increase funding as anticipated; and |
• | U.S. government spending could be impacted by arrangements similar in effect to sequestration, which increases the uncertainty as to U.S. government spending priorities and levels. |
• | the results of our research and product development efforts, including material changes in our research, product and business development workforce; |
• | changes in the focus and direction of our research and product development programs; |
• | competitive and technological advances; |
• | the cost of filing, prosecuting, defending, and enforcing claims with respect to patents; |
• | the regulatory approval process; |
• | cost and availability of raw materials and limitations and impediments to supply chains, especially those related to current and potential geopolitical tensions; |
• | adverse public reaction to the developments in the use of nuclear power; |
• | other costs and contingencies associated with commercialization of these technologies; and |
• | adverse foreign currency exchange, given our cost structure is heavily reliant on the euro. |
• | the terms of customer contracts that affect the timing of revenue recognition; |
• | variability in demand for our services and solutions; |
• | commencement, completion, or termination of contracts during any particular quarter; |
• | timing of shipments and product deliveries; |
• | timing of award or performance incentive fee notices; |
• | timing of significant bid and proposal costs; |
• | the costs of remediating unknown defects, errors, or performance problems of our product offerings; |
• | variable purchasing patterns under blanket purchase agreements and other indefinite delivery/indefinite quantity contracts; |
• | restrictions on and delays related to the export of nuclear articles and services; |
• | costs related to government inquiries; |
• | strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs and joint ventures; |
• | strategic investments or changes in business strategy, including our merger and acquisitions strategy; |
• | changes in the extent to which we use subcontractors; |
• | seasonal fluctuations in our staff utilization rates; |
• | changes in our effective tax rate, including changes in our judgment as to the necessity of the valuation allowance recorded against our deferred tax assets; |
• | the length of sales cycles; |
• | fluctuations in foreign currency exchange rates; and |
• | potential mergers and acquisitions activity. |
• | certain of the Selling Shareholders purchased the securities being registered for resale hereunder at prices that are lower than the current market prices for such securities and, accordingly, may be or are incentivized to sell them under the registration statement of which this prospectus is a part; |
• | sales of a significant number of Ordinary Shares could materially adversely affect the trading prices of our securities; |
• | failure to comply with the Sarbanes-Oxley Act or other laws or regulations; and |
• | failure of securities analysts to initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow us or our failure to meet these estimates or the expectations of investors. |
• | actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to it; |
• | changes in the market’s expectations about operating results; |
• | our operating results failing to meet market expectations in a particular period; |
• | operating and stock price performance of other companies that investors deem comparable to us; |
• | changes in laws and regulations affecting our business; |
• | commencement of, or involvement in, litigation involving us; |
• | changes in our capital structure, such as future issuances of securities or the incurrence of debt; |
• | any significant change in our board or management; |
• | sales of substantial amounts of our Ordinary Shares by our directors, executive officers or significant shareholders or the perception that such sales could occur; and |
• | general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism. |
• | your proportionate ownership interest would decrease; |
• | the amount of cash available per share, including for payment of dividends in the future, may decrease; |
• | the relative voting strength of each previously outstanding Ordinary Share may be diminished; and |
• | the market price of the Ordinary Shares may decline. |
• | the accompanying notes to the unaudited pro forma condensed combined financial information; |
• | the historical unaudited condensed consolidated financial statements of NewCleo Ltd. as of and for the six months ended June 30, 2026, and the related notes included elsewhere in this prospectus; |
• | the historical unaudited condensed financial statements of NewHold as of and for the six months ended June 30, 2026, and the related notes included elsewhere in this prospectus; |
• | the historical audited consolidated financial statements of NewCleo Ltd. for the year ended December 31, 2025, and the related notes included elsewhere in this prospectus; |
• | the historical audited financial statements of NewHold for the year ended December 31, 2025, and the related notes included elsewhere in this prospectus; |
• | the Business Combination Agreement incorporated by reference into this prospectus; and |
• | the sections titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and other financial information relating to NewHold, NewCleo Ltd. and newcleo included elsewhere in this prospectus. |
Historical | Historical | ||||||||||||||||||||||||||||||||
Newcleo Ltd (IFRS) | newcleo Financing Transaction Adjustments (Note 7) | Adjusted Newcleo Ltd | NewHold (US GAAP) (Note 3) | US GAAP Conversion and Presentation Alignment (Note 4) | Adjusted NewHold | Transaction Accounting Adjustments | Pro Forma Combined (IFRS) | ||||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||
Non-current assets | |||||||||||||||||||||||||||||||||
Goodwill | €37,281 | €— | €37,281 | €— | €— | €— | €— | €37,281 | |||||||||||||||||||||||||
Intangible assets | 42,760 | 42,760 | — | — | 42,760 | ||||||||||||||||||||||||||||
Property, plant, and equipment | 115,999 | 115,999 | — | — | 115,999 | ||||||||||||||||||||||||||||
Right-of-use asset | 17,665 | 17,665 | — | — | 17,665 | ||||||||||||||||||||||||||||
Investments | 76 | 76 | — | — | 76 | ||||||||||||||||||||||||||||
Investments in associates | 31,553 | 31,553 | — | — | 31,553 | ||||||||||||||||||||||||||||
Other long term receivables | 34,871 | 34,871 | — | — | 34,871 | ||||||||||||||||||||||||||||
Deferred tax assets | 3,059 | 3,059 | — | — | 3,059 | ||||||||||||||||||||||||||||
Investment held in trust account | — | — | 186,506 | 186,506 | (95,042) | 8(h) | — | ||||||||||||||||||||||||||
(8,627) | 8(j) | ||||||||||||||||||||||||||||||||
(82,837) | 8(m) | ||||||||||||||||||||||||||||||||
Total non-current assets | 283,264 | — | 283,264 | 186,506 | — | 186,506 | (186,506) | 283,264 | |||||||||||||||||||||||||
Current assets | |||||||||||||||||||||||||||||||||
Inventories | 4,843 | 4,843 | — | — | 4,843 | ||||||||||||||||||||||||||||
Short term investments | 2,335 | 2,335 | — | — | 2,335 | ||||||||||||||||||||||||||||
Trade and other receivables, net | 77,768 | 77,768 | — | 154 | 4(c) | 154 | 2,190 | 8(e) | 79,958 | ||||||||||||||||||||||||
(132) | 8(n) | ||||||||||||||||||||||||||||||||
(22) | 8(q) | ||||||||||||||||||||||||||||||||
Cash and cash equivalents | 66,540 | 16,186 | 7(a) | 82,726 | 319 | 319 | 9 | 8(a) | 253,007 | ||||||||||||||||||||||||
(23,095) | 8(c) | ||||||||||||||||||||||||||||||||
(2,158) | 8(f) | ||||||||||||||||||||||||||||||||
8,627 | 8(j) | ||||||||||||||||||||||||||||||||
(65,668) | 8(l) | ||||||||||||||||||||||||||||||||
82,837 | 8(m) | ||||||||||||||||||||||||||||||||
(2,867) | 8(o) | ||||||||||||||||||||||||||||||||
(749) | 8(p) | ||||||||||||||||||||||||||||||||
(7,266) | 8(q) | ||||||||||||||||||||||||||||||||
180,292 | 8(u) | ||||||||||||||||||||||||||||||||
Prepaid expenses | — | — | 154 | (154) | 4(c) | — | — | ||||||||||||||||||||||||||
Total current assets | 151,486 | 16,186 | 167,672 | 473 | — | 473 | 171,998 | 340,143 | |||||||||||||||||||||||||
Total assets | €434,750 | €16,186 | €450,936 | €186,979 | €— | €186,979 | €(14,508) | €623,407 | |||||||||||||||||||||||||
Historical | Historical | ||||||||||||||||||||||||||||||||
Newcleo Ltd (IFRS) | newcleo Financing Transaction Adjustments (Note 7) | Adjusted Newcleo Ltd | NewHold (US GAAP) (Note 3) | US GAAP Conversion and Presentation Alignment (Note 4) | Adjusted NewHold | Transaction Accounting Adjustments | Pro Forma Combined (IFRS) | ||||||||||||||||||||||||||
Liabilities | |||||||||||||||||||||||||||||||||
Non-current liabilities | |||||||||||||||||||||||||||||||||
Provisions - non-current | €4,094 | €— | €4,094 | €— | €— | €— | €— | €4,094 | |||||||||||||||||||||||||
Other non-current liabilities | 8,932 | 8,932 | — | — | 8,932 | ||||||||||||||||||||||||||||
Lease liabilities - non-current | 14,667 | 14,667 | — | — | 14,667 | ||||||||||||||||||||||||||||
Borrowings - non-current | 15,929 | 15,929 | — | — | 15,929 | ||||||||||||||||||||||||||||
Deferred tax liabilities | 4,430 | 4,430 | — | — | 4,430 | ||||||||||||||||||||||||||||
Deferred underwriting fee payable | — | — | 6,170 | 6,170 | (6,170) | 8(o) | — | ||||||||||||||||||||||||||
Warrants liabilities | — | — | — | 8,972 | 4(b) | 8,972 | (47) | 8(i) | 8,888 | ||||||||||||||||||||||||
(37) | 8(r) | ||||||||||||||||||||||||||||||||
Financial liabilities - Class A ordinary shares subject to possible redemption | — | — | — | 186,506 | 4(a) | 186,506 | (95,042) | 8(h) | — | ||||||||||||||||||||||||
(8,627) | 8(j) | ||||||||||||||||||||||||||||||||
(82,837) | 8(v) | ||||||||||||||||||||||||||||||||
Total non-current liabilities | 48,052 | — | 48,052 | 6,170 | 195,478 | 201,648 | (192,760) | 56,940 | |||||||||||||||||||||||||
Current liabilities | |||||||||||||||||||||||||||||||||
Provisions - current | 378 | 378 | — | — | 378 | ||||||||||||||||||||||||||||
Trade and other payables | 60,055 | 60,055 | — | 5,333 | 4(c) | 5,333 | (1,966) | 8(c) | 58,227 | ||||||||||||||||||||||||
2,190 | 8(e) | ||||||||||||||||||||||||||||||||
(2,860) | 8(f) | ||||||||||||||||||||||||||||||||
(4,525) | 8(q) | ||||||||||||||||||||||||||||||||
Lease liabilities - current | 3,545 | 3,545 | — | — | 3,545 | ||||||||||||||||||||||||||||
Borrowings - current | 2,497 | — | 7(a) | 2,497 | — | — | 2,497 | ||||||||||||||||||||||||||
Accounts payable | — | — | 542 | (542) | 4(c) | — | — | ||||||||||||||||||||||||||
Accrued liabilities | — | — | 4,791 | (4,791) | 4(c) | — | — | ||||||||||||||||||||||||||
Deferred compensation - related parties | — | — | 633 | 633 | (633) | 8(p) | — | ||||||||||||||||||||||||||
Total current liabilities | 66,475 | — | 66,475 | 5,966 | — | 5,966 | (7,794) | 64,647 | |||||||||||||||||||||||||
Total liabilities | 114,527 | — | 114,527 | 12,136 | 195,478 | 207,614 | (200,554) | 121,587 | |||||||||||||||||||||||||
Class A ordinary shares subject to possible redemption; 20,125,000 shares issued and outstanding, historical; zero shares issued and outstanding, pro forma combined | — | — | 186,506 | (186,506) | 4(a) | — | — | ||||||||||||||||||||||||||
Historical | Historical | ||||||||||||||||||||||||||||||||
Newcleo Ltd (IFRS) | newcleo Financing Transaction Adjustments (Note 7) | Adjusted Newcleo Ltd | NewHold (US GAAP) (Note 3) | US GAAP Conversion and Presentation Alignment (Note 4) | Adjusted NewHold | Transaction Accounting Adjustments | Pro Forma Combined (IFRS) | ||||||||||||||||||||||||||
Equity | |||||||||||||||||||||||||||||||||
newcleo share capital, €0.01 par value, historical; 504,560,981 shares authorized, issued and outstanding, historical; $0.02 par value (€0.02 par value), pro forma combined; 281,534,950 shares authorized, 279,830,526 shares issued and outstanding, pro forma combined | 5,046 | 39 | 7(a) | 5,085 | — | — | 9 | 8(a) | 5,607 | ||||||||||||||||||||||||
— | 8(b) | ||||||||||||||||||||||||||||||||
(186) | 8(g) | ||||||||||||||||||||||||||||||||
1 | 8(q) | ||||||||||||||||||||||||||||||||
66 | 8(s) | ||||||||||||||||||||||||||||||||
199 | 8(v) | ||||||||||||||||||||||||||||||||
433 | 8(u) | ||||||||||||||||||||||||||||||||
SPAC Class A ordinary shares, $0.0001 par value; 479,000,000 shares authorized; 780,100 shares issued and outstanding, historical; zero shares issued and outstanding, pro forma combined | — | — | — | — | — | 8(i) | — | ||||||||||||||||||||||||||
— | 8(j) | ||||||||||||||||||||||||||||||||
— | 8(s) | ||||||||||||||||||||||||||||||||
— | 8(v) | ||||||||||||||||||||||||||||||||
SPAC Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 6,707,663 shares issued and outstanding, historical; zero shares issued and outstanding, pro forma combined | — | — | 1 | 1 | — | 8(i) | — | ||||||||||||||||||||||||||
— | 8(k) | ||||||||||||||||||||||||||||||||
(1) | 8(s) | ||||||||||||||||||||||||||||||||
Additional paid-in capital | — | — | — | — | — | ||||||||||||||||||||||||||||
Share premium | 23,378 | 16,147 | 7(a) | 39,525 | — | — | — | 8(a) | 226,609 | ||||||||||||||||||||||||
167 | 8(b) | ||||||||||||||||||||||||||||||||
(594) | 8(c) | ||||||||||||||||||||||||||||||||
(170,109) | 8(d) | ||||||||||||||||||||||||||||||||
186 | 8(g) | ||||||||||||||||||||||||||||||||
— | 8(i) | ||||||||||||||||||||||||||||||||
656 | 8(q) | ||||||||||||||||||||||||||||||||
(65) | 8(s) | ||||||||||||||||||||||||||||||||
70,048 | 8(v) | ||||||||||||||||||||||||||||||||
106,936 | 8(t) | ||||||||||||||||||||||||||||||||
179,859 | 8(u) | ||||||||||||||||||||||||||||||||
Earnout reserves | — | — | — | — | 170,109 | 8(d) | 170,109 | ||||||||||||||||||||||||||
Historical | Historical | ||||||||||||||||||||||||||||||||
Newcleo Ltd (IFRS) | newcleo Financing Transaction Adjustments (Note 7) | Adjusted Newcleo Ltd | NewHold (US GAAP) (Note 3) | US GAAP Conversion and Presentation Alignment (Note 4) | Adjusted NewHold | Transaction Accounting Adjustments | Pro Forma Combined (IFRS) | ||||||||||||||||||||||||||
Other reserves | 57,067 | 57,067 | — | — | 57,067 | ||||||||||||||||||||||||||||
Treasury shares | — | — | — | — | (65,368) | 8(l) | (65,368) | ||||||||||||||||||||||||||
Retained earnings (accumulated deficit) | 234,695 | 234,695 | (11,664) | (8,972) | 4(b) | (20,636) | (167) | 8(b) | 107,759 | ||||||||||||||||||||||||
(20,535) | 8(c) | ||||||||||||||||||||||||||||||||
702 | 8(f) | ||||||||||||||||||||||||||||||||
47 | 8(i) | ||||||||||||||||||||||||||||||||
8,627 | 8(j) | ||||||||||||||||||||||||||||||||
(300) | 8(l) | ||||||||||||||||||||||||||||||||
(132) | 8(n) | ||||||||||||||||||||||||||||||||
3,303 | 8(o) | ||||||||||||||||||||||||||||||||
(116) | 8(p) | ||||||||||||||||||||||||||||||||
(3,420) | 8(q) | ||||||||||||||||||||||||||||||||
37 | 8(r) | ||||||||||||||||||||||||||||||||
12,590 | 8(v) | ||||||||||||||||||||||||||||||||
(106,936) | 8(t) | ||||||||||||||||||||||||||||||||
Non-controlling interests | 37 | 37 | — | — | 37 | ||||||||||||||||||||||||||||
Total equity | 320,223 | 16,186 | 336,409 | (11,663) | (8,972) | (20,635) | 186,046 | 501,820 | |||||||||||||||||||||||||
Total shareholders’ equity and liabilities | €434,750 | €16,186 | €450,936 | €186,979 | €— | €186,979 | €(14,508) | €623,407 | |||||||||||||||||||||||||
Historical | Historical | |||||||||||||||||||||||||||||
Newcleo Ltd (IFRS) | newcleo Financing Transaction Adjustments (Note 7) | Adjusted Newcleo Ltd | NewHold (US GAAP) (Note 3) | US GAAP Conversion and Presentation Alignment (Note 4) | Adjusted NewHold | Transaction Accounting Adjustments | Pro Forma Combined (IFRS) | |||||||||||||||||||||||
Revenue | €19,429 | €— | €19,429 | €— | €— | €— | €— | €19,429 | ||||||||||||||||||||||
Cost of sales | (13,299) | (13,299) | — | — | (13,299) | |||||||||||||||||||||||||
Gross profit | 6,130 | — | 6,130 | — | — | — | — | 6,130 | ||||||||||||||||||||||
Other income | 6,554 | 6,554 | — | — | 6,554 | |||||||||||||||||||||||||
Research and development expenses | (34,629) | (34,629) | — | — | (34,629) | |||||||||||||||||||||||||
Selling, general and administrative expenses | (59,170) | (59,170) | (5,458) | (5,458) | (1,095) | 9(c) | (65,286) | |||||||||||||||||||||||
206 | 9(g) | |||||||||||||||||||||||||||||
231 | 9(h) | |||||||||||||||||||||||||||||
Operating loss | (81,115) | — | (81,115) | (5,458) | — | (5,458) | (658) | (87,231) | ||||||||||||||||||||||
Other income | — | — | 3,194 | 3,194 | (3,194) | 9(e) | — | |||||||||||||||||||||||
Loss on disposal of assets | (9) | (9) | — | — | (9) | |||||||||||||||||||||||||
Finance income | 353 | 353 | — | — | 353 | |||||||||||||||||||||||||
Finance costs | (1,448) | (1,448) | — | — | (1,448) | |||||||||||||||||||||||||
Share of loss of associates | (83) | (83) | — | — | (83) | |||||||||||||||||||||||||
Loss before tax | (82,302) | — | (82,302) | (2,264) | — | (2,264) | (3,852) | (88,418) | ||||||||||||||||||||||
Income tax benefit | 321 | — | 321 | — | — | — | — | 321 | ||||||||||||||||||||||
Loss for the period | €(81,981) | €— | €(81,981) | €(2,264) | €— | €(2,264) | €(3,852) | €(88,097) | ||||||||||||||||||||||
Weighted average Class A ordinary shares outstanding – basic and diluted | 20,905,100 | |||||||||||||||||||||||||||||
Net loss per share Class A ordinary shares – basic and diluted | €(0.08) | |||||||||||||||||||||||||||||
Weighted average Class B ordinary shares outstanding – basic and diluted | 6,707,663 | |||||||||||||||||||||||||||||
Net loss per share Class B ordinary shares – basic and diluted net loss per share | €(0.08) | |||||||||||||||||||||||||||||
Weighted average ordinary shares outstanding - basic and diluted | 497,532,570 | 276,452,480 | 9(j) | |||||||||||||||||||||||||||
Net loss per ordinary share - basic and diluted | €(0.16) | €(0.32) | 9(j) | |||||||||||||||||||||||||||
Historical | Historical | |||||||||||||||||||||||||||||
Newcleo Ltd (IFRS) | newcleo Financing Transaction Adjustments (Note 7) | Adjusted Newcleo Ltd | NewHold (US GAAP) (Note 3) | US GAAP Conversion and Presentation Alignment (Note 4) | Adjusted NewHold | Transaction Accounting Adjustments | Pro Forma Combined (IFRS) | |||||||||||||||||||||||
Revenue | €32,769 | €— | €32,769 | €— | €— | €— | €— | €32,769 | ||||||||||||||||||||||
Cost of sales | (24,953) | (24,953) | — | — | (24,953) | |||||||||||||||||||||||||
Gross profit | 7,816 | — | 7,816 | — | — | — | — | 7,816 | ||||||||||||||||||||||
Other income | 19,347 | 19,347 | — | — | 19,347 | |||||||||||||||||||||||||
Research and development expenses | (68,544) | (68,544) | — | — | 233 | 9(d) | (68,311) | |||||||||||||||||||||||
Selling, general and administrative expenses | (98,547) | (98,547) | (1,849) | (1,849) | (167) | 9(a) | (229,147) | |||||||||||||||||||||||
(20,535) | 9(b) | |||||||||||||||||||||||||||||
(2,190) | 9(c) | |||||||||||||||||||||||||||||
469 | 9(d) | |||||||||||||||||||||||||||||
(132) | 9(f) | |||||||||||||||||||||||||||||
354 | 9(g) | |||||||||||||||||||||||||||||
386 | 9(h) | |||||||||||||||||||||||||||||
(106,936) | 9(i) | |||||||||||||||||||||||||||||
Operating loss | (139,928) | — | (139,928) | (1,849) | — | (1,849) | (128,518) | (270,295) | ||||||||||||||||||||||
Other income | — | — | 6,198 | 6,198 | (6,198) | 9(e) | — | |||||||||||||||||||||||
Loss on disposal of assets | (1,630) | (1,630) | — | — | (1,630) | |||||||||||||||||||||||||
Finance income | 1,937 | 1,937 | — | — | 1,937 | |||||||||||||||||||||||||
Finance costs | (2,120) | (2,120) | — | — | (2,120) | |||||||||||||||||||||||||
Share of loss of associates | (48) | (48) | — | — | (48) | |||||||||||||||||||||||||
Income (loss) before tax | (141,789) | — | (141,789) | 4,349 | — | 4,349 | (134,716) | (272,156) | ||||||||||||||||||||||
Income tax benefit | 1,824 | — | 1,824 | — | — | — | — | 1,824 | ||||||||||||||||||||||
Income (loss) for the year | €(139,965) | €— | €(139,965) | €4,349 | €— | €4,349 | €(134,716) | €(270,332) | ||||||||||||||||||||||
Weighted average Class A ordinary shares outstanding – basic and diluted | 17,354,000 | |||||||||||||||||||||||||||||
Net income per share Class A ordinary shares – basic and diluted | €0.18 | |||||||||||||||||||||||||||||
Weighted average Class B ordinary shares outstanding – basic and diluted | 6,707,663 | |||||||||||||||||||||||||||||
Net income per share Class B ordinary shares – basic and diluted | €0.18 | |||||||||||||||||||||||||||||
Weighted average ordinary shares outstanding - basic and diluted | 462,252,560 | 259,493,379 | 9(j) | |||||||||||||||||||||||||||
Net loss per ordinary share - basic and diluted | €(0.30) | €(1.04) | 9(j) | |||||||||||||||||||||||||||
newcleo Ordinary Shares outstanding as of June 30, 2026 | 504,560,981 | ||
newcleo Ordinary Shares issued upon NewCleo Ltd. option exercises subsequent to June 30, 2026 | 941,354 | ||
newcleo Ordinary Shares issued related to the 2026 Capital Raise subsequent to June 30, 2026 | 3,947,805 | ||
newcleo Ordinary Shares issued to suppliers subsequent to June 30, 2026 | 46,341 | ||
Total newcleo Ordinary Shares outstanding prior to the Closing of the Business Combination | 509,496,481 | ||
Recapitalization Factor upon Closing of the Business Combination | 0.4807 | ||
newcleo Ordinary Shares issued to newcleo Shareholders upon Closing of the Business Combination | 244,914,447 | ||
a) | 50% of the newcleo Earnout if the VWAP of newcleo Ordinary Shares equals or exceeds $15.00 (the “Earnout Triggering Event I”) for any twenty trading days in a thirty-trading day period occurring no later than the fifth anniversary of the Closing of the Business Combination (the “Vesting Period”); and |
b) | 50% of the newcleo Earnout if the VWAP of newcleo Ordinary Shares equals or exceeds $18.00 (the “Earnout Triggering Event II,” collectively with the Earnout Triggering Event I, the “Earnout Triggering Events”) for any twenty trading days in a thirty-trading day period during the Vesting Period. |
c) | In the event that, prior to the expiration of the Earnout Period and the occurrence of the Earnout Triggering Events, newcleo consummates a merger, sale, or similar transaction (the “Early Release Event”) in which the holders of newcleo Ordinary Shares have the right to receive cash or securities for their shares and the value received per share equals or exceeds any VWAP of the Earnout Triggering Events, then the Class B Shares will convert into Ordinary Shares immediately prior to the closing of such transaction in the lesser of: |
i. | The number that would have been vested if the transaction value per share had been newcleo’s VWAP for any twenty trading days in a thirty-trading day period during the Vesting Period; and |
ii. | The number of Class B Shares that remain unconverted as of that time. |
a) | 50% of the remaining Sponsor Promote retained at Closing, or 2,700,527 newcleo Ordinary Shares issued, vested immediately (the “Vested Tranche”), |
b) | 25% of the remaining Sponsor Promote retained at Closing, or 1,396,453 newcleo Ordinary Shares issued, will vest if the VWAP of newcleo Ordinary Shares equals or exceeds the Earnout Triggering Event I for any twenty trading-days in a thirty-trading day period during the Vesting Period (the “$15 Tranche”), and |
c) | 25% of the remaining Sponsor Promote retained at Closing, or 307,972 newcleo Ordinary Shares issued, will vest if the VWAP of newcleo Ordinary Shares equals or exceeds the Earnout Triggering Event II for any twenty trading-days in a thirty-trading day period during the Vesting Period (the “$18 Tranche,” collectively with the $15 Tranche, the “Sponsor Promote Earnout”). |
a) | Physical Settlement: If Shareholder Approval has been obtained on or before the Maturity Date and newcleo has sufficient distributable reserves, the FPA Seller will deliver to newcleo the Recycled Shares remaining subject to the Forward Purchase Agreement, net of any Terminated Shares. The Counterparty shall have no delivery obligation to the FPA Seller. Upon settlement, newcleo will reverse the treasury share reserve and the related share capital and share premium amounts associated with the shares returned by the FPA Seller. |
b) | Cash Settlement: If the Forward Purchase Agreement is cash settled, the settlement amount will be determined based on the aggregate of the daily settlement amounts calculated during the Valuation Period. Each daily settlement amount is equal to the product of (a) the Daily Settlement Price and (b) the Daily Share Amount. The Daily Settlement Price is defined as the lower of (i) 95% of the daily VWAP of newcleo Ordinary Shares and (ii) the Reset Price, which initially equals the Initial Price and may thereafter be adjusted downward by mutual written agreement of the parties. The Daily Share Amount is defined as the lesser of (i) 5% of specified trading volume measures and (ii) the number of Recycled Shares remaining subject to settlement. Accordingly, the aggregate cash settlement amount may be less than the Prepayment Amount depending on the trading prices of the shares during the Valuation Period. Upon settlement, newcleo will recognize the cash received and reverse the corresponding treasury share reserve recognized on the date of the Forward Purchase Agreement. |
c) | Mixed Settlement: If Shareholder Approval is obtained after the commencement of the Valuation Period but before its completion, cash settlement will apply only to the Daily Share Amounts previously calculated during the Valuation Period, while the Remaining Unwind Number will be physically settled through delivery of the applicable Recycled Shares to newcleo. Accordingly, the total value received by newcleo through a combination of cash settlement and physical settlement may be less than the original Prepayment Amount depending on the trading prices of the shares during the Valuation Period. Upon settlement, newcleo will recognize any cash received and reverse the treasury share reserve, together with the related share capital and share premium associated with the shares physically returned. |
As of June 30, 2026 | ||||||
Actual Redemption | ||||||
Equity Capitalization Summary Upon Consummation of the Business Combination | Number of Shares Owned | % Ownership | ||||
Holders of Founder Shares and SPAC Private Placement Shares | 3,206,027 | 1.2% | ||||
SPAC Public Shareholders | 9,023,548 | 3.2% | ||||
SPAC Public Shareholders with shares subject to Non-Redemption Agreements | 1,016,158 | 0.4% | ||||
newcleo Shareholders | 244,914,447 | 87.5% | ||||
PIPE Investors | 21,600,000 | 7.7% | ||||
Capital markets advisors | 70,346 | 0.0% | ||||
Total newcleo Ordinary Shares upon Closing of the Business Combination | 279,830,526 | 100.0% | ||||
As of June 30, 2026 | ||||||
Actual Redemption | ||||||
Equity Capitalization Summary (fully diluted basis) | Number of Shares Owned | % Ownership | ||||
Holders of Founder Shares and SPAC Private Placement Shares | 3,206,027 | 0.9% | ||||
SPAC Public Shareholders | 9,023,548 | 2.7% | ||||
SPAC Public Shareholders with shares subject to Non-Redemption Agreements | 1,016,158 | 0.3% | ||||
newcleo Shareholders(1) | 258,486,380 | 76.3% | ||||
PIPE Investors | 21,600,000 | 6.4% | ||||
Capital market advisors | 70,346 | 0.0% | ||||
Holders of Sponsor Promote Earnout(2) | 1,704,424 | 0.5% | ||||
Class B Shareholders(3) | 24,490,918 | 7.2% | ||||
Holders of SPAC Warrants | 10,354,197 | 3.1% | ||||
Holders of Continuing Warrants | 8,855,000 | 2.6% | ||||
Total fully diluted newcleo Ordinary Shares upon Closing of the Business Combination | 338,806,998 | 100.0% | ||||
(1) | The number of shares owned by newcleo Shareholders upon consummation of the Business Combination includes (i) 13,274,757 Continuing Options, based on 27,617,100 NewCleo Ltd. options expected to be outstanding, and (ii) 297,176 Continuing RSUs, based on 618,216 NewCleo Ltd. RSUs expected to be outstanding following the consummation of the Transactions and the Recapitalization Factor of 0.4807. |
(2) | Represents unvested Sponsor Promote Earnout as the Earnout Triggering Events have not been met. |
(3) | Represents unvested newcleo Earnout as the Earnout Triggering Events have not been met. |
Balance Sheet As of June 30, 2026 | |||||||||
Historical NewHold (U.S. GAAP) (Unaudited) | USD Conversion Rate | Historical NewHold (U.S. GAAP) | |||||||
(USD in thousands) | (EUR in thousands) | ||||||||
ASSETS | |||||||||
Cash and cash equivalents | $364 | 0.8759 | €319 | ||||||
Prepaid expenses | 176 | 0.8759 | 154 | ||||||
Total current assets | 540 | 473 | |||||||
Investment held in trust account | 212,934 | 0.8759 | 186,506 | ||||||
Total assets | $213,474 | €186,979 | |||||||
Balance Sheet As of June 30, 2026 | |||||||||
Historical NewHold (U.S. GAAP) (Unaudited) | USD Conversion Rate | Historical NewHold (U.S. GAAP) | |||||||
(USD in thousands) | (EUR in thousands) | ||||||||
LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT | |||||||||
Accounts payable | $619 | 0.8759 | €542 | ||||||
Accrued liabilities | 5,470 | 0.8759 | 4,791 | ||||||
Deferred compensation—related parties | 723 | 0.8759 | 633 | ||||||
Total current liabilities | 6,812 | 5,966 | |||||||
Deferred underwriting fee payable | 7,044 | 0.8759 | 6,170 | ||||||
Total liabilities | 13,856 | 12,136 | |||||||
Commitments and Contingencies | |||||||||
Class A ordinary shares subject to possible redemption; 20,125,000 shares at $10.58 per share | 212,934 | 0.8759 | 186,506 | ||||||
Shareholders’ Deficit | |||||||||
Preference shares, $0.0001 par value; 1,000,000 authorized shares; none issued or outstanding | — | 0.8759 | — | ||||||
Class A ordinary shares, $0.0001 par value; 479,000,000 authorized shares; 780,100 shares issued and outstanding | — | 0.8759 | — | ||||||
Class B ordinary shares, $0.0001 par value, 20,000,000 authorized shares; 6,707,663 shares issued and outstanding | 1 | 0.8759 | 1 | ||||||
Additional paid-in capital | — | 0.8759 | — | ||||||
Accumulated deficit | (13,317) | 0.8759 | (11,664) | ||||||
Total Shareholders’ Deficit | (13,316) | (11,663) | |||||||
Total liabilities, Class A ordinary shares subject to possible redemption and shareholders’ deficit | $213,474 | €186,979 | |||||||
Statement of Operations For the six months ended June 30, 2026 | |||||||||
Historical NewHold (U.S. GAAP) (Unaudited) | USD Conversion Rate | Historical NewHold (U.S. GAAP) | |||||||
(USD in thousands) | (EUR in thousands) | ||||||||
General and administrative expenses | $6,367 | 0.8572 | €5,458 | ||||||
Loss from operations | (6,367) | (5,458) | |||||||
Other income (expense): | |||||||||
Interest income on Trust Account | 3,714 | 0.8572 | 3,184 | ||||||
Interest income on operating account | 12 | 0.8572 | 10 | ||||||
Other income | 3,726 | 3,194 | |||||||
Net income | $ (2,641) | € (2,264) | |||||||
Statement of Operations For the year ended December 31, 2025 | |||||||||
Historical NewHold (U.S. GAAP) (Audited) | USD Conversion Rate | Historical NewHold (U.S. GAAP) | |||||||
(USD in thousands) | (EUR in thousands) | ||||||||
General and administrative expenses | $2,090 | 0.8845 | €1,849 | ||||||
Loss from operations | (2,090) | (1,849) | |||||||
Other income (expense): | |||||||||
Interest income on Trust Account | 6,964 | 0.8845 | 6,159 | ||||||
Interest income on operating account | 44 | 0.8845 | 39 | ||||||
Other income | 7,008 | 6,198 | |||||||
Net income | $4,918 | €4,349 | |||||||
a) | To reflect the reclassification of SPAC Class A Ordinary Shares subject to possible redemption from mezzanine equity under U.S. GAAP to liabilities under IFRS, as the shareholders have the right to require NewHold to redeem their pro rata share of the funds in the Trust Account and NewHold has an irrevocable obligation to deliver cash or another financial instrument for such redemption. |
b) | To reflect the reclassification of SPAC Warrants from equity classification under U.S. GAAP to liability classification under IFRS, due to SPAC Warrants having net share cashless settlement provisions that permit settlement in a variable number of shares, which preclude equity classification under IAS 32. Given NewHold’s additional paid-in capital was zero on the historical balance sheet as of June 30, 2026, the IFRS adjustment in equity related to the classification was reflected in accumulated deficit. |
c) | To reflect the reclassification adjustments to align NewHold’s historical financial statement balances with the presentation of NewCleo Ltd.’s historical financial statements. |
• | newcleo’s existing shareholders (the “newcleo Shareholders”) have held a majority of the voting power of the combined company; |
• | newcleo is the larger entity in terms of substantive operations and employee base; |
• | newcleo designates a majority of the members of the board of directors of the combined company; |
• | newcleo’s operations comprises the ongoing operations of the combined company; and |
• | newcleo’s existing senior management comprises all of the senior management of the combined company. |
Actual Redemption | |||
newcleo Ordinary Shares outstanding as of June 30, 2026 | 504,560,981 | ||
newcleo Ordinary Shares issued upon NewCleo Ltd. option exercises subsequent to June 30, 2026 | 941,354 | ||
newcleo Ordinary Shares issued related to the 2026 Capital Raise subsequent to June 30, 2026 | 3,947,805 | ||
newcleo Ordinary Shares issued to suppliers subsequent to June 30, 2026 | 46,341 | ||
Total newcleo Ordinary Shares outstanding prior to the closing of the Business Combination | 509,496,481 | ||
Recapitalization Factor | 0.4807 | ||
newcleo Ordinary Shares issued to newcleo Shareholders upon Closing of the Business Combination | 244,914,447 | ||
Holders of Founder Shares and SPAC Private Placement Shares | 3,206,027 | ||
SPAC Public Shareholders | 9,023,548 | ||
SPAC Public Shareholders with shares subject to Non-Redemption Agreements | 1,016,158 | ||
PIPE Investors | 21,600,000 | ||
Capital market advisors | 70,346 | ||
Total newcleo Ordinary Shares upon Closing of the Business Combination | 279,830,526 | ||
a) | To reflect the issuance of 3,947,805 newcleo Ordinary Shares at a subscription price of €4.10 per share in connection with the 2026 Capital Raise completed in July 2026, resulting in aggregate gross proceeds of approximately €16.2 million. The adjustment reflects the receipt of cash proceeds of €16.2 million and a corresponding increase in share capital at par value with the remainder to share premium. See note 1 – 2026 Capital Raise. |
a) | To reflect the exercise of 941,354 NewCleo Ltd. options with a per-share exercise price of €0.01 subsequent to June 30, 2026. |
b) | To reflect the issuance of 46,341 newcleo Ordinary Shares subsequent to June 30, 2026, at a price of €3.60 per share, as consideration for services rendered by certain suppliers. An adjustment is recognized to increase share capital at par value and share premium for €0.2 million related to the share issuance, and accumulated deficit of €0.2 million. A corresponding €0.2 million expense is also reflected in the pro forma condensed combined statement of operations for the year ended December 31, 2025. |
c) | To reflect an additional €20.5 million of unpaid transaction costs incurred by newcleo in connection with the Business Combination, including advisory, legal, accounting and auditing fees and other professional fees. |
d) | To reflect the newcleo Earnout issuable to newcleo Shareholders for the estimated fair value of €170.1 million that may vest upon the occurrence of Earnout Triggering Events (see note 1 – newcleo Earnout). The pro forma fair value of the newcleo Earnout is calculated using a Monte Carlo simulation. The significant assumptions utilized in estimating the fair value of newcleo Earnout include the following: (1) newcleo Ordinary Share price of $10.00 or €8.76 per share; (2) risk-free rate of 3.85%; (3) transaction date of September 21, 2026, with a maximum lock-up period covering 180 days; and (4) the expected equity volatility of 109% based on historical volatility of selected peer companies that matches the expected remaining life of the newcleo Earnout. The newcleo Earnout is determined to be classified as equity and recognized as earnout reserves with a corresponding offset recorded in share premium in the unaudited pro forma condensed combined balance sheet. The newcleo Earnout estimates and inputs are subject to change as additional information becomes available and additional analyses are performed and such changes could be material once the final valuation is determined at the effective time. |
e) | To reflect the accrual of the new directors and officers liability insurance (the “D&O Insurance Policy”) of €2.2 million to be paid subsequent to the Closing in connection with the consummation of Business Combination. Accordingly, the adjustment reflects an increase in trade and other receivables, net of €2.2 million, with a corresponding increase to trade and other payables. A related €2.2 million expense is also reflected in the pro forma condensed combined statement of operations for the year ended December 31, 2025. |
f) | To reflect the settlement of cash bonuses of €2.2 million paid to certain executives and employees of NewCleo Ltd. at Closing in connection with the consummation of the Business Combination, resulting in a decrease to trade and other payables of €2.9 million and a decrease to accumulated deficit of €0.7 million. A corresponding reduction of €0.7 million in expense is also reflected in the pro forma condensed combined statement of operations for the year ended December 31, 2025. |
g) | To reflect the Recapitalization pursuant to the Business Combination Agreement, the conversion and exchange of all outstanding shares of capital stock of NewCleo Ltd. based on the Recapitalization Factor into 244,914,447 newcleo Ordinary Shares, a par value of $0.02288 (€0.02004 at June 30, 2026) per share. As a result of the Recapitalization, an adjustment reducing newcleo share capital by €0.2 million is recognized, reflecting the historical par value of €0.01 per newcleo Ordinary Share prior to the Recapitalization, with a corresponding increase in share premium of €0.2 million. |
h) | To reflect the net redemption payment of €95.0 million made from the Trust Account for the SPAC Public Shareholders of the SPAC Class A Ordinary Share, who exercised their redemption rights with respect to 10,177,672 SPAC Class A Ordinary Shares prior to the consummation of the Business Combination at a redemption price of $10.6615 per share. See note 1 – Actual Redemption. |
i) | Immediately prior the closing of the First Merger, the Sponsor Promote consists of 552,600 SPAC Private Placement Shares, 6,429,663 Founder Shares, and 276,300 SPAC Private Placement Warrants. Pursuant to the Business Combination Agreement, 20% of the Sponsor Promote is forfeited, resulting in 110,520 SPAC Private Placement Shares and 1,285,933 Founder Shares, representing 1,396,453 shares in aggregate, and 55,260 SPAC Private Placement Warrants included in the Sponsor Forfeited Equity. See note 1 – Sponsor Promote. |
j) | To reflect the reclassification of 923,780 SPAC Class A Ordinary Shares that are subject to redemption prior to the Closing, or €8.6 million calculated based on the redemption price of $10.6615 as of September 21, 2026, to SPAC Class A Ordinary Shares at par value and accumulated deficit of NewHold in connection with the Non-Redemption Agreements. The reclassification of shares has been recorded as a reduction to the Trust Account and an increase in cash. Pursuant to the Non-Redemption Agreements, the NRA Investors waived the redemption rights associated with 923,780 SPAC Class A Ordinary Shares upon the completion of the Business Combination. Given NewHold’s additional paid-in capital was zero on the historical balance sheet as of June 30, 2026, the reclassification adjustment in equity related to the Non-Redemption Agreements was reflected in accumulated deficit. These 923,780 SPAC Class A Ordinary Shares are converted into 923,780 newcleo Ordinary Shares upon the consummation of the First Merger. |
k) | To reflect 92,378 SPAC Class B Ordinary Shares forfeited by the Sponsor and assigned to the NRA Investors pursuant to the Non-Redemption Agreements. |
l) | To reflect the Forward Purchase Agreement with an adjustment to recognize (i) a decrease in cash of €65.7 million, (ii) an increase in treasury shares of €65.4 million and (iii) an increase to accumulated deficit of €0.3 million. See note 1 – Forward Purchase Agreement. |
m) | To reflect the release of €82.8 million from the cash held in Trust Account to cash upon the completion of the Business Combination, after giving effect to the SPAC Public Shareholders exercised their redemption rights to have their SPAC Class A Ordinary Shares redeemed for their pro rata share of the Trust Account (see note 8(g)) and the NRA Investors waived the redemption rights associated with 923,780 SPAC Class A Ordinary Shares (see note 8(i)). |
n) | To reflect the write-off of prepayments recognized in prepaid expenses of €0.1 million in connection with i) the existing D&O Insurance Policy incurred for the benefit of NewHold’s directors and officers, and ii) transfer agent fees and filing fees. Most of NewHold’s directors and officers did not continue as directors and officers in the post combination entity. These balances did not represent any future benefit for the post combination entity. A corresponding €0.1 million expense is also reflected in the pro forma condensed combined statement of operations for the year ended December 31, 2025. |
o) | To reflect the cash settlement of €2.9 million of Deferred Underwriting Fees pursuant to terms of the underwriting agreement executed in connection with the SPAC IPO that was paid upon the consummation of the Business Combination by (i) decreasing deferred underwriting fee payable of €6.2 million and (ii) decreasing accumulated deficit of €3.3 million in the unaudited pro forma condensed combined balance sheet. Given NewHold’s additional paid-in capital was zero on the historical balance sheet as of June 30, 2026, the adjustment in equity related to the settlement of Deferred Underwriting Fees was reflected in accumulated deficit. See note 1 – Deferred Underwriting Fees. |
p) | To record the cash settlement of deferred compensation to NewHold’s executive officers of €0.7 million which was paid upon the consummation of the Business Combination by (i) eliminating the obligation related to deferred compensation – related parties of €0.6 million and (ii) increasing accumulated deficit of €0.1 million. |
q) | To reflect the recognition of additional unpaid transaction expenses, such as advisory, legal, accounting, and other professional fees, of €3.4 million incurred by NewHold through accumulated deficit by (i) decreasing trade and other receivables, net and cash of €7.3 million, (ii) decreasing trade and other payables of €4.5 million, and (iii) increasing newcleo share capital and share premium of €0.7 million for the portion of transaction costs settled through the issuance of 70,346 newcleo Ordinary Shares. |
r) | To reflect the additional forfeiture of 1,088,481 unvested shares within the $18 Tranche of the Sponsor Promote Earnout and 43,073 SPAC Private Placement Warrants as the sum of the total capital raised from the PIPE Financing and retained from the Trust Account was less than $400.0 million pursuant to the Business |
s) | To reflect the issuance of 3,206,027 newcleo Ordinary Shares related to the Sponsor Promote issuable to the Sponsor, NewHold’s directors (the “Directors”) and the Underwriter in exchange for Founder Shares and SPAC Private Placement Shares. This Sponsor Promote adjustment increases newcleo share capital at par value, a par value of $0.02288 (€0.02004 at June 30, 2026) per share, and derecognizes SPAC Class A Ordinary Shares and SPAC Class B Ordinary Shares, with a corresponding offset in share premium. |
newcleo Capital issuable to the Sponsor, the Directors and the Underwriter | |||||||||
Actual Redemption | |||||||||
Shares | Sponsor Promote Earnout | Warrants | |||||||
Sponsor’s SPAC Private Placement Shares | 552,600 | — | — | ||||||
Sponsor’s Founder Shares | 6,429,663 | — | — | ||||||
Sponsor’s SPAC Private Placement Warrants | — | — | 276,300 | ||||||
Subtotal | 6,982,263 | — | 276,300 | ||||||
SPAC Private Placement Share forfeiture, see Note 8(i) | (110,520) | — | — | ||||||
Founder Share forfeiture, see Note 8(i) | (1,285,933) | — | — | ||||||
SPAC Private Placement Warrant forfeiture, see Note 8(i) | — | — | (55,260) | ||||||
Sponsor Forfeited Equity, see Note 8(i) | (1,396,453) | — | (55,260) | ||||||
Remaining Sponsor Promote(1) | 5,585,810 | — | 221,040 | ||||||
Remaining Sponsor Promote Shares (50%) and Earnout (50%) Allocation: | |||||||||
Vested Tranche see Note 8(i)(2) | 2,792,905 | — | — | ||||||
$15 Tranche of Sponsor Promote Earnout, see Note 8(i)(3) | — | 1,396,453 | — | ||||||
$18 Tranche of Sponsor Promote Earnout, see Note 8(i)(4) | — | 1,396,452 | — | ||||||
Remaining SPAC Private Placement Warrants | — | — | 221,040 | ||||||
Subtotal | 2,792,905 | 2,792,905 | 221,040 | ||||||
$15 Tranche of Sponsor Promote Earnout forfeiture, see Note 8(r) | — | — | — | ||||||
$18 Tranche of Sponsor Promote Earnout forfeiture, see Note 8(r) | — | (1,088,481) | — | ||||||
Additional SPAC Private Placement Warrant forfeiture, see Note 8(r) | — | — | (43,073) | ||||||
Additional forfeitures, see Notes 8(i) and 8(r) | — | (1,088,481) | (43,073) | ||||||
Remaining Sponsor Promote, see Notes 8(i), 8(r) and 8(s) | 2,792,905 | 1,704,424 | 177,967 | ||||||
Founder Shares forfeited in connection with Non-Redemption Agreements, see Note 8(k) | (92,378) | — | — | ||||||
Underwriter’s SPAC Private Placement Shares, see Note 8(s) | 227,500 | — | — | ||||||
Underwriter’s SPAC Private Placement Warrants, see Note 8(s) | — | — | 113,750 | ||||||
Directors’ SPAC Class B Ordinary Shares | 278,000 | — | — | ||||||
Total | 3,206,027 | 1,704,424 | 291,717 | ||||||
(1) | Given the sum of the total capital raised from the PIPE Financing and retained from the Trust Account equaled to €282.1 million or $322.1 million, the remaining Sponsor Promote will be subject to vesting and forfeiture provisions pursuant to the terms of the Sponsor Support Agreement. |
(2) | 50% of the remaining Sponsor Promote retained at Closing will become the Vested Tranche. |
(3) | 25% of the remaining Sponsor Promote retained at Closing will become the $15 Tranche. |
(4) | 25% of the remaining Sponsor Promote retained at Closing will become the $18 Tranche. |
t) | To reflect the listing services expense of €106.9 million recognized in accordance with IFRS 2 for the excess of the deemed cost of newcleo Ordinary Shares issued by newcleo and the fair value of NewHold’s identifiable net assets at the date of the Business Combination as an increase to the accumulated deficit, with a corresponding increase recorded in share premium. The fair value of newcleo Ordinary Shares was based on the closing trade price of SPAC Class A Ordinary Shares of €7.59 or $8.67 as of September 18, 2026. |
Actual Redemption | ||||||
Shares | Amount | |||||
(in thousands of €, except share amounts) | ||||||
NewHold shareholders | ||||||
SPAC Public Shareholders, see Notes 8(h), 8(j) and 8(k) | 10,039,706 | €76,241 | ||||
Sponsor, Underwriter and Directors, see Notes 8(i), 8(j), 8(k), 8(r) and 8(s) | 3,206,027 | 24,346 | ||||
Total newcleo Ordinary Shares to be issued to NewHold shareholders | 13,245,733 | €100,587 | ||||
Fair value of Sponsor Promote Earnout (a) | 11,886 | |||||
Total fair value of share consideration | €112,473 | |||||
Net assets of NewHold as of June 30, 2026 | €174,843 | |||||
Add: Effect of Sponsor Forfeited Equity, see Note 8(i) | 47 | |||||
Add: Deferred Underwriting Fees paid from the Trust Account, see Note 8(o) | 3,303 | |||||
Add: Effect of Sponsor Forfeited Equity resulting from the total cash proceeds less than $400.0 million, see Note 8(r) | 37 | |||||
Less: Effect of recognition of warrant liability, see Note 4(b) | (8,972) | |||||
Less: Effect of actual redemption of SPAC Class A Ordinary Shares, see Note 8(h) | (95,042) | |||||
Less: Effect of the Forward Purchase Agreement, see Note 8(l) | (65,668) | |||||
Less: Derecognition of the prepaid expenses, see Note 8(n) | (132) | |||||
Less: Deferred compensation expense paid from the Trust Account, see Note 8(p) | (116) | |||||
Less: Transaction expenses paid from the Trust Account, see Note 8(q) | (2,763) | |||||
Adjusted net assets of NewHold as of June 30, 2026 | €5,537 | |||||
IFRS 2 charge for listing services | €106,936 | |||||
(a) | The estimated fair value of the Sponsor Promote Earnout is calculated using a Monte Carlo simulation. The significant assumptions utilized in estimating the fair value of Sponsor Promote Earnout include the following: (1) newcleo Ordinary Share price of $10.00 or €8.76 per share; (2) risk-free rate of 3.85%; (3) transaction date of September 21, 2026, with a maximum lock-up period covering 180 days; (4) the expected equity volatility of 109%. The Sponsor Promote Earnout estimates and inputs are subject to change as additional information becomes available and additional analyses are performed and such changes could be material once the final valuation is determined at the effective time. See note 1 – Sponsor Promote. |
u) | To reflect the aggregate issuance and sale of 21,600,000 newcleo Ordinary Shares to PIPE Investors pursuant to the PIPE Subscription Agreements, for aggregate net proceeds of €180.3 million. The proceeds of the PIPE Financing are recorded net of transaction costs of approximately €8.9 million. The issuance of newcleo Ordinary Shares in connection with the PIPE Financing is recorded at the par value of $0.02288 (€0.02004 at June 30, 2026) per share, with the remaining net proceeds of €179.9 million recorded in share premium. |
v) | To reflect i) the derecognition of €82.8 million financial liability related to the GAAP to IFRS conversion reclassification as described in note 4(a) and the removal of redemption rights for the NRA Investors as |
Adjustment impacts to NewHold’s Accumulated Deficit | Notes | NewHold’s Accumulated Deficit | ||||
(in thousands of €) | ||||||
Elimination of NewHold’s historical equity carrying value | €(11,664) | |||||
Reclassification of SPAC Warrants from equity classification from U.S. GAAP to IFRS | 4(b) | (8,972) | ||||
Recognition of the Sponsor Forfeited Equity | 8(i) | 47 | ||||
Removal of redemption rights for an investor pursuant to Non-Redemption Agreements | 8(j) | 8,627 | ||||
Recognition of the Forward Purchase Agreement | 8(l) | (300) | ||||
Derecognition of prepaid expenses | 8(n) | (132) | ||||
Cash settlement of Deferred Underwriting Fees | 8(o) | 3,303 | ||||
Cash settlement of deferred compensation expense | 8(p) | (116) | ||||
Cash settlement of unpaid transaction expenses incurred by NewHold | 8(q) | (3,420) | ||||
Recognition of additional Sponsor Forfeiture Equity | 8(r) | 37 | ||||
Total | € (12,590) | |||||
a) | To reflect the recognition of expenses to certain suppliers for services incurred subsequent to December 31, 2025, assuming the adjustment described in note 8(b) was made on January 1, 2025. |
b) | To reflect the transaction costs that are expected to be incurred by newcleo in connection with the Business Combination, such as advisory, legal, accounting and auditing fees and other professional fees, that were allocated to the newly listed but previously existing shares, assuming that the adjustment described in note 8(c) was made on January 1, 2025. |
c) | To reflect the recognition of expense related to the new D&O Insurance Policy of €2.2 million and is recorded as an adjustment to selling, general and administrative expenses, assuming that the adjustment described in note 8(e) was made on January 1, 2025. |
d) | To reflect the derecognition of €0.7 million of compensation expense associated with €2.2 million of cash bonuses paid to certain executives and employees of NewCleo Ltd., which were included within the historical accrued payable balance of €2.9 million, assuming the adjustment described in Note 8(f) had occurred on January 1, 2025. Of the total expense derecognized, €0.2 million relates to research and development expenses and €0.5 million relates to selling, general and administrative expenses. |
e) | To reflect the derecognition of investment income related to the investments held in the Trust Account as if the Business Combination had occurred on January 1, 2025. |
f) | To reflect the write-off of prepayments recognized in prepaid expenses of €0.1 million in connection with i) the D&O Insurance Policy incurred for the benefit of NewHold’s directors and officers, and ii) transfer agent fees and filing fees. Most of NewHold’s directors and officers did not continue as directors and officers in the post combination entity. These balances do not represent any future benefit for the post combination entity and are recorded as an adjustment to selling, general and administrative expenses, as if the adjustment described in note 8(n) was made on January 1, 2025. |
g) | To reflect an adjustment to eliminate administrative fee expenses and the amounts due to the Sponsor of $40,000 per month for office space and administrative and support services provided by the Sponsor. The adjustment reflects the elimination of 10 months of such expenses in the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025, and six months of such expenses in the unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2026, as if the Business Combination had occurred on January 1, 2025. |
h) | To derecognize the deferred compensation expense to NewHold’s executive officers that will be paid upon the closing of the Business Combination, as if the adjustment described in note 8(p) was made on January 1, 2025. |
i) | To reflect the stock exchange listing expense recognized, in accordance with IFRS 2, for the excess of the fair value of newcleo Ordinary Shares issued and the fair value of NewHold’s identifiable net assets acquired from the Transactions, assuming that the adjustment described in note 8(t) was made on January 1, 2025. |
j) | The pro forma basic and diluted net loss per share amounts presented in the unaudited pro forma condensed combined statement of operations are based upon the number of newcleo Ordinary Shares outstanding at Closing, as if the Transactions had occurred on January 1, 2025. For periods in which NewHold, NewCleo Ltd., or the combined company reported a net loss, diluted loss per share is the same as basic loss per share, since dilutive potential shares are not assumed to have been issued as their effect would be anti-dilutive. The calculation of weighted-average shares outstanding for pro forma basic and diluted net loss per share assumes that the shares issuable in connection with the Transactions have been outstanding for the entirety of the period presented. |
Six Months Ended June 30, 2026 | |||
Actual Redemption | |||
(in thousands of €, except share and per share amounts) | |||
Numerator: | |||
Pro forma net loss - basic and diluted | €(88,097) | ||
Denominator: | |||
Historical weight average number of newcleo Ordinary Shares outstanding | 497,532,570 | ||
newcleo Ordinary Shares issued upon Newcleo Ltd option exercises subsequent to June 30, 2026 | 941,354 | ||
newcleo Ordinary Shares issued related to the 2026 Capital Raise subsequent to June 30, 2026 | 3,947,805 | ||
newcleo Ordinary Shares issued to suppliers subsequent to June 30, 2026 | 46,341 | ||
Total newcleo Ordinary Shares outstanding prior to the Closing of the Business Combination | 502,468,070 | ||
Recapitalization Factor | 0.4807 | ||
newcleo Ordinary Shares expected to be issued to newcleo Shareholders, assuming consummation of the Business Combination as of January 1, 2025 | 241,536,401 | ||
newcleo Ordinary Shares issued to the Sponsor, the Directors and the Underwriters | 3,206,027 | ||
newcleo Ordinary Shares issued to the SPAC Public Shareholders | 9,023,548 | ||
newcleo Ordinary Shares issued to the SPAC Public Shareholders with shares subject to Non-Redemption Agreements | 1,016,158 | ||
Six Months Ended June 30, 2026 | |||
Actual Redemption | |||
(in thousands of €, except share and per share amounts) | |||
newcleo Ordinary Shares issued to the PIPE Investors | 21,600,000 | ||
newcleo Ordinary Shares issued to the capital markets advisors | 70,346 | ||
Weighted average newcleo Ordinary Shares outstanding used in basic and diluted net loss per share | 276,452,480 | ||
Pro forma net loss per share of newcleo - basic and diluted | €(0.32) | ||
Year Ended December 31, 2025 | |||
Actual Redemption | |||
(in thousands of €, except share and per share amounts) | |||
Numerator: | |||
Pro forma net loss - basic and diluted | €(270,332) | ||
Denominator: | |||
Historical weight average number of newcleo Ordinary Shares outstanding | 462,252,560 | ||
newcleo Ordinary Shares issued upon Newcleo Ltd option exercises subsequent to June 30, 2026 | 941,354 | ||
newcleo Ordinary Shares issued related to the 2026 Capital Raise subsequent to June 30, 2026 | 3,947,805 | ||
newcleo Ordinary Shares issued to suppliers subsequent to June 30, 2026 | 46,341 | ||
Total newcleo Ordinary Shares outstanding prior to the Closing of the Business Combination | 467,188,060 | ||
Estimated Recapitalization Factor | 0.4807 | ||
Estimated newcleo Ordinary Shares expected to be issued to newcleo Shareholders, assuming consummation of the Business Combination as of January 1, 2025 | 224,577,300 | ||
newcleo Ordinary Shares issued to the Sponsor, the Directors and the Underwriters | 3,206,027 | ||
newcleo Ordinary Shares issued to the SPAC Public Shareholders | 9,023,548 | ||
newcleo Ordinary Shares issued to the SPAC Public Shareholders with shares subject to Non-Redemption Agreements | 1,016,158 | ||
newcleo Ordinary Shares issued to the PIPE Investors | 21,600,000 | ||
newcleo Ordinary Shares issued to the capital markets advisors | 70,346 | ||
Weighted average newcleo Ordinary Shares outstanding used in basic and diluted net loss per share | 259,493,379 | ||
Pro forma net loss per share of newcleo - basic and diluted | €(1.04) | ||
• | Ranked #11 out of 63 SMR designs overall, with a total score of 22/36; |
• | Ranked #2 among 17 fast reactor designs globally, closely following TerraPower’s Natrium; |
• | Ranked #1 among eight European fast reactors designs; |
• | Ranked #1 among 10 French SMR designs; |
• | Ranked #1 among marine-capable fast reactors; and |
• | Positioned #2 among 19 European SMRs overall, just behind Rolls-Royce SMR and ahead of NUWARD. |
• | Existing de-risked, safe technology, with an innovative approach—Our LFR and MOX technologies are based upon decades of established nuclear engineering and operating experience, including the use of fast reactor technology, lead as a coolant and MOX fuel fabrication in existing nuclear programs. We believe this provides a de-risked technical foundation relative to technologies that depend on wholly novel physics, fuel forms or reactor concepts. At the same time, our approach applies these established principles through a modernized reactor design, modular construction model and prefabricated critical components, which we believe can reduce on-site construction complexity, support more efficient project execution, enhance design safety characteristics and provide greater siting and application flexibility compared to certain other reactor and fuel technologies. |
• | Unique, vertically integrated business model—Our capabilities span reactor design, MOX fuel manufacturing, engineering and manufacturing of key reactor components, which we believe will create revenue opportunities across the nuclear value chain. In addition to manufacturing MOX fuel for customers building and operating our LFR, we believe our manufacturing, engineering, procurement and construction management subsidiaries will enable us to generate pre-COD revenues from engineering services and key reactor components, as well as post-COD revenues from ongoing engineering, component maintenance and replacement services over the life of the LFR and MOX infrastructure. |
• | Differentiated fuel supply—Our LFR is designed to operate with MOX fuel, produced spent plutonium and/or depleted uranium, avoiding costs for natural uranium sourcing and for any enrichment services. We believe this provides us with a significant security-of-supply advantage, as the existing spent nuclear fuel can be recycled, and potentially recycled multiple times, to provide centuries’ worth of energy, exploiting a closed fuel cycle, and mitigating risks associated with market volatility and geopolitical uncertainty. |
• | Inherent benefits of fast fission power—Our LFR employs fast neutron fission technology, which is designed to use uranium and plutonium more efficiently, greatly reducing both the volume and radiotoxicity of spent nuclear material. As a result, we believe that the application areas and cost profile of power produced through our LFR technology could be competitive with that of traditional, higher emissions energy sources. |
• | Experienced and technical team led by seasoned founders—Our founders are nuclear engineers and physicists with decades-long track records of developing and deploying complex nuclear technologies, while possessing senior executive experience at publicly traded companies. Our technical leadership and engineering organization harnesses deep European scientific and engineering expertise across lead-cooled reactor technologies and MOX fuel manufacturing activities, which we plan to leverage across global markets. |
• | IP license fees for the right to use of our tightly integrated, proprietary reactor design specifications, technical documentation, engineering standards, safety systems, fuel-cycle integration concepts and know-how that are essential to plant construction and operation and cannot be replicated by third parties. IP license fees are recognized based on contractually specified project milestones. |
• | Supply of our highly specialized, reactor specific components such as LFR pumps, steam generators, vessels, shutdown and control rods, decay heat removal systems, fuel handling systems and related hardware that are produced by our partners or us, for which there are limited qualified alternative suppliers besides us. |
• | EPCM services, provided through our engineering subsidiaries and partners, with a focus on areas where we have developed technical expertise, such as nuclear-grade pump systems, liquid lead components manufacturing and operator training and commissioning support. |
• | Advisory and technical services related to site development, regulatory processes, environmental impact assessment and permitting activities. |
• | Profit-sharing arrangements dependent on our minority ownership in specific LFR projects or subject to project-specific agreements. |
• | For our owned MOX manufacturing facilities: fuel supply sales, including to newcleo and third-party operators of our LFRs, with the potential to supply traditional light-water reactors and alternative SMR designs. |
• | For third-party owned MOX manufacturing facilities: IP license fees for MOX fuel manufacturing plant technology, EPCM services, training and advisory services provided in connection with the deployment of additional MOX fuel manufacturing modules, and potential profit-share dependent on our minority ownership in specific projects. |
• | Complementary product portfolio—Our LFR and MOX activities are complementary, allowing us to provide technology and services across multiple stages of the nuclear value chain. We anticipate that prospective customers will perceive our holistic suite of services as differentiated and will pursue commercial opportunities across both product portfolios. |
• | Advantaged licensing strategy—We have initiated discussions with the NRC for both our LFR design and MOX manufacturing facility. Our track record of success with European regulators provides us with a strong basis and strategic advantage as we continue NRC engagement. |
• | Scalable, asset-light business model—We believe our focus on an IP license-based and services-oriented business model enables the accelerated and concurrent deployment of LFR and MOX manufacturing facilities with multiple partners, without requiring significant upfront capital investment. We plan on owning 20% to 100% of early LFR and MOX projects to de-risk FOAK deployment and limit project capital expenditure. This also accelerates the receipt of cash flows years ahead of COD, which helps scale our business rapidly. |
• | Developed and integrated supply chain—Through selective hiring and targeted acquisitions, we have internalized key capabilities across design, manufacturing and project execution components in the advanced nuclear space, mitigating potential supply-chain risks and delays in future deployments. |
• | Strategic partnerships—We have pursued strategic partnerships to leverage specific core competencies of other industry players to further accelerate the deployment of LFR and MOX products. We have established partnerships with several national laboratories and agencies, including the DOE’s Savannah River National Lab (pending approval by the DOE), French Alternative Energies and Atomic Energy Commission, the ENEA and the Japanese Atomic Energy Agency (“JAEA”), to enhance our R&D, licensing and fuel supply efforts. JAEA’s owns and operates Joyo, the only reactor with a high-flux fast neutron spectrum accessible in the western world. Together, we and JAEA expect to conduct irradiation tests in Joyo on structural and core materials, supporting our qualification efforts and fuel manufacturing strategy. We believe that continuing to develop strategic partnerships will enhance our technology and offering and enable us to scale rapidly. |
• | International expansion—While our current activities focus on the United States and Europe, we may evaluate opportunities in additional jurisdictions over time. Although each market has nuances around environmental reviews, authorization regimes and export compliance, our technology is adaptable to meet specific requirements in connection with the right local partner. In the United States, our near-term commercialization strategy focuses on opportunities where AI infrastructure growth, demand for firm clean power, government support for advanced nuclear and available nuclear-sector expertise may support deployment. We are pursuing this strategy through, among other initiatives, our cooperation with Oklo, our collaboration with IP3 Corporation and other partners, our response to the DOE/NNSA Savannah River Site artificial intelligence infrastructure and energy generation request for proposal and our engagement with the NRC. |
• | Mergers and acquisitions —We may selectively pursue acquisitions, investments, joint ventures or other strategic transactions that complement our existing capabilities, accelerate our technology development or deployment timelines, expand our geographic reach, strengthen our supply chain or provide access to additional technical, regulatory, manufacturing or commercial expertise. Any such transactions would be evaluated based on their strategic fit, execution feasibility and ability to support our long-term growth objectives. |
• | Commercial pipeline and U.S. deployment strategy—As of the date of this prospectus, we estimate that our commercial pipeline includes non-binding opportunities representing approximately 9.2 GW of potential aggregate LFR deployment capacity across international markets, including opportunities relating to AI infrastructure, industrial heat, utility generation and fuel-cycle applications. This pipeline does not represent contracted backlog, committed revenue or binding customer obligations. Many of these opportunities are preliminary, and their progression will depend on feasibility studies, definitive agreements, regulatory approvals, financing, site selection, customer demand, governmental support and other technical and commercial conditions. |
• | Utilities and nuclear operators—These customers include national or regional, state owned or privately owned entities responsible for operating existing nuclear infrastructure and, in some cases, developing additional nuclear generation capacity. In addition to electricity generation, these organizations have obligations related to spent fuel management, radioactive waste disposal and facility decommissioning, all of which persist over multiple decades and are subject to political scrutiny. Our offering can serve the holistic needs of these groups through the provision of power generation, future fuel supply, reduction of current nuclear liabilities, and ongoing plant optimization in a manner that is both economically compelling and politically defensible. |
• | Industrial and infrastructure energy users —These customers operate across a range of industries, including data centers, chemicals, refining, steel, cement, maritime, glass, ceramics and paper, and require both electricity and industrial heat to support their operations. Our LFR technology is intended to support applications involving electricity generation and industrial heat, including configurations designed to operate behind the meter or in islanded settings for dedicated industrial or infrastructure loads. |
• | Traditional baseload power generation—Traditional baseload generation includes natural gas, coal, oil and conventional large-scale nuclear power plants, each of which may compete on the basis of installed capacity, existing infrastructure, operating history and, in some markets, lower near-term execution risk. |
• | Renewable generation with or without storage—Wind, solar, hydroelectric and other renewable technologies, whether deployed on a standalone basis or paired with battery or other storage solutions, compete as low-carbon alternatives for utilities, industrial customers and other off-takers seeking to decarbonize their energy supply. |
• | Fossil fuel generation with carbon capture—Natural gas and other thermal generation technologies paired with carbon capture may compete as dispatchable lower-carbon alternatives, particularly where customers prioritize reliability, grid support or industrial heat applications. |
• | Other advanced nuclear technologies—A number of companies are pursuing advanced reactor and SMR technologies based on different technical approaches. These include pressurized light-water reactor technologies, such as NuScale’s Power Module; boiling water reactor technologies, such as GE Vernova Hitachi’s BWRX-300; high-temperature gas-cooled reactor technologies, such as X-energy’s Xe-100, which uses TRISO fuel; and fast reactor technologies using alternative coolants and fuel-cycle approaches, such as TerraPower’s Natrium sodium-cooled fast reactor with integrated molten-salt energy storage and Oklo’s Aurora fast reactor product line. By contrast, our approach is focused on lead-cooled fast reactor technology using MOX fuel as part of a closed fuel-cycle strategy. |
• | Nuclear Safety Directive—Council Directive 2009/71/Euratom, as amended by Council Directive 2014/87/Euratom, establishes a Community framework for the nuclear safety of nuclear installations and requires Member States to maintain national legislative, regulatory and organizational frameworks for nuclear safety, including systems of licensing and regulatory oversight. |
• | Spent Fuel and Radioactive Waste Directive—Council Directive 2011/70/Euratom establishes a Community framework for the responsible and safe management of spent fuel and radioactive waste and requires Member States to maintain national programs covering the management of these materials. |
• | Basic Safety Standards Directive—Council Directive 2013/59/Euratom lays down basic safety standards for protection against the dangers arising from exposure to ionizing radiation and is relevant to radiation protection, occupational exposure, public health and environmental monitoring. |
• | Euratom safeguards—The European Commission administers Euratom safeguards, a nuclear material supervision system established under the Euratom Treaty. A significant recent development is Commission Regulation (Euratom) 2025/974, which entered into force in July 2025 and replaced the prior safeguards regulation. Among other things, the new framework introduces “safeguards-by-design” concepts for certain complex installations, including new builds and major modifications, which may require safeguards considerations to be integrated into facility design at an early stage. |
• | Investment communications and radioactive waste opinions—Article 41 of the Euratom Treaty requires certain investment projects in the nuclear field to be communicated to the European Commission in advance, before binding investment commitments are made or, for projects carried out with an entity’s own resources, before work begins. In addition, Article 37 of the Euratom Treaty provides for Commission opinions regarding general data relating to plans for the disposal of radioactive waste where transboundary radiological impacts may be relevant. These opinions are not formally binding, but may influence national regulatory review, require additional engagement with the Commission or national regulators and affect the timing of national authorizations. These EU-level processes can operate in parallel with national authorization processes. |
• | Paris Convention—The Paris Convention on Third Party Liability in the Field of Nuclear Energy establishes a nuclear third-party liability and compensation regime for participating countries. The Paris Convention generally addresses liability for nuclear damage arising from nuclear incidents, including principles relating to the channeling of liability to the operator of a nuclear installation, financial security and jurisdiction. The Paris Convention is principally relevant in jurisdictions that are contracting parties to the Paris Convention and has been implemented through national legislation in those jurisdictions. |
• | Brussels Supplementary Convention—The Brussels Convention Supplementary to the Paris Convention provides a supplementary compensation regime for nuclear damage in participating countries. It is linked to the Paris Convention and is open only to contracting parties to the Paris Convention. The Brussels Supplementary Convention may be relevant where compensation available under the Paris Convention and applicable national law is supplemented by additional compensation tiers (including public funds) established under the convention and national implementing legislation. |
• | Vienna Convention—The Vienna Convention on Civil Liability for Nuclear Damage establishes a separate international civil liability framework for nuclear damage. The Vienna Convention is intended to harmonize the national laws of contracting parties by establishing minimum standards for financial protection against damage resulting from certain peaceful uses of nuclear energy. It may be relevant in jurisdictions that are parties to the Vienna Convention and where national implementing legislation applies to the relevant nuclear installation, activity or incident. |
• | Joint Protocol—The Joint Protocol Relating to the Application of the Vienna Convention and the Paris Convention is intended to link the Vienna Convention and Paris Convention regimes and reduce potential conflicts between them. Where applicable, the Joint Protocol may affect how liability and compensation rules apply to nuclear damage involving jurisdictions that participate in different convention regimes. |
• | Convention on Supplementary Compensation—The Convention on Supplementary Compensation for Nuclear Damage, or CSC, is intended to establish a broader supplementary compensation framework for nuclear damage. The CSC generally provides for a minimum national compensation amount and additional public funds to be made available by contracting parties if the national amount is insufficient to compensate nuclear damage. The CSC may be relevant in jurisdictions that are contracting parties and have implemented the convention through national law. |
• | France—Our principal French facilities and development sites support our MOX fuel, licensing and project-development activities. In Chusclan, France, we operate the FASTER Research and Training Center, a multifunctional non-nuclear center located in the Marcel Boiteux industrial park in Occitanie. FASTER is dedicated to the readiness of our planned MOX fuel manufacturing plant and integrates several capabilities, including a training center equipped with real operating systems and virtual-reality environments to prepare operators, experimental halls for rapid design, prototyping, testing and validation of equipment, and pre-installation and commissioning zones that allow qualification of components before their integration into the MOX fuel factory. The initial FASTER building has been acquired and is operational, and the planned FASTER 2 expansion building is under evaluation. Key capabilities associated with FASTER include HELIO, GAINA and PRIMO, including glove-box training and other fuel development and qualification activities. At Nogent-sur-Seine, France, we are also advancing the site for a planned MOX facility in France. The conceptual and basic design for the MOX fuel manufacturing plant has been completed, initial regulatory feedback has been received on the safety-options file and the site is being advanced in parallel with public debate, licensing and land-acquisition workstreams. On November 5, 2025, we were granted an option to purchase the land that will serve as the site for the Nogent plant by the local authorities. The option is irrevocable and the purchase is subject to customary conditions precedent. |
• | Italy—In Italy, our principal facility is located at the ENEA Brasimone Research Center, which supports our engineering, research, development and technology qualification activities and serves as our lead-cooled fast reactor research, development and qualification platform. Brasimone is the world’s largest center for lead-cooling technology development and qualification. Since our agreement with ENEA in 2022, we have invested approximately €81.5 million in the facility, with 30 engineers working on-site as of the date of this prospectus. Brasimone houses OTHELLO, a 2 MWt loop designed to validate key components of our LFR primary system, including the steam generator, primary pump and core, which was completed in the fourth quarter of 2025. Brasimone is also the site of PRECURSOR, a 10 MWt non-nuclear testbed designed to integrate subsystems to produce power and to be representative of commercial-scale operations, with completion anticipated by the end of 2026. PRECURSOR is intended to demonstrate overall system integration, including major non-nuclear subsystems, and to validate the thermal-hydraulic performance of our lead-cooled design. PRECURSOR’s expected primary vessel is designed to have a diameter of approximately 2.15 meters, a height of approximately 6.5 meters and approximately 104 tons of lead. |
• | Slovakia—In Slovakia, our principal development site is the retired Bohunice nuclear site, which is being advanced through our joint venture with JAVYS, the Slovak state-owned nuclear company. This joint venture contemplates the deployment of up to four LFR-AS-200 reactors at Bohunice. The site is expected to be contributed by JAVYS, and site-development work with local partners is expected to be a next step in the project. The contemplated reactors would be powered by MOX fuel using Slovakia’s spent nuclear fuel. |
• | United Kingdom, Switzerland and United States—In addition to the principal facilities and project sites described above, we maintain offices and operating entities in the United Kingdom, Switzerland and the United States, as well as additional offices and operating entities in France, Italy and Slovakia. Our corporate structure includes newcleo Generation (UK) Ltd in the United Kingdom, newcleo SA and Rütschi Fluid AG in Switzerland and newcleo Americas LLC in the United States, together with multiple operating subsidiaries in France, Italy and Slovakia. These offices and operating entities support, or are intended to support, corporate, engineering, licensing, project-development, manufacturing, supply-chain and commercial activities across our platform. |
• | Manufacturing and installation of equipment and spare parts – Revenue is recognized over time based on the extent of progress towards completion of the performance obligation, measured using the cost-to-cost method for long-term contracts relating to (i) the sales and manufacture of complex pumps and components that have a long lead time, (ii) the sales of engineered pumps customized to customer technical specifications for nuclear projects and power plants, and (iii) specialized projects for sales of militarized pumps for nuclear or conventional submarines. |
• | Consultancy Services – Revenue is recognized using a cost-to-cost input method, under which revenue is recognized based on the ratio of actual costs incurred to total estimated costs. |
For the Six Months Ended June 30, | ||||||||||||
2026 | 2025 | € Change | % Change | |||||||||
(in thousands, except percentages) | ||||||||||||
Revenue from products and services | €19,429 | €13,347 | €6,082 | 46% | ||||||||
Cost of sales | (13,299) | (9,193) | (4,106) | 45% | ||||||||
Gross Profit | 6,130 | 4,154 | 1,976 | 48% | ||||||||
Other income | 6,554 | 4,763 | 1,791 | 38% | ||||||||
Research and development expenses | (34,629) | (35,450) | 821 | -2% | ||||||||
Selling, General and Administrative expenses | (59,170) | (48,932) | (10,238) | 21% | ||||||||
Operating loss | (81,115) | (75,465) | (5,650) | 7% | ||||||||
(Loss) gain on disposal of assets | (9) | (3) | (6) | 200% | ||||||||
Finance income | 353 | 1,581 | (1,228) | -78% | ||||||||
Finance costs | (1,448) | (991) | (457) | 46% | ||||||||
Share of loss of associates | (83) | — | (83) | n/a | ||||||||
Loss before income tax | (82,302) | (74,878) | (7,424) | 10% | ||||||||
Income tax benefit (expense) | 321 | 585 | (264) | -45% | ||||||||
Net loss | €(81,981) | €(74,293) | €(7,688) | 10% | ||||||||
For the Six Months Ended June 30, | ||||||||||||
2026 | 2025 | € Change | % Change | |||||||||
(in thousands, except percentages) | ||||||||||||
Manufacturing and installation of equipment and spare parts | €14,296 | €10,992 | €3,304 | 30% | ||||||||
Consultancy services | 5,133 | 2,355 | 2,778 | 118% | ||||||||
Total revenue from products and services | €19,429 | €13,347 | €6,082 | 46% | ||||||||
For the Year Ended December 31, | ||||||||||||
2025 | 2024 | € Change | % Change | |||||||||
(in thousands, except percentages) | ||||||||||||
Revenue from products and services | €32,769 | €46,743 | €(13,974) | -30% | ||||||||
Cost of sales | (24,953) | (34,999) | 10,046 | -29% | ||||||||
Gross Profit | 7,816 | 11,744 | (3,928) | -33% | ||||||||
Other income | 19,347 | 17,746 | 1,601 | 9% | ||||||||
Research and development expenses | (68,544) | (58,473) | (10,071) | 17% | ||||||||
Selling, General and Administrative expenses | (98,547) | (86,815) | (11,732) | 14% | ||||||||
Operating loss | (139,928) | (115,798) | (24,130) | 21% | ||||||||
(Loss) gain on disposal of assets | (1,630) | 180 | (1,810) | -1,006% | ||||||||
Finance income | 1,937 | 5,232 | (3,295) | -63% | ||||||||
Change in fair value of financial assets measured at FVTPL | — | 1,798 | (1,798) | -100% | ||||||||
Finance costs | (2,120) | (1,977) | (143) | 7% | ||||||||
Share of loss of associates | (48) | — | (48) | 100% | ||||||||
Loss before income tax | (141,789) | (110,565) | (31,224) | 28% | ||||||||
Income tax benefit (expense) | 1,824 | 402 | 1,422 | 354% | ||||||||
Net loss | €(139,965) | €(110,163) | €(29,802) | 27% | ||||||||
For the Year Ended December 31, | ||||||||||||
2025 | 2024 | € Change | % Change | |||||||||
(in thousands, except percentages) | ||||||||||||
Manufacturing and installation of equipment and spare parts | €27,883 | €40,739 | €(12,856) | -32% | ||||||||
Consultancy services | 4,886 | 6,004 | (1,118) | -19% | ||||||||
Total revenue from products and services | €32,769 | €46,743 | €(13,974) | -30% | ||||||||
For the Year Ended December 31, | ||||||||||||
2025 | 2024 | € Change | % Change | |||||||||
(in thousands, except percentages) | ||||||||||||
R&D tax credits | €9,995 | €8,351 | €1,644 | 20% | ||||||||
Grant income | 8,619 | 7,006 | 1,613 | 23% | ||||||||
Other income | 733 | 2,389 | (1,656) | -69% | ||||||||
Total other income | €19,347 | €17,746 | €1,601 | 9% | ||||||||
For the Year Ended December 31, | ||||||||||||
2025 | 2024 | € Change | % Change | |||||||||
(in thousands, except percentages) | ||||||||||||
Staff costs | €(44,019) | €(32,757) | €(11,262) | 34% | ||||||||
External services | (12,919) | (19,801) | 6,882 | -35% | ||||||||
Legal and professional | (5,963) | (2,421) | (3,542) | 146% | ||||||||
Depreciation and amortization | (13,226) | (11,610) | (1,616) | 14% | ||||||||
Office costs | (5,294) | (6,029) | 735 | -12% | ||||||||
Recruitment costs | (188) | (963) | 775 | -80% | ||||||||
Advertising and promotion | (1,302) | (1,439) | 137 | -10% | ||||||||
Travel and subsistence | (3,921) | (4,219) | 298 | -7% | ||||||||
IT costs | (7,394) | (5,790) | (1,604) | 28% | ||||||||
Other costs | (4,321) | (1,786) | (2,535) | 142% | ||||||||
Selling, general and administrative expenses | €(98,547) | €(86,815) | €(11,732) | 14% | ||||||||
• | the results of research and development activities, including changes in scope, scale or workforce composition; |
• | shifts in the focus or direction of research, development or commercialization programs; |
• | competitive developments and technological advances; |
• | the cost of protecting and enforcing intellectual property rights; |
• | the length, complexity and outcome of regulatory approval and licensing processes; |
• | the cost and availability of raw materials, components and specialized services, including supply chain disruptions arising from geopolitical tensions; |
• | public perception of, or opposition to, nuclear energy developments; |
• | other costs, contingencies and risks associated with commercialization; and |
• | foreign currency exchange fluctuations, particularly given that a substantial portion of our cost base is denominated in euros. |
As of June 30, | As of December 31, | ||||||||
2026 | 2025 | 2024 | |||||||
(in thousands) | |||||||||
Senior Secured Refinancing Facility | €16,733 | €16,733 | €— | ||||||
State-guaranteed loans | 1,693 | 2,156 | 3,279 | ||||||
Unsecured Term Loans | — | — | 763 | ||||||
Total borrowings | €18,426 | €18,889 | €4,042 | ||||||
Current | €2,497 | €2,583 | €1,759 | ||||||
Non-current | 15,929 | 16,306 | 2,283 | ||||||
Total borrowings from third parties | €18,426 | €18,889 | €4,042 | ||||||
Carrying Amount | Contractual Cash Flow | Within 1 Year | Between 1 and 5 Years | Beyond | |||||||||||
(in thousands) | |||||||||||||||
Lease liabilities | €18,212 | €22,626 | €4,556 | €12,258 | €5,812 | ||||||||||
Senior Secured Refinancing Facility | 16,733 | 20,506 | 2,740 | 12,091 | 5,675 | ||||||||||
State-guaranteed loans | 1,693 | 1,930 | 671 | 1,259 | — | ||||||||||
Total | €36,638 | €45,062 | €7,967 | €25,608 | €11,487 | ||||||||||
For the Six Months Ended June 30, | For the Year Ended December 31, | |||||||||||
2026 | 2025 | 2025 | 2024 | |||||||||
(in thousands) | ||||||||||||
Net cash flows used in operating activities | €(53,687) | €(72,233) | €(119,678) | €(104,477) | ||||||||
Net cash flows from (used in) investing activities | (26,967) | (16,683) | (48,284) | 126,266 | ||||||||
Net cash flows from financing activities | 41,861 | 28,302 | 80,721 | 55,805 | ||||||||
Net change in cash and cash equivalents | €(38,793) | €(60,614) | €(87,241) | €77,594 | ||||||||
• | Expected volatility: the volatility assumption is derived from the observed share-price volatility of publicly listed companies operating in an industry comparable to us. |
• | Expected life: the expected life used in the model is adjusted for the effects of the graded vesting scheme, non-transferability, exercise restrictions, and behavioral considerations, as well as management’s best estimate of the time to a qualifying exit event. |
• | Risk-free rate: the risk-free rate applied in the valuation corresponds to the yield on U.K. government bonds, using a maturity consistent with the expected exit horizon. |
• | Expected dividend: we have never paid, and do not anticipate paying cash dividends on our Ordinary Shares. Therefore, the expected dividend yield was assumed to be zero. |
• | Fair value of our Ordinary Share: See the subsection titled “—Fair Value of Share-Based Awards” below. |
• | the lack of an active public market for our Ordinary Shares; |
• | external market conditions affecting the SMR industry and trends within the industry; |
• | our financial position, including cash and cash equivalents on hand, and our historical and forecasted performance and operating results; |
• | the likelihood of achieving a liquidity event, such as an initial public offering or sale of newcleo in light of prevailing market conditions; and |
• | the analysis of initial public offerings and the market performance of similar companies in the SMR industry |
Grant Date | Award Type | Number of Shares Subject to Awards Granted | Per Share Exercise Price of Awards | Per Share Fair Value of Ordinary Shares | Per Share Estimated Grant Date Fair Value of Awards | ||||||||||
July 1, 2025 | Stock Options | 10,712 | €0.01 | €2.85 | €2.84 | ||||||||||
July 31, 2025 | Stock Options | 45,220 | €0.01 | €2.85 | €2.84 | ||||||||||
September 1, 2025 | Stock Options | 820,978 | €0.01 | €2.85 | €2.84 | ||||||||||
October 1, 2025 | Stock Options | 92,300 | €0.01 | €2.85 | €2.84 | ||||||||||
November 1, 2025 | Stock Options | 5,000 | €0.01 | €2.85 | €2.84 | ||||||||||
November 5, 2025 | Stock Options | 116,000 | €0.01 | €2.85 | €2.84 | ||||||||||
December 1, 2025 | Stock Options | 19,549,602 | €0.01 | €2.85 | €2.84 | ||||||||||
December 1, 2025 | Restricted Stock Unit | 270,000 | n/a | €2.85 | €2.85 | ||||||||||
December 23, 2025 | Stock Options | 37,722 | €0.01 | €2.85 | €2.84 | ||||||||||
December 29, 2025 | Stock Options | 72,146 | €0.01 | €2.85 | €2.84 | ||||||||||
January 5, 2026 | Restricted Stock Units | 140,000 | n/a | €2.85 | €2.85 | ||||||||||
February 2, 2026 | Stock Options | 44,599 | €0.01 | €3.40 | €3.39 | ||||||||||
March 11, 2026 | Stock Options | 27,778 | €0.01 | €3.40 | €3.39 | ||||||||||
April 1, 2026 | Stock Options | 5,555 | €0.01 | €3.60 | €3.59 | ||||||||||
April 13, 2026 | Restricted Stock Units | 30,000 | n/a | €3.60 | €3.60 | ||||||||||
April 20, 2026 | Restricted Stock Units | 80,000 | n/a | €3.60 | €3.60 | ||||||||||
April 22, 2026 | Stock Options | 7,353 | €0.01 | €3.60 | €3.59 | ||||||||||
Grant Date | Award Type | Number of Shares Subject to Awards Granted | Per Share Exercise Price of Awards | Per Share Fair Value of Ordinary Shares | Per Share Estimated Grant Date Fair Value of Awards | ||||||||||
April 29, 2026 | Stock Options | 306,666 | €0.01 | €3.60 | €3.59 | ||||||||||
May 6, 2026 | Restricted Stock Units | 128,216 | n/a | €3.60 | €3.60 | ||||||||||
May 6, 2026 | Stock Options | 10,000 | €0.01 | €3.60 | €3.59 | ||||||||||
May 12, 2026 | Restricted Stock Units | 10,000 | n/a | €3.60 | €3.60 | ||||||||||
May 18, 2026 | Restricted Stock Units | 30,000 | n/a | €3.60 | €3.60 | ||||||||||
June 11, 2026 | Stock Options | 5,000 | €0.01 | €3.60 | €3.59 | ||||||||||
June 15, 2026 | Stock Options | 50,000 | €0.01 | €3.60 | €3.59 | ||||||||||
• | Expected volatility: the volatility assumption is derived from the observed share-price volatility of publicly listed companies operating in an industry comparable to ours. |
• | Expected life: the expected life used in the model is based on the contingent payment dates |
• | Risk-free rate: the risk-free rate applied in the valuation corresponds to the yield on French government bonds, using a maturity consistent with the expected contingent payment dates. |
• | Expected dividend: we have never paid, and do not anticipate paying, cash dividends on our ordinary shares. Therefore, the expected dividend yield was assumed to be zero. |
• | Fair value of our Ordinary Shares: the fair value of Ordinary Shares was estimated at €2.85 based on the value of our share price as of the transaction date. |
Name | Age | Position(s) | ||||
Executive Officers: | ||||||
Stefano Buono(3) | 60 | Chief Executive Officer and Director | ||||
Elisabeth Rizzotti(2) | 61 | Deputy Chief Executive Officer, Chief Operating Officer and Director | ||||
Jon Stranske | 47 | Group Chief Financial Officer | ||||
Non-Executive Directors: | ||||||
Jeffrey J. Lyash(1) | 64 | Chairman | ||||
Anne-François de Bourdoncle de Saint Salvy(2) | 72 | Director | ||||
Raffaele Petrone(3) | 61 | Director | ||||
Andrea Ruben Osvaldo Levi(2) | 62 | Director | ||||
Manfredi Lefebvre d’Ovidio de Clunières di Balsorano(3) | 73 | Director | ||||
Suzy Taherian(1) | 57 | Director | ||||
Heinz Maeusli(1) | 63 | Director | ||||
(1) | Member of the audit and risk committee. |
(2) | Member of the compensation committee. |
(3) | Member of the nominating and corporate governance committee. |
• | the Class I directors are Andrea Ruben Osvaldo Levi, Raffaele Petrone and Anne-François de Bourdoncle de Saint Salvy, and their terms will expire at the annual general meeting of shareholders in 2027; |
• | the Class II directors are Manfredi Lefebvre d’Ovidio de Clunières di Balsorano, Elisabeth Rizzotti and Suzy Taherian, and their terms will expire at the annual general meeting of shareholders in 2028; and |
• | the Class III directors are Stefano Buono, Jeffrey J. Lyash and Heinz Maeusli, and their terms will expire at the annual general meeting of shareholders in 2029. |
• | Nasdaq Rule 5605(b)(1), requiring that independent directors comprise a majority of a company’s board of directors—as allowed by the laws of England and Wales, independent directors do not comprise a majority of our board of directors; |
• | Nasdaq Rule 5605(b)(2), requiring that the independent directors have regularly scheduled meetings with only the independent directors present—the laws of England and Wales do not require that independent directors regularly have scheduled meetings at which only independent directors are present; |
• | Nasdaq Rule 5605(e)(1), requiring that a company have a nominating committee comprised solely of “independent directors” as defined by Nasdaq—as allowed by the laws of England and Wales, our nominating and corporate governance committee is not comprised solely of independent directors; |
• | Nasdaq Rules 5605(d) & (e), requiring that compensation for our executive officers and selection of our director nominees be determined by a majority of independent directors—as allowed by the laws of England and Wales, our compensation committee is not comprised solely of independent directors; |
• | Nasdaq Rule 5250(b)(3), requiring that we disclose third-party compensation of our directors or director nominees—the laws of England and Wales require only that we disclose information regarding compensation of our directors for services as a director of an undertaking that is our subsidiary and as a director of any other undertaking of which a director is appointed by virtue of our nomination (directly or indirectly) but not other third-party compensation of our directors or director nominees; |
• | Nasdaq Rule 5610, requiring that we disclose any waivers under our code of conduct within four Business Days—while have adopted a code of business conduct and ethics, English law does not require us to publicly disclose waivers from this code that have been approved by our board of directors within four Business Days, and we expect to report any such waivers in subsequent annual reports on Form 20-F; and |
• | Nasdaq Rule 5620(b), that sets forth certain requirements regarding the solicitation of proxies—English law does not have a regulatory regime for the solicitation of proxies applicable to us. |
• | appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm; |
• | evaluating and discussing with our independent registered public accounting firm their independence from management; |
• | reviewing, with our independent registered public accounting firm, the scope and results of their audit; |
• | approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm; |
• | reviewing and discussing with our independent registered public accounting firm the responsibilities, budget, and staffing of the Company’s internal audit function and any recommended changes to its scope; |
• | reviewing and discussing the results, performance and effectiveness of our internal audit function; |
• | overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the quarterly and annual financial statements that newcleo files with the SEC; |
• | overseeing our financial and accounting controls and compliance with legal and regulatory requirements; |
• | reviewing and overseeing our policies on risk assessment and risk management, including reviewing our cybersecurity and other information technology risks, controls and procedures, including our plans to mitigate cybersecurity risks and to respond to data breaches; |
• | reviewing related person transactions; and |
• | establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters. |
• | reviewing and approving the corporate goals and objectives, evaluating the performance of and reviewing and approving the compensation of our chief executive officer; |
• | in consultation with our Chief Executive Officer, overseeing an evaluation of the performance of and reviewing and setting or making recommendations to newcleo Board regarding the compensation of our other executive officers; |
• | overseeing our overall compensation structure and material benefit plans; |
• | reviewing and approving or making recommendations to newcleo Board regarding our incentive compensation and equity-based plans, policies and programs; |
• | reviewing and approving all employment agreements and severance arrangements for our executive officers; |
• | making recommendations to newcleo Board regarding the compensation of our directors; |
• | determining stock ownership guidelines for our independent directors and executive officers and monitoring compliance with such guidelines; and |
• | retaining and overseeing any compensation consultants. |
• | identifying individuals qualified to become members of newcleo Board (and its committees), consistent with criteria approved by the Board; |
• | reviewing succession planning for our Chief Executive Officer and other executive officers; |
• | periodically reviewing the newcleo Board’s leadership structure and recommending any proposed changes to newcleo Board; |
• | overseeing the process for evaluating the effectiveness of newcleo Board, its committees and each individual director; |
• | developing, evaluating and recommending to the newcleo Board a set of corporate governance guidelines applicable to us; and |
• | periodically reviewing and assessing policies, practices, risk assessments and risk management regarding corporate social responsibility and sustainability performance, including environmental, social and governance matters. |
• | certain financial institutions; |
• | dealers or traders in securities who use a mark-to-market method of tax accounting; |
• | persons holding Ordinary Shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the Ordinary Shares; |
• | persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; |
• | entities classified as partnerships or S corporations for U.S. federal income tax purposes; |
• | persons who acquire our Ordinary Shares through the exercise of an option or otherwise as compensation; |
• | tax-exempt entities, including an “individual retirement account” or “Roth IRA”; |
• | real estate investment trusts or regulated investment companies; |
• | persons that own or are deemed to own 10% or more of our shares (by vote or value); or |
• | persons holding Ordinary Shares in connection with a trade or business conducted outside of the United States. |
• | a citizen or individual resident of the United States; |
• | a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or |
• | an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. |
a. | to act in the way he or she considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole; |
b. | to avoid a situation in which he or she has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the company; |
c. | to act in accordance with the company’s constitution and only exercise his or her powers for the purposes for which they are conferred; |
d. | to exercise independent judgment; |
e. | to exercise reasonable care, skill and diligence; |
f. | not to accept benefits from a third party conferred by reason of his or her being a director or doing (or not doing) anything as a director; and |
g. | to declare any interest that he or she has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the company. |
a. | a shareholder or shareholders representing at least 5% of the total voting rights of all the shareholders having a right to vote on the resolution at the annual general meeting (excluding voting rights attached to any treasury shares); or |
b. | at least 100 shareholders with the right to vote on the resolution at the annual general meeting and each holding, on average, at least £100 of paid-up share capital. |
• | an acquisition process is conducted in an orderly manner; |
• | all our shareholders are treated equally and fairly and in a similar manner; |
• | an optimum price is achieved for our Ordinary Shares; |
• | our success would be promoted for the benefit of our shareholders as a whole; |
• | our long-term interests and those of our employees, our shareholders and business would be safeguarded; |
• | we would not suffer serious economic harm; and/or |
• | the board of directors would have time to gather relevant information and pursue appropriate strategies. |
• | the use of abusive tactics by any person in connection with such acquisition would be prevented; |
• | unequal treatment of shareholders would be prevented; |
• | an acquisition which would undervalue us would be prevented; |
• | harm to the prospects of our success for the benefit of our shareholders as a whole would be prevented; |
• | our long-term interests and those of our employees, our shareholders and our business would be safeguarded; and/or |
• | we would not suffer serious economic harm. |
• | in whole and not in part; |
• | at a price of $0.01 per Company Public Warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption; and |
• | if, and only if, the closing price of the Ordinary Shares equals or exceeds $18.00 per share, as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a Company Public Warrant as described below, for any 20 Trading Days within a 30-Trading Day period ending three Business Days before we send the notice of redemption to the holders of the Company Public Warrants. |
• | each person who is known to be the beneficial owner of more than 5% of the outstanding Ordinary Shares; |
• | each of our named executive officers or directors, and all directors and executive officers as a group. |
Number of Ordinary Shares Beneficially Owned | Percentage of Ordinary Shares Beneficially Owned | |||||
Executive Officers and Directors | ||||||
Stefano Buono(2) | 20,123,335 | 7.13% | ||||
Elisabeth Rizzotti(3) | 763,423 | 0.27% | ||||
Jon Stranske | — | — | ||||
Anne-François de Bourdoncle de Saint Salvy(4) | 34,334 | 0.01% | ||||
Manfredi Lefebvre d’Ovidio de Clunières di Balsorano(5) | 4,435,490 | 1.58% | ||||
Andrea Ruben Osvaldo Levi(6) | 4,855,070 | 1.72% | ||||
Raffaele Petrone(7) | 20,301,194 | 7.21% | ||||
Suzy Taherian | 32,000 | 0.01% | ||||
Heinz Maeusli | — | — | ||||
Jeffrey J. Lyash | — | — | ||||
All executive officers and directors as a group (ten individuals)(8) | 50,544,846 | 17.87% | ||||
Other 5% Holders | ||||||
Fin Posillipo S.p.A.(7) | 20,301,194 | 7.21% | ||||
Elysia Capital I SCSp(2) | 19,210,290 | 6.82% | ||||
Simon Fiduciaria S.p.A.(9) | 15,079,795 | 5.36% | ||||
(1) | Unless otherwise noted, the business address of each of the persons and entities listed above is 55 South Audley Street, London, W1K 2QH, United Kingdom. |
(2) | Consists of 19,210,290 Ordinary Shares held of record by Elysia Capital I SCSp, whose business address is 2 Place de Strasbourg, Luxembourg, Grand Duchy of Luxembourg, and 119,603 Ordinary Shares held of record by Stefano Buono and 793,442 Ordinary Shares issuable upon the exercise of options that are exercisable within 60 days of the date of this prospectus. Stefano Buono is the ultimate beneficial owner of Elysia Capital I SCSp and as such has sole voting and dispositive power over the Ordinary Shares held by Elysia Capital I SCSp. |
(3) | Consists of 324,472 Ordinary Shares held of record by Elisabeth Rizzotti and 438,951 Ordinary Shares issuable upon the exercise of options that are exercisable within 60 days of the date of this prospectus. |
(4) | Consists of 34,334 Ordinary Shares issuable upon the exercise of fully vested options that are exercisable by Anne-François de Bourdoncle de Saint Salvy within 60 days of the date of this prospectus. |
(5) | Consists of 4,435,490 Ordinary Shares held through Emmeplus Limited, over which Mr. Lefebvre has sole ultimate investment and voting power. |
(6) | Consists of 3,749,460 Ordinary Shares held through Parabensa S.R.L. and 1,105,610 Ordinary Shares held through Dal 1802 Educazione Cultura Salute Ambiente Tecnologia S.R.L. |
(7) | Consists of 20,301,194 Ordinary Shares held of record by Fin Posillipo S.p.A., whose business address is Viale della Liberazione 111, Napoli (NA), 80125 Italy. Raffaele Petrone is the ultimate beneficial owner of Fin Posillipo S.p.A. and as such has sole voting and dispositive power over the Ordinary Shares held by Fin Posillipo S.p.A. |
(8) | Consists of 49,278,119 Ordinary Shares beneficially owned by our executive officers and directors and 1,266,727 Ordinary Shares issuable upon the exercise of options held by our executive officers and directors that are exercisable within 60 days of the date of this prospectus. |
(9) | Consists of 15,079,795 Ordinary Shares held of record by Simon Fiduciaria S.p.A., whose business address is Via Giannone 10, 10121 Turin, Italy. Simon Fiduciaria S.p.A holds such shares in a fiduciary or nominee capacity for the benefit of certain underlying investors and not for the account of any single controlling person. The underlying investors retain the right to direct the voting and disposition of the Ordinary Shares held by Simon Fiduciaria S.p.A for their respective accounts, and Simon Fiduciaria S.p.A acts in accordance with such instructions. Accordingly, no individual person is known by the Company to have or share voting or dispositive power over all of the Ordinary Shares held of record by Simon Fiduciaria S.p.A. No underlying investor for whom Simon Fiduciaria S.p.A holds Ordinary Shares beneficially owns more than 5% of the Ordinary Shares outstanding. |
• | up to 4,910,451 Ordinary Shares issued to the Sponsor, BTIG and certain directors of SPAC in exchange for SPAC Ordinary Shares. These Ordinary Shares are subject to lock-up restrictions under the Sponsor Support Agreement and are entitled to resale registration under the Registration Rights Agreement; |
• | up to 5,410,058 Ordinary Shares issued to Pre-PIPE Investors and Post-PIPE Investors in connection with certain capital raises carried out by the Company in March, April and July 2026; |
• | up to 21,600,000 Ordinary Shares issued to the PIPE Investors pursuant to PIPE Subscription Agreements at a purchase price of $10.00 per share; |
• | up to 168,237,194 Ordinary Shares held by RRA Shareholders. Certain of these shares are subject to lock-up restrictions under the Lock-up Arrangements and are entitled to resale registration under the Registration Rights Agreement. |
• | up to 17,677,233 Ordinary Shares issuable upon the conversion of Class B Shares held by certain Selling Securityholders. The Class B Shares will convert into Ordinary Shares only if the applicable volume weighted average price vesting conditions of are satisfied (as described in Certain Relationships and Related Person Transactions—Transactions Related to the Business Combination—Business Combination Agreement—Earnout Arrangements”). None of those conditions has been satisfied as of the date of this prospectus and they may never be satisfied, in which case no Ordinary Shares will be issued in respect of the Class B Shares. |
Ordinary Shares Beneficially Owned Prior to the Offering | Ordinary Shares to be Sold in the Offering | Ordinary Shares Beneficially Owned After the Offering | ||||||||||||||||
Name of Selling Securityholder(1) | Number | % | Number | % | Number | % | ||||||||||||
26 Worldwide S.C.I.(2) | 118,972 | 0.04 | 108,972 | 90.75 | 10,000 | * | ||||||||||||
3i, LP(3) | 100,000 | 0.04 | 100,000 | 100.00 | — | — | ||||||||||||
Abdulai Daribi(4) | 35,014 | 0.01 | 27,804 | 77.35 | 7,210 | * | ||||||||||||
Adolfo Fucci(5) | 138,008 | 0.04 | 128,008 | 92.03 | 10,000 | * | ||||||||||||
Andrea Ruben Osvaldo Levi(6) | 5,340,577 | 1.72 | 5,340,577 | 100.00 | — | — | ||||||||||||
Antomuca S.L.(7) | 31,450 | 0.01 | 31,450 | 100.00 | — | — | ||||||||||||
Antonio Briscese(8) | 12,896 | * | 12,896 | 100.00 | — | — | ||||||||||||
Art S.r.l.(9) | 63,358 | 0.02 | 63,358 | 100.00 | — | — | ||||||||||||
Audentia Capital SICAV-RAIF – Stonewake Capital Fund(10) | 500,000 | 0.18 | 500,000 | 100.00 | — | — | ||||||||||||
Aura Consulting S.r.l.(11) | 158,631 | 0.05 | 158,631 | 100.00 | — | — | ||||||||||||
Avior S.A.(12) | 72,450 | 0.02 | 72,450 | 100.00 | — | — | ||||||||||||
AZ Allocation – Trend(13) | 450,000 | 0.16 | 450,000 | 100.00 | — | — | ||||||||||||
AZ Equity – Future Opportunities(14) | 50,000 | 0.02 | 50,000 | 100.00 | — | — | ||||||||||||
Azimut Direct Investment Newcleo SCSp(15) | 7,050,266 | 2.28 | 7,040,266 | 99.84 | 10,000 | * | ||||||||||||
BE International Equities SIF SICAV(16) | 106,409 | 0.04 | 106,409 | 100.00 | — | — | ||||||||||||
BF & F S.r.l.(17) | 8,812,832 | 2.85 | 8,802,832 | 99.88 | 10,000 | * | ||||||||||||
Bigfoot Investments LLC(18) | 1,000,000 | 0.36 | 1,000,000 | 100.00 | — | — | ||||||||||||
Blackstone Aqua Master Sub-Fund, a sub-fund of Blackstone Global Master Fund ICAV.(19) | 1,000,000 | 0.36 | 1,000,000 | 100.00 | — | — | ||||||||||||
Blockstream Capital Holdings(20) | 14,918,112 | 4.82 | 14,918,112 | 100.00 | — | — | ||||||||||||
Blu Acquario Prima S.p.A.(21) | 2,734,199 | 0.88 | 2,724,199 | 99.60 | 10,000 | * | ||||||||||||
Bluehold 5 Ltd(22) | 6,482,327 | 2.09 | 6,472,327 | 99.83 | 10,000 | * | ||||||||||||
Brian Pierre Mathis(23) | 32,000 | 0.01 | 32,000 | 100.00 | — | — | ||||||||||||
Brookers S.p.A.(24) | 63,358 | 0.02 | 63,358 | 100.00 | — | — | ||||||||||||
BTIG, LLC(25) | 341,250 | 0.12 | 341,250 | 100.00 | — | — | ||||||||||||
Burkehill Master Fund LP(26) | 500,000 | 0.18 | 500,000 | 100.00 | — | — | ||||||||||||
Carlo Roccio(27) | 31,781 | 0.01 | 21,781 | 65.39 | 10,000 | * | ||||||||||||
Carlo Tassara S.p.A.(28) | 370,139 | 0.12 | 360,139 | 97.03 | 10,000 | * | ||||||||||||
Céline Laurence Fabienne Viviant(29) | 14,642 | * | 13,055 | 88.08 | 1,587 | * | ||||||||||||
Claudia Maria Bertoni(30) | 31,450 | 0.01 | 31,450 | 100.00 | — | — | ||||||||||||
Cornelis Marinus Pieter Vrins(31) | 88,826 | 0.03 | 78,826 | 87.81 | 10,000 | * | ||||||||||||
Crossfid S.p.A.(32) | 279,072 | 0.09 | 269,072 | 96.06 | 10,000 | * | ||||||||||||
Davide Gerbaudo(33) | 65,773 | 0.02 | 55,773 | 83.28 | 10,000 | * | ||||||||||||
Denis Etienne François Enz(34) | 480,261 | 0.16 | 470,261 | 97.71 | 10,000 | * | ||||||||||||
Ordinary Shares Beneficially Owned Prior to the Offering | Ordinary Shares to be Sold in the Offering | Ordinary Shares Beneficially Owned After the Offering | ||||||||||||||||
Name of Selling Securityholder(1) | Number | % | Number | % | Number | % | ||||||||||||
DMG Partners S.r.l.s.(35) | 12,896 | * | 12,896 | 100.00 | — | — | ||||||||||||
Dockside Fund I LP(36) | 51,895 | 0.02 | 51,895 | 100.00 | — | — | ||||||||||||
Duneane Asset Management Ltd(37) | 120,972 | 0.04 | 110,972 | 90.91 | 10,000 | * | ||||||||||||
Ecoline S.r.l.(38) | 541,509 | 0.18 | 541,509 | 100.00 | — | — | ||||||||||||
Elisabeth Rizzotti(39) | 356,919 | 0.12 | 356,919 | 100.00 | — | — | ||||||||||||
Energy Investimenti S.r.l.(40) | 109,461 | 0.04 | 99,461 | 89.95 | 10,000 | * | ||||||||||||
Enrico Maria Pecchio(41) | 12,896 | * | 12,896 | 100.00 | — | — | ||||||||||||
Erminia Leonardi(42) | 304,042 | 0.10 | 294,042 | 96.38 | 10,000 | * | ||||||||||||
Ettore Carello(43) | 31,450 | 0.01 | 31,450 | 100.00 | — | — | ||||||||||||
Eurofinim S.r.l.(44) | 48,324 | 0.02 | 38,324 | 77.24 | 10,000 | * | ||||||||||||
EVRG 18, LP(45) | 5,199,571 | 1.68 | 5,189,571 | 99.79 | 10,000 | * | ||||||||||||
EXTERNEQ 1 LP(46) | 326,200 | 0.12 | 326,200 | 100.00 | — | — | ||||||||||||
Fidim S.p.A.(47) | 7,050,266 | 2.28 | 7,040,266 | 99.84 | 10,000 | * | ||||||||||||
Fior Di Loto S.C.P.(48) | 5,160,392 | 1.67 | 5,150,392 | 99.79 | 10,000 | * | ||||||||||||
Flavio Del Monte(49) | 18,184 | * | 13,377 | 70.92 | 4,807 | * | ||||||||||||
Fleurance Investissement S.C.(50) | 31,781 | 0.01 | 21,781 | 65.39 | 10,000 | * | ||||||||||||
Francesco Manniello(51) | 89,890 | 0.03 | 79,890 | 87.76 | 10,000 | * | ||||||||||||
Francesco Sassu(52) | 12,896 | * | 12,896 | 100.00 | — | — | ||||||||||||
Futura S.S.(53) | 37,013 | 0.01 | 27,013 | 70.28 | 10,000 | * | ||||||||||||
Gaudenzio Roveda(54) | 6,213,047 | 2.01 | 6,203,047 | 99.82 | 10,000 | * | ||||||||||||
Giovanni Sapone(55) | 32,254 | 0.01 | 22,254 | 65.90 | 10,000 | * | ||||||||||||
Graham Credit Opportunities Ltd.(56) | 245,300 | 0.09 | 245,300 | 100.00 | — | — | ||||||||||||
Graham Macro Strategic Ltd.(57) | 1,984,700 | 0.70 | 1,984,700 | 100.00 | — | — | ||||||||||||
Guido Giletta(58) | 209,392 | 0.07 | 199,392 | 94.75 | 10,000 | * | ||||||||||||
Healthcap S.r.l.(59) | 383,357 | 0.12 | 373,357 | 97.13 | 10,000 | * | ||||||||||||
HIF Solitude Ltd(60) | 176,310 | 0.06 | 176,310 | 100.00 | — | — | ||||||||||||
Hofima S.p.A.(61) | 9,234,573 | 2.98 | 9,224,573 | 99.88 | 10,000 | * | ||||||||||||
Ilusa S.r.l.(62) | 79,465 | 0.03 | 69,465 | 86.16 | 10,000 | * | ||||||||||||
James Matthew Yerbic(63) | 32,000 | 0.01 | 32,000 | 100.00 | — | — | ||||||||||||
K-On Energy S.r.l.(64) | 83,828 | 0.03 | 83,828 | 100.00 | — | — | ||||||||||||
Kibotion S.r.l.(65) | 644,840 | 0.21 | 644,840 | 100.00 | — | — | ||||||||||||
Kryger Enhanced Master Fund(66) | 184,928 | 0.07 | 184,928 | 100.00 | — | — | ||||||||||||
Kryger Event Master Fund(67) | 115,072 | 0.04 | 115,072 | 100.00 | — | — | ||||||||||||
LIFTT S.C.A.(68) | 2,559,129 | 0.83 | 2,549,129 | 99.57 | 10,000 | * | ||||||||||||
Lorenz Di Mattioli Alvaro S.S.(69) | 12,954 | * | 12,954 | 100.00 | — | — | ||||||||||||
Luciano Cinotti(70) | 5,837,620 | 1.88 | 5,827,620 | 99.81 | 10,000 | * | ||||||||||||
Luisa Carena(71) | 50,726 | 0.02 | 40,726 | 78.32 | 10,000 | * | ||||||||||||
Luleo S.A.(72) | 9,234,573 | 2.98 | 9,224,573 | 99.88 | 10,000 | * | ||||||||||||
LuminArx Opportunistic Alternative Solutions Holdings II Fund LP(73) | 168,067 | 0.06 | 168,067 | 100.00 | — | — | ||||||||||||
LuminArx Pavo Holdings II LP(74) | 57,828 | 0.02 | 57,828 | 100.00 | — | — | ||||||||||||
Manfredi Lefebvre d’Ovidio de Clunières di Balsorano(75) | 4,761,539 | 1.58 | 4,761,539 | 100.00 | — | — | ||||||||||||
Marco Aria(76) | 42,245 | 0.02 | 32,245 | 76.33 | 10,000 | * | ||||||||||||
Marie Helene Polo(77) | 177,137 | 0.06 | 167,137 | 93.79 | 10,000 | * | ||||||||||||
Mario Felicetti(78) | 32,103 | 0.01 | 22,103 | 65.74 | 10,000 | * | ||||||||||||
Merewether Investment Management, LP as investment adviser to Merewether Cyclicals Master Fund, LP(79) | 1,806,070 | 0.64 | 1,806,070 | 100.00 | — | — | ||||||||||||
Merewether Investment Management, LP as investment adviser to Merewether Energy Transformation Master Fund, Ltd.(80) | 315,835 | 0.11 | 315,835 | 100.00 | — | — | ||||||||||||
Ordinary Shares Beneficially Owned Prior to the Offering | Ordinary Shares to be Sold in the Offering | Ordinary Shares Beneficially Owned After the Offering | ||||||||||||||||
Name of Selling Securityholder(1) | Number | % | Number | % | Number | % | ||||||||||||
MGM S.r.l.(81) | 79,902 | 0.03 | 69,902 | 86.23 | 10,000 | * | ||||||||||||
MI Capital S.r.l.(82) | 365,410 | 0.12 | 365,410 | 100.00 | — | — | ||||||||||||
Mimosa Beck Peccoz(83) | 31,838 | 0.01 | 21,838 | 65.45 | 10,000 | * | ||||||||||||
Mission Pure Alpha Master LP(84) | 223,690 | 0.08 | 223,690 | 100.00 | — | — | ||||||||||||
MMCAP International Inc. SPC(85) | 3,000,000 | 1.07 | 3,000,000 | 100.00 | — | — | ||||||||||||
MMF LT, LLC(86) | 200,000 | 0.07 | 200,000 | 100.00 | — | — | ||||||||||||
Moore Global Investments, LLC(87) | 400,000 | 0.14 | 400,000 | 100.00 | — | — | ||||||||||||
Navig S.A.S.(88) | 1,179,157 | 0.38 | 1,169,157 | 99.07 | 10,000 | * | ||||||||||||
NewHold Industrial Technology III, LLC(89) | 4,582,918 | 1.63 | 4,582,918 | 100.00 | — | — | ||||||||||||
Nextchem S.p.A.(90) | 12,166,171 | 4.09 | 12,166,171 | 100.00 | — | — | ||||||||||||
Nicola Treves(91) | 12,896 | * | 12,896 | 100.00 | — | — | ||||||||||||
Novacapital S.r.l.(92) | 5,640,212 | 1.82 | 5,630,212 | 99.80 | 10,000 | * | ||||||||||||
Octium Life DAC(93) | 5,287,700 | 1.71 | 5,277,700 | 99.79 | 10,000 | * | ||||||||||||
Padmanee Sharma(94) | 25,000 | * | 25,000 | 100.00 | — | — | ||||||||||||
PB Investment Ltd(95) | 293,760 | 0.09 | 293,760 | 100.00 | — | — | ||||||||||||
Philip Horlock(96) | 100,000 | 0.04 | 100,000 | 100.00 | — | — | ||||||||||||
Philippe Jabre(97) | 134,073 | 0.04 | 134,073 | 100.00 | — | — | ||||||||||||
Piergiorgio Strata(98) | 99,878 | 0.03 | 89,878 | 88.99 | 10,000 | * | ||||||||||||
Pietro Quaranta(99) | 42,517 | 0.01 | 42,517 | 100.00 | — | — | ||||||||||||
Pietro Sorrentino(100) | 169,206 | 0.05 | 169,206 | 100.00 | — | — | ||||||||||||
Prando S.r.l.(101) | 44,612 | 0.01 | 34,612 | 75.34 | 10,000 | * | ||||||||||||
Principal Global Multi-Strategy Fund(102) | 454 | * | 454 | 100.00 | — | — | ||||||||||||
Quantum Containment Systems LLC(103) | 1,000,000 | 0.36 | 1,000,000 | 100.00 | — | — | ||||||||||||
Raffaele Petrone(104) | 22,331,313 | 7.21 | 22,331,313 | 100.00 | — | — | ||||||||||||
Reaves Utility Income Fund(105) | 4,500,000 | 1.60 | 4,500,000 | 100.00 | — | — | ||||||||||||
Renilde Joanna J. Vanden Broeck(106) | 16,421 | * | 13,216 | 78.53 | 3,205 | * | ||||||||||||
Ro.Ro Società Semplice(107) | 4,362,352 | 1.41 | 4,352,352 | 99.75 | 10,000 | * | ||||||||||||
Roberto Italia(108) | 158,631 | 0.05 | 158,631 | 100.00 | — | — | ||||||||||||
Romolo Bardin(109) | 115,023 | 0.04 | 105,023 | 90.44 | 10,000 | * | ||||||||||||
Scott Philip Scharfman(110) | 32,000 | 0.01 | 32,000 | 100.00 | — | — | ||||||||||||
Sebco Investment Group Ltd(111) | 557,529 | 0.18 | 547,529 | 98.03 | 10,000 | * | ||||||||||||
Sezaneh Taherian(112) | 32,000 | 0.01 | 32,000 | 100.00 | — | — | ||||||||||||
Sforzesca Investimenti S.r.l.(113) | 39,657 | 0.01 | 29,657 | 72.26 | 10,000 | * | ||||||||||||
Silvia Fiorucci(114) | 4,758,930 | 1.54 | 4,748,930 | 99.77 | 10,000 | * | ||||||||||||
Simon Fiduciaria S.p.A.(115) | 16,587,774 | 5.36 | 16,577,774 | 99.93 | 10,000 | * | ||||||||||||
Stefano Buono(116) | 21,262,882 | 6.87 | 21,262,882 | 100.00 | — | — | ||||||||||||
The European Organization for Nuclear Research for the benefit of its Pension Fund(117) | 676,623 | 0.17 | 676,623 | 100.00 | — | — | ||||||||||||
The Merger Fund(118) | 40,808 | 0.01 | 40,808 | 100.00 | — | — | ||||||||||||
The Merger Fund VL(119) | 423 | * | 423 | 100.00 | — | — | ||||||||||||
Thomas J. Sullivan(120) | 50,000 | 0.02 | 50,000 | 100.00 | — | — | ||||||||||||
Tiziana Giletta(121) | 35,337 | 0.01 | 25,337 | 68.87 | 10,000 | * | ||||||||||||
Tosca Focus(122) | 500,000 | 0.18 | 500,000 | 100.00 | — | — | ||||||||||||
Unico S.r.l.(123) | 33,573 | 0.01 | 23,573 | 67.24 | 10,000 | * | ||||||||||||
Virtus Westchester Credit Event Fund(124) | 693 | * | 693 | 100.00 | — | — | ||||||||||||
Vox Sualem S.r.l.(125) | 63,452 | 0.02 | 53,452 | 82.66 | 10,000 | * | ||||||||||||
Xantium Partners L.P.(126) | 500,000 | 0.18 | 500,000 | 100.00 | — | — | ||||||||||||
XS Consulting S.r.l.(127) | 113,921 | 0.04 | 113,921 | 90.34 | 10,000 | * | ||||||||||||
(*) | Represents beneficial ownership of less than 0.01% of the outstanding Ordinary Shares. |
(1) | In calculating the percentages of Ordinary Shares outstanding, (a) the numerator is calculated by adding the number of Ordinary Shares held by such beneficial owner and the number of Ordinary Shares issuable upon the exercise of Company Warrants or NextChem Warrants held by such beneficial owner (if any); and (b) the denominator is calculated by adding the total aggregate number of Ordinary Shares outstanding and the number of Ordinary Shares issuable upon the exercise of Company Warrants or NextChem Warrants held by such beneficial owner, if any (but not the number of Ordinary Shares issuable upon the exercise of Company Warrants or NextChem Warrants held by any other beneficial owner). The number of Ordinary Shares shown for each Selling Securityholder in the columns captioned “Ordinary Shares Beneficially Owned Prior to the Offering” and “Ordinary Shares to be Sold in the Offerin”” includes Ordinary Shares issuable upon the conversion of Class B Shares held by such Selling Securityholder. Such Class B Shares will convert into Ordinary Shares only upon satisfaction of the volume weighted average price vesting conditions of $15.00 and $18.00 per Ordinary Share (as described in Certain Relationships and Related Person Transactions—Transactions Related to the Business Combination—Business Combination Agreement—Earnout Arrangements”), none of which has been satisfied as of the date of this prospectus, and may never convert. The percentages shown in the table are calculated by reference to the 281,534,950 Ordinary Shares outstanding as of the date of this prospectus and do not give effect to the conversion of any Class B Shares. |
(2) | 26 Worldwide S.C.F. is a family-owned French civil-law company (société civile familaile) registered and based in Saint-Barthelemy. France. Balbinc Ducray. co-manager and director or26 WORLDWIDE S.C.F ., has voting and investment control over the Registrable Securities. Eric Moulin acts as the local relationship manager for 26 Worldwide S.C.I. and does not exercise independent voting or dispositive control over the Registrable Securities. ODDO 13HF provides portfolio management and custody services only and does not exercise independent voting or dispositive control over the Registrable Securities. The registered address of 26 Worldwide S.C.I. is 2 rue des Normands, 97133 St Barthélemy. |
(3) | 3i Management LLC is the general partner of 3i, LP, and Maier Joshua Tarlow is the manager of 3i Management LLC. As such, Mr. Tarlow exercises sole voting and dispositive power over securities beneficially owned directly or indirectly by 3i, LP and 3i Management LLC. Mr. Tarlow disclaims beneficial ownership of the securities beneficially owned directly by 3i, LP and indirectly by 3i Management LLC. The business address of each of the aforementioned parties is 2 Wooster Street, 2nd Floor, New York, NY 10013. We have been advised that none of Mr. Tarlow, 3i Management LLC or 3i, LP is a member of the Financial Industry Regulatory Authority (“FINRA”) or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. |
(4) | The registered address of Abdulai Daribi is 885 Rue Jean de Gingin, Divonne-Les-Bains, 1220, France. |
(5) | The registered address of Adolfo Fucci is 294 Route De Meyrin, 1217 Meyrin, Switzerland. |
(6) | Consists of 1,105,610 Ordinary Shares held through Dal 1802 Educazione Cultura Salute Ambiente Tecnologia S.r.l. and 3,749,460 Ordinary Shares held through Parabensa S.r.l. (comprising 1,345,960 Ordinary Shares and 2,403,500 Ordinary Shares) and 485,507 Class B Shares. Dal 1802 Educazione Cultura Salute Ambiente Tecnologia S.R.L. is a corporation and Andrea Ruben Osvaldo Levi is the only director that has the power to vote and dispose of the Shares.The registered address of Dal 1802 Educazione Cultura Salute Ambiente Tecnologia S.r.l. is Corso Massimo d’Azeglio, 21, 10126, Torino (TO), Italy. Parabensa S.R.L. is a corporation and Andrea Ruben Osvaldo Levi is the only director that has the power to vote and dispose of the Shares. The registered address of Parabensa S.r.l. is Corso d’Azeglio, 21, 10126, Torino (TO), Italy. |
(7) | Ricardo Iglesias and family are the shareholders of Antomuca SL. The registered address of Antomuca S.L. is Calle Villanueva, 8 bj-iz, Madrid, 28001, Spain. |
(8) | The registered address of Antonio Briscese is Strada Corini 4B, 12050 Roddino (CN), Italy. |
(9) | The shares are held of record by Art S.r.l., a limited liability company (società a responsabilità limitata) incorporated under the laws of Italy, with its registered office at Via Vincenzo Gioberti 8, 20123 Milan, Italy. The board of directors of ART S.R.L. is composed of two members: Arturo Vicari, who serves as Chairman of the board of directors and to whom all powers of ordinary and extraordinary administration have been granted pursuant to a resolution of the board of directors dated December 12, 2024, and Manfredi Vianini Tolomei, who serves as a director and is authorized to exercise the powers of the Chairman in the event of the Chairman’s absence or incapacity. Each of Arturo Vicari and Manfredi Vianini Tolomei may therefore be deemed to share voting and dispositive power over the Registrable Securities held by Art S.r.l. The registered address of Art S.r.l. is Via Vincenzo Gioberti, 8, 20123 Milano (MI), Italy. |
(10) | Audentia Capital SICAV-RAIF – Stonewake Capital Fund is a corporation and its board of directors has the power to vote and dispose of the Shares. The board of directors is composed of three individuals named Alex Vilchez, Luka Vlahovic, and Ivaylo Markov. The registered address of Audentia Capital SICAV-RAIF – Stonewake Capital Fund is 7 Rue Lou Hemmer, Senningerberg L-1748, Luxemberg. |
(11) | Aura Consulting S.r.l. and its board of directors have the power to vote and dispose of the shares. The registered address of Aura Consulting S.r.l. is Via della Repubblica, 8, 40046 Alto Reno Terme (BO), Italy. |
(12) | The registered address of Avior S.A. is Rue Eugene Ruppert, 11, L-2453 Luxembourg, Luxembourg. |
(13) | AZ Allocation - Trend is a sub-fund of an umbrella structure. Voting and investment control over the Ordinary Shares held by AZ Allocation - Trend is exercised by Azimut Investments S.A., its management company, acting through its board of directors. |
(14) | AZ Equity - Future Opportunities is a sub-fund of an umbrella structure. Voting and investment control over the Ordinary Shares held by AZ Equity - Future Opportunities is exercised by Azimut Investments S.A., its management company, acting through its board of directors. |
(15) | Azimut Direct Investment Newcleo SCSp is a Luxembourg Special Limited Partnership (SCSp). The General Partner is Azimut Private Capital Managements s.à r.l. and the Alternative Investment Fund Manager (AIFM) of the Selling Shareholder is Azimut Investments S.A., a Luxembourg management company authorized and regulated by the Commission de Surveillance du Secteur Financier (CSSF). Voting and investment power over the Ordinary Shares held by Azimut Direct Investment Newcleo SCSp is exercised by Azimut Investments S.A., acting through its Board of Directors and authorized signatories, including Salvatore Andrea Sberna (Head of Alternative Investments & Conducting Officer). The registered address of Azimut Direct Investment Newcleo SCSP is 2a, Rue Eugène Ruppert, 2453 Luxembourg, Luxembourg. |
(16) | BEIE GP S.a r.l. is the general partner of BE International Equities SIF SICAV, a Luxembourg specialised investment fund managed by its board of directors, and has the sole voting and dispositive power over the Ordinary Shares held by BE International Equities SIF SICAV. |
(17) | BF&F S.r.l. is a company incorporate under Italian law. The board of directors of BF&F S.r.l. has power to vote and dispose of the shares. The registered address of BF&F S.r.l. is Stradello Marche, 6, 43121, Parma (PR), Italy. The members of the board of directors of BF&F Srl are as follows: Francesco Bormioli born in Milano on 25 March 1964 (President), Leonardo Bormioli born in Milano on 8 January 1994 (CEO) Agata Bormioli born in Milano on 26 October 1996 (Director). The registered address of BF& F S.r.l. is Stradello Marche, 6, 43121 Parma (PR), Italy. |
(18) | Bigfoot Investments LLC is a Delaware limited liability company. Oklo Inc., a Delaware corporation publicly traded on the New York Stock Exchange, is the sole member of Bigfoot Investments LLC and may be deemed the beneficial owner of the securities. |
(19) | Reflects securities held directly by Blackstone Aqua Master Sub-Fund, a sub-fund of Blackstone Global Master Fund ICAV (the “Aqua Fund”). Blackstone Alternative Solutions L.L.C. is the investment manager of the Aqua Fund. Blackstone Holdings I L.P. is the sole member of Blackstone Alternative Solutions L.L.C. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone Holdings I L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C. Blackstone Group Management L.L.C. is the sole holder of the Series II preferred stock of Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities and Mr. Schwarzman may be deemed to beneficially own the securities beneficially owned by the Aqua Fund directly or indirectly controlled by it or him, but each (other than the Aqua Fund to the extent of its direct holdings) disclaims beneficial ownership of such securities. The contact information of each of the entities listed in this Rider A is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154; BXMAAquaFundOps@blackstone.com; 646-313-6718. |
(20) | Consists of 13,561,920 Ordinary Shares and 1,356,192 Class B Shares held of record by Blockstream Capital Holdings. Blockstream Capital Holdings is a Cayman Islands Company limited by shares. The Board of Directors of Blockstream Capital Holdings has the power to vote and dispose of the shares. The Board of Directors of Blockstream Capital Holdings is comprised of Oleg Mikhalskiy and PeterPaul Pardi. The registered address of Blockstream Capital Holdings is c/o Hermes Corporate Services Ltd., P.O. Box 31493, Fifth Floor, Zephyr House, 122 Mary Street, George Town, Grand Cayman, KY1-1206, Cayman Islands. |
(21) | The ordinary shares are held of record by Blu Acquario Prima S.p.A. (“BAP”), a joint stock company (societa per azioni) incorporated under the laws of Italy, with registered office at Via E. de Sonnaz, 19, 10121, Torino, Italy. Voting and investment power with respect to the ordinary shares held by BAP is exercised by BAP’s board of directors, which is composed of Mr. Marco Drago (Managing Director), Mr. Enrico Drago (Director) and Mr. Nicola Drago (Director). The only beneficial owner of Blu Acquario Prima S.p.A. is Mr. Marco Drago. The registered address of Blu Acquario Prima S.p.A. is Via E. de Sonnaz, 19, 10121, Torino Italy. |
(22) | Bluehold 5 Ltd is a corporation and the director has the power to vote and dispose of the shares. The sole director is Nigel Rowley. The registered address of Bluehold 5 Ltd is Conyers Trustee Services (BVI) Limited, Commerce House, Wickhams Cay 1, P.O. Box 3140, Road Town, Tortola, VG1110, British Virgin Islands. |
(23) | The registered address of Brian Pierre Mathis is c/o NewHold Investment Corp III, 52 Vanderbilt Avenue, Suite 2005 New York, NY 10017. |
(24) | The shares are held of record by Brookers S.p.A., a privately held company (societa per azioni) incorporated under the laws of Italy, with its registered office at Via Emilia S. Pietro 34, 42121 Reggio Emilia (RE), Italy. The Board of directors of Brookers S.p.A. is composed of one member: Macchiaverna Alfredo, who serves as sole director of the company and to whom all powers of ordinary and extraordinary administration have been granted pursuant to a resolution of the board of directors dated 28th June 2022. Macchiaverna Alfredo may therefore be deemed to share voting and dispositive power over the Registrable Securities held by Brookers S.p.A. The registered address of Brookers S.p.A. is Via Emilia San Pietro, 34, 42121 Reggio Emilia (RE), Italy. |
(25) | Consists of 227,500 Ordinary Shares and 113,750 Company Private Warrants. Anton Leroy, in his capacity as Chief Executive Officer of BTIG, LLC may be deemed to have voting and investment control with respect to the shares held by BTIG, LLC, and therefore may be deemed to be the beneficial owner of such shares. The principal address of BTIG, LLC is 350 Bush Street, San Francisco, CA 94111. |
(26) | Burkehill Global Management, LP (“Burkehill”) serves as investment manager to Burkehill Master Fund LP, a Cayman Islands exempted limited partnership (“Admiral Fund”). As such, Burkehill has been granted investment discretion over the securities owned by the Admiral Fund. Christopher Rich serves as Managing Partner of Burkehill, the Managing Member of Burkehill Global LLC (“Burkehill GP”), the general partner of Burkehill, and the Managing Member of Burkehill Fund GP LLC (“Burkehill Fund GP”), the general partner of the Admiral Fund. Each of Burkehill, Burkehill GP, Burkehill Fund GP and Mr. Rich disclaim beneficial ownership of the Securities held by the Admiral Fund except to the extent of their or its pecuniary interest therein. The address for the Admiral Fund is c/o Burkehill Global Management, LP, 280 Park Avenue, New York, NY 10017. |
(27) | The registered address of Carlo Roccio is Via Molino Vecchio, 153, 28065 Cerano (NO), Italy. |
(28) | Carlo Tassara S.p.A. is a corporation and its board of directors has the power to vote and dispose of the Shares. The names of all the members of the board of directors are: Marco Mattei Chairman, Romain Zaleski CEO, Marco Farisoglio, Simonetta Ciocchi, Konstantin Zaleski, Maria Tassara, Pierluigi Portalupi. Under Italian Law, the Beneficial Owner of Carlo Tassara S.p.A. is Mr. Romain Zaleski, based on the criterion of control over voting rights at shareholders’ meetings. The registered address of Carlo Tassara S.p.A. is Via Leonardo da Vinci, 3, 25043 Breno (BS), Italy. |
(29) | The registered address of Céline Laurence Fabienne Viviant is Rue de la cour, 26, Annecy le Vieux, 74940, France. |
(30) | The registered address of Claudia Maria Bertoni is Piazza Graf, 132, 10126 Torino (TO), Italy. |
(31) | The registered address of Cornelis Marinus Pieter Vrins is 32 Avenue des Vergys, Chene-Bourg, 1225, Switzerland. |
(32) | The shares are being by Crossfid S.p.A. as a fiduciary company operating pursuant to and for the purposes of Italian Law No. 1966 of 1939, as subsequently amended and supplemented. Consists of (i) 13,352 ordinary shares of which beneficial owner of the relevant company is Massimo De Carlo; (ii) 96,140 ordinary shares beneficially owned by the lnsieme Trust, the control over which is exercised by the trustee of the lnsieme Trust, namely Crossfid S.p.A., whose ultimate beneficial owner is Andre Jean Antonin Audergon; and (iii) 144,210 shares beneficially owned by Massimo De Carlo, who exercises control over the shares through the fiduciary company Crossfid S.p.A.; and (iv) 25,370 Class B Shares. The registered address of Crossfid S.p.A. is Via Borgonuovo, 3, 20121 Milano (MI), Italy. |
(33) | The registered address of Davide Gerbaudo is Strada Suniglia, 5, 12038 Savigliano (CN), Italy. |
(34) | The registered address of Denis Etienne François Enz is Haltli, 1, Walchwil, 6318, Switzerland. |
(35) | Maurizio Di Marcotullio as pro-tempore sole director of DMG Partners SRLS. Consists of 11,724 Ordinary Shares and 1,172 Class B Shares held through DMG PARTNERS SRLS and its board of directors or its sole director or its delegate have the power to vote and dispose of the shares. The registered address of DMG PARTNERS SRLS is Piazza Cavour, 17, 00193, Rome (RM) Italy. The registered address of DMG Partners S.r.l.s. is Piazza Cavour, 17, 00193 Rome (RM), Italy. |
(36) | Dockside Fund I LP (“Dockside”) beneficially owns 51,895 shares of Ordinary Shares of the Company (“Shares”) held directly by it. Dockside GP LLC- Series VI, the general partner of Dockside, has voting and investment power over the securities held by Dockside and thus may be deemed to beneficially own the securities held by Dockside. William England controls Dockside GP LLC- Series VI and thus may be deemed to beneficially own the securities held by Dockside. Merewether Investment Management, LP (“Merewether”), an investment manager to Dockside, has voting and investment power over the Shares held by Dockside as described herein and thus may be deemed to |
(37) | Donall McCann is the sole shareholder of Duneane Asset Management Ltd and has the power to vote and dispose of the shares. The registered address of Duneane Asset Management Ltd is 28, Church Road, Stanmore, Middlesex, HA7 4XR, England. |
(38) | The beneficial owners of Ecoline S.r.l. are the following individuals: Luca Davide Farina (45%), Stefano Fedele Farina (45%), Lorenzo Tonoli (5%), Stefano Zaglio (5%). |
(39) | The registered address of Elisabeth Rizzotti is Corso Palestro, 14, 25121 Brescia (BS), Italy. |
(40) | Energy Investimenti S.r.l., Via Guerrazzi 1/A, Bologna (Bo), Italy, fiscal code and Companies Register of Bologna no. 04126181207. The owner of the securities is Energy Investimenti S.r.l., an Italian limited liability company with 28 shareholders. None of these shareholders controls the Company, because none of them holds a participation higher than 17% of the share capital. The sole director is Antonella Grassigli and, according to the company’s by-laws, she has the power to vote and to dispose of the ordinary shares held by Energy Investimenti S.r.l. To authorize the sole director to sell the securities held by Energy Investimenti S.r.l., the sole director needs the prior authorization of the majority of 51% of the shareholders. The registered address of Energy Investimenti S.r.l. is Via Guerrazzi, 1/A, 40125 Bologna (BO), Italy. |
(41) | The registered address of Enrico Maria Pecchio is Via Luigi Einaudi, 55, 10040 Rivalta di Torino (TO), Italy. |
(42) | The registered address of Erminia Leonardi is Via Roma, 101, 09124 Cagliari (CA), Italy. |
(43) | The registered address of Ettore Carello is Strada Castelvecchio, 27/Bis, 10024 Moncalieri (TO), Italy. |
(44) | EUROFINIM SRL is the registered holder of the securities. Voting and dispositive power over the securities is exercised by the Board of Directors, composed of Paolo Covre (Sole Shareholder and Chairman), Massimo Covre (Managing Director) and Marco Covre (Director). Voting and dispositive power may also be exercised individually by Paolo Covre and Massimo Covre. The registered address of Eurofinim S.r.l. is Via della Ferriera, 22, 33170 Pordenone (PN), Italy. |
(45) | Exor Seeds GP B.V., the general partner of EVRG 18, LP, has the power to vote and dispose of the securities. The registered address of EVRG 18, LP is 331 Park Ave S, Floor 7, New York, New York 10010. |
(46) | EXTERNEQ 1 LP (“EXTERNEQ”) beneficially owns 326,200 shares of Ordinary Shares of the Company (“Shares”) held directly by it, consisting of 142,035 Shares held in the Class A Portfolio and 184,165 Shares held in the Class B Portfolio. BSSG Inc., the general partner of EXTERNEQ may be deemed to beneficially own the securities held by EXTERNEQ. Merewether Investment Management, LP (“Merewether”), an investment manager to EXTERNEQ, has voting and investment power over the Shares held by EXTERNEQ and thus may be deemed to beneficially own the Shares held by EXTERNEQ. Merewether Management GenPar, LLC is the sole general partner of Merewether and thus may be deemed to beneficially own the Shares held by EXTERNEQ. Rod Saddington is the manager of Merewether Management GenPar, LLC and thus may be deemed to beneficially own the Shares held by EXTERNEQ. |
(47) | The shares are held by Fidim S.p.A., a company organized under the law of Italy with registered address in Via Valosa di Sopra 9 - 20900 Monza (MB) Italy, with tax code 00843200157, and the chairman and the vice chairman of the board of directors, respectively Mr Lucio Rovati and Mr Luca Rovati have the powers to vote and dispose of the shares. The registered address of Fidim S.p.A. is Via Valosa di Sopra, 9, 20900 Monza (MB), Italy. |
(48) | The director of Fior di Loto S.C.P., Stefano Ceriani, has investment control over the securities. The registered address of Fior Di Loto S.C.P. is 49, Bd d’Italie, 98000 Monaco, Monaco. |
(49) | The registered address of Flavio Del Monte is Via Lecco, 10, 20124 Milano (MI), Italy. |
(50) | The registered address of Fleurance Investissement S.C. is 34, Marimont, Ban de Laveline, 88520, France. |
(51) | The registered address of Francesco Manniello is Corso Italia, 212B, 80063 Sorrento (NA), Italy. |
(52) | The registered address of Francesco Sassu is Via Costantino Nivola, 8, 07100 Sassari (SS), Italy. |
(53) | The securities are held by the company FUTURA s.s. The company’s shareholders are the company CONTRACTA s.r.l., BRIC s.r.l. and GOLDEN s.r.l. The administration and representation of the company FUTURA s.s. shall be vested in all partners, acting severally, for all acts of ordinary administration, without exception. Acts of extraordinary administration shall require the consent of all partners. The legal representatives of the FUTURA member companies are Cravero Stefano (Contracta), Bertazzo Maurizio (Bric) and Vietti Piergiuseppe (Golden). These individuals may be deemed to have shared voting and dispositive power over the Ordinary Shares held by FUTURA s.s.. Each of these individuals disclaims beneficial ownership of such securities, except to the extent of his or her pecuniary interest therein. The registered address of Futura s.s. is 15, Piazza Vittorio Veneto - 13900 Biella Italy. The registered address of Futura S.S. is Piazza Vittorio Veneto, 15, 13900 Biella (BI), Italy. |
(54) | The registered address of Gaudenzio Roveda is Via Roma, 5, 26017 Pieranica (CR), Italy. |
(55) | The registered address of Giovanni Sapone is Corso Re Umberto, 53, 10128 Torino (TO), Italy. |
(56) | The reported securities are directly owned by Graham Credit Opportunities Ltd. Kenneth G. Tropin ultimately solely controls KGT GP LLC, which is the general partner of Graham Capital Management, L.P., which is the investment advisor of Graham Credit Opportunities Ltd., and shares voting and investment power over the Shares held by Graham Credit Opportunities Ltd. with Graham Capital Management, L.P. and Graham Credit Opportunities Ltd. The principal business address of Graham Credit Opportunities Ltd. is c/o Graham Capital Management, L.P., 40 Highland Avenue Rowayton, CT 06853. |
(57) | The reported securities are directly owned by Graham Macro Strategic Ltd. Kenneth G. Tropin ultimately solely controls KGT GP LLC, which is the general partner of Graham Capital Management, L.P., which is the investment advisor of Graham Macro Strategic Ltd., and shares voting and investment power over the Shares held by Graham Macro Strategic Ltd. with Graham Capital Management, L.P. and Graham Macro Strategic Ltd. The principal business address of Graham Macro Strategic Ltd. is c/o Graham Capital Management, L.P., 40 Highland Avenue Rowayton, CT 06853 |
(58) | The registered address of Guido Giletta is Via Saluzzo, 47, 12036 Revello (TO), Italy. |
(59) | The registered address of Healthcap S.r.l. is Via Carducci, 10, 00181 Roma (RM), Italy. |
(60) | HIF Solitude Ltd (“HIF”) is managed by Monashee Investment Management, LLC (“Monashee Management”). Jeff Muller is CCO of Monashee Management and has sole voting and dispositive power over Monashee Management and, accordingly, may be deemed to have beneficial ownership of the Ordinary Shares held by HIF. Jeff Muller disclaims beneficial ownership of the Ordinary Shares held by HIF, except to the extent of his pecuniary interest therein. The business address of HIF and Mr. Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 4th Floor, Boston, Massachusetts 02116. |
(61) | Hofima S.p.A. is an Italian corporation organized under Italian law controlled by Davide Malacalza, who has the power to direct Hofima S.p.A. how to vote and dispose of the shares. The registered address of Hofima S.p.A. is Via XII Ottobre, 2, 16121 Genova (GE), Italy. |
(62) | The registered address of Ilusa S.r.l. is Avenue de la Laiterie, 6, 4000 Liège, Belgium. |
(63) | The business address of James Matthew Yerbic is c/o NewHold Investment Corp III, 52 Vanderbilt Avenue, Suite 2005 New York, NY 10017. |
(64) | K-On Energy S.r.l. is a corporation, duly established under the laws of Italy, and its board (a sole director, with full delegation of power by the General Assembly of shareholders) has the power to vote and dispose of the Shares. Salvatore Pelleriti is the sole director of K-On Energy S.r.l. The registered address of K-On Energy S.r.l. is Via della Conciliazione, 44, 00193 Roma (RM), Italy. |
(65) | Silvia Merlo, Sole Director of Kibotion Sri, has voting and investment power over the Registrable Securities held by Kibotion Sri. The registered address of Kibotion S.r.l. is Via Vittorio Amedeo II, 3, 12100 Cuneo, Italy. |
(66) | Kryger Capital LLC acts as the investment manager for Kryger Enhanced Master Fund and has full investment control over the reported securities. |
(67) | Kryger Capital LLC acts as the investment manager for Kryger Event Master Fund and has full investment control over the reported securities. |
(68) | Azimut Private Capital Management S.à r.l., the general partner (actionnaire commandité-gérant) of LIFTT S.C.A., is managed by three managers (gérants), who share voting and investment control over the Registrable Securities: Salvatore Andrea Sberna, Roberto Martinangelo and Marco Rabito Maneri. The registered address of LIFTT S.C.A. is Rue Eugène Ruppert, 2A, L-2453 Luxembourg, Luxembourg. |
(69) | The registered address of Lorenz Di Mattioli Alvaro S.S. is Corso della Repubblica, 94, 47121 Forlì (FC), Italy. |
(70) | The registered address of Luciano Cinotti is Via Vittorio Veneto, 49, 16036 Recco (GE), Italy. |
(71) | The registered address of Luisa Carena is Corso Germano Sommeiller, 26, 10128 Torino (TO), Italy. |
(72) | The board of directors of Luleo S.A., composed of Mattia Malacalza, Duilio Benigna, Guido Casellini, Roberto Galeri, and Christian Magistra, has the voting and dispositive powers over the securities. The registered address of Luleo S.A. is Via Dufour, 7, 6900 Lugano, Switzerland. |
(73) | The securities are held by LuminArx Opportunistic Alternative Solutions Holdings II Fund LP. The sole general partner of LuminArx Opportunistic Alternative Solutions Holdings II Fund LP is LuminArx Capital Fund GP LP. LuminArx Capital Fund GP LP is ultimately controlled by Min Htoo and Gideon Berger. These individuals may be deemed to have shared voting and dispositive power over the Ordinary Shares held by LuminArx Opportunistic Alternative Solutions Holdings II Fund LP. Each of these individuals disclaims beneficial ownership of such securities, except to the extent of his or her pecuniary interest therein. The registered address of LuminArx Opportunistic Alternative Solutions Holdings II Fund LP is 23rd Floor, 712 Fifth Avenue, New York, 10019, United States. |
(74) | The securities are held by LuminArx Pavo Holdings II LP. The sole general partner of LuminArx Pavo Holdings II LP is LuminArx Capital Fund GP LP. LuminArx Capital Fund GP LP is ultimately controlled by Min Htoo and Gideon Berger. These individuals may be deemed to have shared voting and dispositive power over the Ordinary Shares held by LuminArx Pavo Holdings II LP. Each of these individuals disclaims beneficial ownership of such securities, except to the extent of his or her pecuniary interest therein. The registered address of LuminArx Pavo Holdings II LP is 23rd Floor, 712 Fifth Avenue, New York, 10019, United States. |
(75) | Consists of 4,435,490 Ordinary Shares and 326,049 Class B Shares held through Emmeplus Limited, over which Mr. Lefebvre has sole ultimate investment and voting power. |
(76) | The registered address of Marco Aria is Via Castello, 18/BIS, 12069 Santa Vittoria d’Alba (CN), Italy |
(77) | The registered address of Marie Helene Polo is Via Caprera, 12, 07052 San Teodoro (SS), Italy. |
(78) | The registered address of Mario Felicetti is 6 Allée de L’Eperviere, 26000 Valence, France. |
(79) | Merewether Investment Management, LP (“Merewether”), the investment manager of Merewether Cyclicals Master Fund, LP (“Cyclicals Master Fund”), has sole voting and investment power over the securities held by Cyclicals Master Fund and thus may be deemed to beneficially own the securities held by Cyclicals Master Fund. Merewether Management GenPar, LLC (the “General Partner”) is the sole general partner of Merewether and thus may deemed to beneficially own the securities held by Cyclicals Master Fund. Rod Saddington is the manager of the General Partner and thus may be deemed to beneficially own the securities held by Cyclicals Master Fund. In addition, Merewether has voting and investment power over the securities held by Merewether Energy Transformation Master Fund, Ltd. (“Energy Transformation Master Fund”), Dockside Fund I LP (“Dockside”) and EXTERNEQ 1 LP (“EXTERNEQ”) and thus may be deemed to beneficially own the securities held by Cyclicals Master Fund, Dockside and EXTERNEQ as described herein. Merewether is deemed to beneficially own 2,500,000 Ordinary Shares in the aggregate of the Company. |
(80) | Merewether Investment Management, LP (“Merewether”), the investment manager of Merewether Energy Transformation Master Fund, Ltd. (“Energy Transformation Master Fund”), has sole voting and investment power over the securities held by Energy Transformation Master Fund and thus may be deemed to beneficially own the securities held by Energy Transformation Master Fund. Merewether Management GenPar, LLC (the “General Partner”) is the sole general partner of Merewether and thus may deemed to beneficially own the securities held by Energy Transformation Master Fund. Rod Saddington is the manager of the General Partner and thus may be deemed to beneficially own the securities held by Energy Transformation Master Fund. In addition, Merewether has voting and investment power over the securities held by Merewether Cyclicals Master Fund, LP (“Cyclicals Master Fund”), Dockside Fund I LP (“Dockside”) and EXTERNEQ 1 LP (“EXTERNEQ”) and thus may be deemed to beneficially own the securities held by Cyclicals Master Fund, Dockside and EXTERNEQ as described herein. Merewether is deemed to beneficially own 2,500,000 Ordinary Shares in the aggregate of the Company. |
(81) | Giulian Prigione, the Chief Executive Officer of MGM S.r.l., has sole voting and dipositive power over the securities. The registered address of MGM S.r.l. is Via Galvani 20/a, 15121 Alessandria (AL), Italy. |
(82) | The board of director of MI Capital S.r.l. is vested with voting or investment control over the securities listed above. Accordingly, pursuant to MI Capital S.r.l.’s Articles of Association currently in force, meeting of the board of directors shall be validly constituted provided that at least an effective majority of the directors then in office is present, and resolutions shall be adopted by the affirmative vote of an effective majority of the directors present at the meeting. As of the date hereof, the board of directors of MI Capital S.r.l. is composed as follows: Alessandra Ricci (Chairman), Luigi Alfieri (Vice Chairman), Simone Pierangeli (Chief Executive Officer), Stefano Fiorini, and Massimo Di Amato. The registered address of MI Capital S.r.l. is Piazzale Flaminio, 9, 00196 Roma (RM), Italy. |
(83) | The registered address of Mimosa Beck Peccoz is Via Giuseppe Pomba, 14, 10123 Torino (TO), Italy. |
(84) | Mission Pure Alpha Master LP (“MPAM”) is managed by Monashee Investment Management, LLC (“Monashee Management”). Jeff Muller is CCO of Monashee Management and has sole voting and dispositive power over Monashee Management and, accordingly, may be deemed to have beneficial ownership of the ordinary shares held by MPAM. Jeff Muller disclaims beneficial ownership of the ordinary shares held by MPAM, except to the extent of his pecuniary interest therein. The business address of MPAM and Mr. Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 4th Floor, Boston, Massachusetts 02116. |
(85) | Matthew MacIsaac, Secretary of MM Asset Management Inc., as investment advisor to MMCAP International Inc. SPC, has sole voting and dispositive power over the Ordinary Shares held by MMCAP International Inc. SPC. The business address of Matthew MacIsaac and MMCAP International Inc. SPC is 161 Bay Street, TD Canada Trust Tower, Suite 2240, Toronto, ON M5J 2S1, Canada. |
(86) | Moore Capital Management, LP, the investment manager of MMF LT, LLC, has voting and investment control of the shares held by MMF LT, LLC. Mr. Louis M. Bacon controls the general partner of Moore Capital Management, LP and may be deemed the beneficial owner of the shares of the Company held by MMF LT, LLC. Mr. Bacon also is the indirect majority owner of MMF LT, LLC. The address of MMF LT, LLC, Moore Capital Management, LP and Mr. Bacon is 11 Times Square, New York, New York 10036. |
(87) | Moore Capital Management, LP, the investment manager of Moore Global Investments, LLC (“MGI LLC”), has voting and investment control of the shares held by MGI LLC. Mr. Louis M. Bacon controls the general partner of Moore Capital Management, LP and may be deemed the beneficial owner of the shares of the Company held by MGI LLC. Mr. Bacon also is the indirect majority owner of MGI LLC. The address of MGI LLC, Moore Capital Management, LP and Mr. Bacon is 11 Times Square, New York, New York 10036. |
(88) | The securities are held by Navig S.A.S. and its board of directors have the power to vote and dispose of the shares. Navig S.A.S. is ultimately controlled by GIORGIO ZAFFARONI, VITTORIA ZAFFARONI and ALBERTO ZAFFARONI with controlling stakes of 34.4%, 35.1%, and 30.5%, respectively. The registered address of Navig S.A.S. is Foro Buonaparte, 69, 20121 Milano, Italy. The registered address of Navig S.A.S. is Foro Buonaparte, 69 20121, Milano (MI), Italy. |
(89) | Consists of 4,404,951 Ordinary Shares and 177,967 Ordinary Shares issuable upon the exercise of Company Private Warrants. NewHold Industrial Technology III LLC, the Sponsor, is the record holder of such shares. Samy Hammad, Polly Schneck and Kevin Charlton are the managing members of NewHold Industrial Technology III LLC and hold voting and investment discretion with respect to SPAC Ordinary Shares held of record by the Sponsor. Samy Hammad, Polly Schneck and Kevin Charlton disclaim any beneficial ownership of the securities held by NewHold Industrial Technology III LLC other than to the extent of any pecuniary interest they may individually have therein, directly or indirectly. |
(90) | Consists of 3,010,156 Ordinary Shares and 301,015 Class B Shares held of record by NextChem S.p.A. and approximately 8,855,000 Ordinary Shares issuable upon the exercise of the NextChem Warrants. The board of directors of NextChem S.p.A. is vested with voting or investment control over the Registrable Securities listed in Item (2) above. Pursuant to NextChem S.p.A.’s articles of association as currently in force, meetings of the board of directors shall be validly constituted provided that at least an absolute majority of the directors then in office is present, and resolutions shall be adopted by the affirmative vote of an absolute majority of the directors present at the meeting. As of the date hereof, the board of directors of NextChem S.p.A. is composed as follows: Alessandro Bernini (Chairman), Fabio Fritelli (Chief Executive Officer), Sara Frassine, Daniele Provenziani, Massimo Di Amato, Alessandra Ricci and Susanna Maria Invernizzi. NextChem S.p.A. is a company subject to the direction and coordination of MAIRE S.p.A. The registered address of NextChem S.p.A. is Via di Vannina 88/94, 00156 Rome (RM), Italy. |
(91) | The registered address of Nicola Treves is Via Maria Vittoria, 8, 10123 Torino (TO), Italy. |
(92) | NovaCapital S.r.l. is managed by its board of directors (Paolo Merloni, Carlo Germano Ravina and Simone Sarachini). Pursuant to NovaCapital S.r.l.’s corporate governance rules, the power to approve acquisitions or disposals of participations and financial instruments is vested in the board of directors and in the Executive Chairman, Paolo Merloni. The registered address of Novacapital S.r.l. is Via Broletto, 44, 20123 Milano (MI), Italy. |
(93) | Octium Life DAC is a corporation and its board of directors has the power to vote and dispose of the Shares. The names of all the members of the board of directors are the following: A Brogden, D. Hurley, D. FitzGerald, J. Collins, J. Finnegan, S. Hughes. The registered address of Octium Life DAC is College Park House, South Frederick Street, Dublin, D02 VY46, Republic of Ireland. |
(94) | The registered address of Padmanee Sharma is 4014 Portsmouth St., Houston, TX 77027. |
(95) | PB Investment Ltd is a Private Limited Liability Company Ltd, incorporated in Malta and its board of directors has the power to vote and dispose of the Shares. The names of all the members of the board are: Patrick Bierbaum, Joanne Psaila. The registered address of PB Investment Ltd is Quad Central, Tower Q3, Level 5, Unit 1, Triq l-Esportaturi, CBD 1040, Birkirkara, Malta. |
(96) | The business address of Philip Horlock is c/o NewHold Investment Corp III, 52 Vanderbilt Avenue, Suite 2005 New York, NY 10017. |
(97) | The registered address of Philippe Jabre is Avenue du Parc, 24, Minet El Hosn, Beirut, Lebanon. |
(98) | The registered address of Piergiorgio Strata is Via dei Mille, 52, 10123 Torino (TO), Italy. |
(99) | The registered address of Pietro Quaranta is Via Pupino, 15, 74123 Taranto (TA), Italy. |
(100) | The registered address of Pietro Sorrentino is Apartment n.3B, Oak st, 84, Brooklyn, New York, 11222, United States. |
(101) | Federico Prando, as Chief Executive Officer of Prando S.r.l., has voting and investment control over the Registrable Securities held by Prando S.r.l. The registered address of Prando S.r.l. is Corso Roma, 52, 15121, Alessandria (AL) Italy. |
(102) | Pursuant to investment subadvisory agreements, Westchester Capital Management, LLC (“Westchester”) acts as the investment sub-advisor to The Merger Fund, The Merger Fund VL, Virtus Westchester Credit Event Fund, and Principal Global Multi-Strategy Fund. Westchester has the ability to make decisions with respect to the voting and disposition of the shares held by the selling securityholder. Under the terms of the respective agreements with the selling security holders, Westchester has the overall responsibility for directing the investments for the selling security holder in accordance with its investment objectives, policies and limitations. |
(103) | Quantum Containment System LLC is a limited liability company which is managed by its sole member, PEP Base Zero NC Holdings LP, which is itself a limited partnership which is managed by its sole general partner, Pelican Energy Partners Base Zero GP LP, which is itself a limited partnership which is managed by its sole general partner, Pelican Energy Partners Base Zero UGP LLC, which is itself a limited liability company managed by its sole managing member, John J. Surina Jr. Mr. Surina, in such capacity, has the power to vote and dispose of the Shares on behalf of Quantum Containment System LLC. |
(104) | Consists of 20,301,194 Ordinary Shares and 2,030,119 Class B Shares held of record by Fin Posillipo S.p.A. Raffaele Petrone is the ultimate beneficial owner of Fin Posillipo S.p.A. and as such has sole voting and dispositive power over the Ordinary Shares held by Fin Posillipo S.p.A. The registered address of Fin Posillipo S.p.A. is Viale della Liberazione, 111, 80125 Naples (NA), Italy. |
(105) | Reaves Utility Income Fund is a reporting company under the Exchange Act and an investment company, or a subsidiary of an investment company, subject to the Investment Company Act of 1940. The address of the selling stockholder is 1700 Broadway, Suite 1850, Denver, CO 80290. |
(106) | The registered address of Renilde Joanna J. Vanden Broeck is Place des Augustins, 1, Genève, 1205, Switzerland. |
(107) | Ro.Ro Società Semplice is an Italian società semplice. A società semplice is a partnership that, under Italian law, may not engage in commercial activities. It may only carry out agricultural activities or act as a holding company for equity interests. Ro.Ro Società Semplice operates exclusively as a holding company for equity interests. The directors of Ro.Ro Società Semplice are the spouses Gaudenzio Roveda and Rossana Rovida. They are also its sole partners, holding the following ownership interests: Gaudenzio Roveda: 95%, Rossana Rovida: 5%. The directors have the power to vote and to dispose of the Shares. The registered address of Ro.Ro Società Semplice is Via Fontana, 18, 20122 Milano (MI), Italy. |
(108) | The registered address of Roberto Italia is Via Noale, 8A, Sorengo, 6924, Switzerland. |
(109) | The registered address of Romolo Bardin is 28, Rue Paul Palgen, L-2358 Luxembourg, Luxembourg. |
(110) | The registered address of Scott Philip Scharfman is c/o NewHold Investment Corp III, 52 Vanderbilt Avenue, Suite 2005 New York, NY 10017. |
(111) | Harald Borna exercises voting and investment/dispositive control over the registrable securities on behalf of Sebco Investment Group Ltd. Sebco Investment Group Ltd is the registered holder and beneficial owner of the registrative securities. Harald Borna has voting and investment/dispositive control over the registrative securities on behalf of Sebco Investment Group LTD. The registered address of Sebco Investment Group Ltd is Trident Chambers, P.O. Box 146, Road Town, Tortola, VG1110, British Virgin Islands. |
(112) | The registered address of Sezaneh Taherian is 300 Edinburgh Circe, Danville, CA 94526. |
(113) | The registered address of Sforzesca Investimenti S.r.l. is Corso Vittorio Emanuele II, 284, 00186 Roma (RM), Italy. |
(114) | The registered address of Silvia Fiorucci is 14 Rue Princesse Marie de Lorraine, 98000 Monaco, Monaco. |
(115) | Consists of 15,079,795 Ordinary Shares and 1,507,979 Class B Shares held of record by Simon Fiduciaria S.p.A. Simon Fiduciaria S.p.A. holds such shares in a fiduciary or nominee capacity for the benefit of certain underlying investors and not for the account of any single controlling person. The underlying investors retain the right to direct the voting and disposition of the Ordinary Shares held by Simon Fiduciaria S.p.A. for their respective accounts, and Simon Fiduciaria S.p.A. acts in accordance with such instructions. Accordingly, no individual person is known by the Company to have or share voting or dispositive power over all of the Ordinary Shares held of record by Simon Fiduciaria S.p.A. No underlying investor for whom Simon Fiduciaria S.p.A. holds Ordinary Shares beneficially owns more than 5% of the Ordinary Shares outstanding. The registered address of Simon Fiduciaria S.p.A. is Via Pietro Giannone, 10, 10121 Turin (TO), Italy. |
(116) | Consists of 19,210,290 Ordinary Shares held of record by Elysia Capital I SCSp and 119,603 Ordinary Shares held directly by Mr. Buono, as well as 1,932,989 Class B Shares held of record by Elysia Capital I SCSp and Mr. Buono. Stefano Buono is the ultimate beneficial owner of Elysia Capital I SCSp and as such has sole voting and dispositive power over the Ordinary Shares held by Elysia Capital I SCSp. Elysia Capital I SCSp is a Luxembourg Partnership and is managed by its General Partner – Elysia GP S.a.r.l. Directors of Elysia GP S.a.r.l. are Luca ALEMANI, David LUKSENBURG, Dominique PÉRILLEUX. The business address of Elysia Capital I SCSP is 2, Place de Strasbourg 2562, Luxembourg, Luxembourg. The registered address of Stefano Buono is Via Duchessa Jolanda, 13A, 10138 Turin (TO), Italy. |
(117) | The European Organization for Nuclear Research for the benefit of its Pension Fund is an intergovernmental body established under treaty. Its CEO Doug Heron as legal representative of the fund has the power to vote and dispose of the shares. |
(118) | Pursuant to investment subadvisory agreements, Westchester Capital Management, LLC (“Westchester”) acts as the investment sub-advisor to The Merger Fund, The Merger Fund VL, Virtus Westchester Credit Event Fund, and Principal Global Multi-Strategy Fund. Westchester has the ability to make decisions with respect to the voting and disposition of the shares held by the selling securityholder. Under the terms of the respective agreements with the selling security holders, Westchester has the overall responsibility for directing the investments for the selling security holder in accordance with its investment objectives, policies and limitations. |
(119) | Pursuant to investment subadvisory agreements, Westchester Capital Management, LLC (“Westchester”) acts as the investment sub-advisor to The Merger Fund, The Merger Fund VL, Virtus Westchester Credit Event Fund, and Principal Global Multi-Strategy Fund. Westchester has the ability to make decisions with respect to the voting and disposition of the shares held by the selling securityholder. Under the terms of the respective agreements with the selling security holders, Westchester has the overall responsibility for directing the investments for the selling security holder in accordance with its investment objectives, policies and limitations. |
(120) | The registered address of Thomas J. Sullivan is c/o NewHold Investment Corp III, 52 Vanderbilt Avenue, Suite 2005 New York, NY 10017. |
(121) | The registered address of Tiziana Giletta is Corso Bernardino Telesio, 103, 10146 Torino (TO), Italy. |
(122) | Tosca Focus is a mutual fund managed by Toscafund Assets Management LLP, which has sole voting and dispositive power over the Ordinary Shares held by Tosca Focus and is controlled by Mr. Martin Hughes. |
(123) | Unico S.r.l. is a corporation and its sole directors has the power to vote and dispose of the Shares. The names of the Director is CORTASSA GIANCARLO, born on July 30, 1947, in Beinasco (Tourin), Italy, resident in Almese (Tourin), Italy (10040), Streat Rubiana n. 52, italian fiscal code CRTGCR47L30A734N. The registered address of Unico S.r.l. is Via Alberto da Rivoli, 16, 10098 Rivoli (TO), Italy. |
(124) | Pursuant to investment subadvisory agreements, Westchester Capital Management, LLC (“Westchester”) acts as the investment sub-advisor to The Merger Fund, The Merger Fund VL, Virtus Westchester Credit Event Fund, and Principal Global Multi-Strategy Fund. Westchester has the ability to make decisions with respect to the voting and disposition of the shares held by the selling securityholder. Under the terms of the respective agreements with the selling security holders, Westchester has the overall responsibility for directing the investments for the selling security holder in accordance with its investment objectives, policies and limitations. |
(125) | Samuel Voccia, as sole director of Vox Sualem S.r.l., has sole voting and investment control over the Registrable Securities held by Vox Sualem S.r.l. The registered address of Vox Sualem S.r.l. is Avenue de la Laiterie, 6, 4000 Liège, Belgium. |
(126) | Tudor Investment Corporation (“Tudor”) acts as trading advisor to Xantium Partners L.P. (“Xantium”). As a result, Tudor may be deemed to be the beneficial owner of shares owned by Xantium. Tudor disclaims such beneficial ownership. Paul Tudor Jones, II is the Chief Investment Officer and controlling shareholder of Tudor. As a result, Mr. Jones may be deemed to be the beneficial owner of shares deemed beneficially owned by Tudor and Xantium. Mr. Jones expressly disclaims such beneficial ownership. |
(127) | Sergio Zocchi, the sole director of XS Consulting s.r.l., has the sole voting and dispositive powers over the securities. The registered address of XS Consulting S.r.l. is Via Voghera, 7, 20144 Milano (MI), Italy. |
• | we or one of our subsidiaries has been or is to be a participant; |
• | the amount involved exceeded or exceeds $120,000; and |
• | any of our directors, executive officers or holders of more than 5% of our share capital prior to the business combination, or any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest. |
• | 50% of the Lock-Up Shares will be released immediately if the volume weighted average trading price of the Ordinary Shares on the principal exchange on which such securities are then listed or quoted is at or above $12.00 for any 20 Trading Days, which need not be consecutive, during any 30-Trading Day period beginning at any time after the Closing Date; |
• | 25% of the Lock-Up Shares will be released immediately if the volume weighted average trading price of the Ordinary Shares on the principal exchange on which such securities are then listed or quoted is at or above $15.00 for any 20 Trading Days, which need not be consecutive, during any 30-Trading Day period beginning at any time after the Closing Date; |
• | the remaining 25% of the Lock-Up Shares will be released immediately if the volume weighted average trading price of the Ordinary Shares on the principal exchange on which such securities are then listed or quoted is at or above $18.00 for any 20 Trading Days, which need not be consecutive, during any 30-Trading Day period beginning at any time after the Closing Date; and |
• | if an Early Release Event (as defined in the newcleo A&R Articles) occurs during the Lock-Up Period, all Lock-Up Shares that have not previously been released will be released immediately prior to the consummation of such Early Release Event and will no longer be subject to the transfer restrictions set forth in the Lock-Up Arrangements. |
• | 1% of the total number of Ordinary Shares then outstanding; and |
• | the average weekly reported trading volume of the Ordinary Shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
• | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
• | block trades in which the broker-dealer will attempt to sell the Ordinary Shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
• | purchases by a broker-dealer as principal and resale by the broker-dealer for its own account; |
• | an exchange distribution in accordance with the rules of the applicable exchange; |
• | privately negotiated transactions; |
• | short sales effected after the registration statement of which this prospectus forms a part is declared effective by the SEC; |
• | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
• | in market transactions, including transactions on a national securities exchange or quotation service or in the over-the-counter market; |
• | directly to one or more purchasers; |
• | through agents; |
• | through agreements with broker-dealers that may agree with a Selling Securityholder to sell a specified number of Ordinary Shares at a stipulated price per share; |
• | through a combination of any such methods of sale; or |
• | through any other method permitted by applicable law. |
SEC registration fee | $146,234.84 | ||
Legal fees and expenses | $435,000.00 | ||
Accountants’ fees and expenses | $52,500.00 | ||
Printing expenses | $30,000.00 | ||
Transfer agent fees and expenses | * | ||
Miscellaneous fees and expenses | $36,265.16 | ||
Total | $700,000.00 | ||
* | These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time. |
Page | |||
Unaudited Financial Statements | |||
Audited Financial Statements | |||
Page | |||
Unaudited Condensed Consolidated Interim Financial Statements | |||
Audited Financial Statements | |||
June 30, 2026 | December 31, 2025 | |||||
(unaudited) | ||||||
ASSETS | ||||||
Current assets: | ||||||
Cash and cash equivalents | $364,000 | $1,198,000 | ||||
Prepaid expenses | 176,000 | 136,000 | ||||
Total current assets | 540,000 | 1,334,000 | ||||
Investments held in Trust Account | 212,934,000 | 209,220,000 | ||||
Total assets | $213,474,000 | $210,554,000 | ||||
LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT | ||||||
Current liabilities: | ||||||
Accounts payable (including approximately $0 and $75,000 of offering costs at June 30, 2026 and December 31, 2025, respectively) | $619,000 | $104,000 | ||||
Accrued liabilities | 5,470,000 | 694,000 | ||||
Deferred compensation – related parties | 723,000 | 453,000 | ||||
Total current liabilities | 6,812,000 | 1,251,000 | ||||
Other liabilities: | ||||||
Deferred underwriting fee payable | 7,044,000 | 7,044,000 | ||||
Total liabilities | 13,856,000 | 8,295,000 | ||||
Commitments and contingencies | ||||||
Class A ordinary shares subject to possible redemption; 20,125,000 and 20,125,000 shares at $10.58 and $10.40 per share at June 30, 2026 and December 31, 2025, respectively | 212,934,000 | 209,220,000 | ||||
Shareholders’ deficit: | ||||||
Preference shares, $0.0001 par value; 1,000,000 authorized shares; none issued or outstanding at June 30, 2026 and December 31, 2025 | — | — | ||||
Class A ordinary shares, $0.0001 par value; 479,000,000 authorized shares; 780,100 shares issued and outstanding at June 30, 2026 and December 31, 2025 (excluding 20,125,000 shares subject to possible redemption) | — | — | ||||
Class B ordinary shares, $0.0001 par value, 20,000,000 authorized shares; 6,707,663 shares issued and outstanding at June 30, 2026 and December 31, 2025 | 1,000 | 1,000 | ||||
Additional paid-in capital | — | — | ||||
Accumulated deficit | (13,317,000) | (6,962,000) | ||||
Total shareholders’ deficit | (13,316,000) | (6,961,000) | ||||
Total liabilities, Class A ordinary shares subject to possible redemption and shareholders’ deficit | $213,474,000 | $210,554,000 | ||||
For the three months ended June 30, | For the six months ended June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
General and administrative expenses | $5,216,000 | $269,000 | $6,367,000 | $536,000 | ||||||||
Loss from operations | (5,216,000) | (269,000) | (6,367,000) | (536,000) | ||||||||
Other income: | ||||||||||||
Income earned on investments in Trust Account | 1,867,000 | 2,141,000 | 3,714,000 | 2,798,000 | ||||||||
Income earned on operating account | 4,000 | 16,000 | 12,000 | 19,000 | ||||||||
Other income | 1,871,000 | 2,157,000 | 3,726,000 | 2,817,000 | ||||||||
Net income (loss) | $(3,345,000) | $1,888,000 | $(2,641,000) | $2,281,000 | ||||||||
Weighted average shares of Class A ordinary outstanding - basic and diluted | $20,905,100 | 20,905,100 | 20,905,100 | 13,744,000 | ||||||||
Class A ordinary shares – basic and diluted net income (loss) per share | $(0.12) | $0.07 | $(0.10) | $0.11 | ||||||||
Weighted average Class B ordinary shares outstanding – basic and diluted | $6,707,663 | 6,707,663 | 6,707,663 | 6,707,663 | ||||||||
Class B ordinary shares – basic and diluted net income (loss) per share | $(0.12) | $0.07 | $(0.10) | $0.11 | ||||||||
Ordinary Shares | |||||||||||||||||||||
Class A Ordinary Shares | Amount | Class B Ordinary Shares | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Deficit | |||||||||||||||
Balances, March 31, 2026 (unaudited) | 780,100 | $— | 6,707,663 | $1,000 | $— | $(8,105,000) | $(8,104,000) | ||||||||||||||
Accretion in value of Class A ordinary shares | — | — | — | — | — | (1,867,000) | (1,867,000) | ||||||||||||||
Net loss | — | — | — | — | — | (3,345,000) | (3,345,000) | ||||||||||||||
Balances, June 30, 2026 (unaudited) | 780,100 | $— | 6,707,663 | $1,000 | $— | $(13,317,000) | $(13,316,000) | ||||||||||||||
Ordinary Shares | |||||||||||||||||||||
Class A Ordinary Shares | Amount | Class B Ordinary Shares | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Deficit | |||||||||||||||
Balances, March 31, 2025 (unaudited) | 780,100 | $— | 6,707,663 | $1,000 | $— | $(5,180,000) | $(5,179,000) | ||||||||||||||
Accretion in value of Class A ordinary shares | — | — | — | — | — | (2,141,000) | (2,141,000) | ||||||||||||||
Net income | — | — | — | — | — | 1,888,000 | 1,888,000 | ||||||||||||||
Balances, June 30, 2025 (unaudited) | 780,100 | $— | 6,707,663 | $1,000 | $— | $(5,433,000) | $(5,432,000) | ||||||||||||||
Ordinary Shares | |||||||||||||||||||||
Class A Ordinary Shares | Amount | Class B Ordinary Shares | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Deficit | |||||||||||||||
Balances, December 31, 2025 | 780,100 | $— | 6,707,663 | $1,000 | $— | $(6,962,000) | $(6,961,000) | ||||||||||||||
Accretion in value of Class A ordinary shares | — | — | — | — | — | (3,714,000) | (3,714,000) | ||||||||||||||
Net loss | — | — | — | — | — | (2,641,000) | (2,641,000) | ||||||||||||||
Balances, June 30, 2026 (unaudited) | 780,100 | $— | 6,707,663 | $1,000 | $— | $(13,317,000) | $(13,316,000) | ||||||||||||||
Ordinary Shares | |||||||||||||||||||||
Class A Ordinary Shares | Amount | Class B Ordinary Shares | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Deficit | |||||||||||||||
Balances, December 31, 2024 | — | $— | 6,707,663 | $1,000 | $24,000 | $(90,000) | $(65,000) | ||||||||||||||
Issuance of 780,100 Private Placement Units to Sponsor and underwriters at $10.00 per unit | 780,100 | — | — | — | 7,801,000 | — | 7,801,000 | ||||||||||||||
Estimated fair value of 10,062,500 Public Warrants issued as part of Units sold in the Offering | — | — | — | — | 1,509,000 | — | 1,509,000 | ||||||||||||||
Allocated value of transaction costs to Public and Private Warrants | — | — | — | — | (107,000) | — | (107,000) | ||||||||||||||
Accretion in value of Class A ordinary shares | — | — | — | — | (9,227,000) | (7,624,000) | (16,851,000) | ||||||||||||||
Net income | — | — | — | — | — | 2,281,000 | 2,281,000 | ||||||||||||||
Balances, June 30, 2025 (unaudited) | 780,100 | $— | 6,707,663 | $1,000 | $— | $(5,433,000) | $(5,432,000) | ||||||||||||||
For the six months ended June 30, | ||||||
Cash flows from operating activities | 2026 | 2025 | ||||
Net income (loss) | $(2,641,000) | $2,281,000 | ||||
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||
Income earned on investments held in Trust Account | (3,714,000) | (2,798,000) | ||||
Changes in operating assets and liabilities: | ||||||
(Increase) in prepaid expenses | (40,000) | (235,000) | ||||
Increase in accounts payable | 515,000 | 19,000 | ||||
Increase in accrued expenses and other | 4,776,000 | 96,000 | ||||
Increase in deferred compensation | 270,000 | — | ||||
Net cash used in operating activities | (834,000) | (637,000) | ||||
Cash flows from investing activities | ||||||
Investment of cash into Trust Account | — | (202,256,000) | ||||
Net cash used in investing activities | — | (202,256,000) | ||||
Cash flows from financing activities | ||||||
Proceeds from Sponsor Note | — | 2,000 | ||||
Repayment of Sponsor Note | — | (242,000) | ||||
Proceeds from sale of Units | — | 201,250,000 | ||||
Proceeds from sale of Private Placement Units | — | 7,801,000 | ||||
Payment of underwriting discounts and reimbursements | — | (4,075,000) | ||||
Payment of offering costs | — | (331,000) | ||||
Net cash provided by financing activities | — | 204,405,000 | ||||
Net change in cash and cash equivalents | (834,000) | 1,512,000 | ||||
Cash and cash equivalents – beginning of period | 1,198,000 | 55,000 | ||||
Cash and cash equivalents – end of period | $364,000 | $1,567,000 | ||||
Supplemental disclosure of noncash activities: | ||||||
Deferred underwriting costs payable | $— | $7,044,000 | ||||
Deferred offering costs included in accounts payable | $— | $75,000 | ||||
(a) | The share premium account of the Company shall be reduced by such amount as is deemed to be required by the Company in good faith, among other things, to permit the Company to satisfy the condition, set out at section 90(2) of the Companies Act 2006 of the United Kingdom (“UK Companies Act”), to re-register as a public limited company. |
(b) | The Company shall be re-registered as a public limited company and all filings with Companies House required to effect such re-registration in accordance with the UK Companies Act shall be made. |
(c) | The amended and restated articles of association of the Company (the “Company A&R Articles”), substantially in the form to be attached to the registration statement on Form F-4 (the “Registration Statement”) to be filed with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Business Combination, with such changes thereto as may be made by the Company in good faith (such changes to be consistent with the parties’ intentions for the Transactions) shall become effective. |
(d) | Immediately prior to the Recapitalization (as defined below), the issued and outstanding share capital of the Company shall be redenominated as U.S. dollar shares of a par value to be determined by the Company in good faith in accordance with the UK Companies Act (the “Redenomination”). |
(e) | Immediately following the Redenomination and prior to the First Merger Effective Time, all of the issued and outstanding ordinary shares in the capital of the Company (the “Company Ordinary Shares”) as of immediately prior to such consolidation shall be consolidated into such number of Company Ordinary Shares as is equal to the number of issued and outstanding Company Ordinary Shares multiplied by the Recapitalization Factor (the “Recapitalization”), subject to any restriction or alternative treatment in the sole discretion of the Company Board in relation to the issuance of fractional shares, or any equitable adjustment to the Recapitalization Factor (as defined below), in each case, as set forth in the Business Combination Agreement. |
(i) | each outstanding unit of the SPAC (including the private placement units sold simultaneously with the closing of the initial public offering of the SPAC, each, a “SPAC Unit”)), consisting of one (1) Class A ordinary share of the SPAC (the “SPAC Class A Ordinary Shares”) and one-half (1/2) of one warrant to purchase one SPAC Class A Ordinary Share (each, a “SPAC Warrant”) will automatically be detached and the holder thereof will be deemed to hold one (1) SPAC Class A Ordinary Share and one-half (1/2) of one SPAC Warrant (the |
(ii) | each of the SPAC Class A Ordinary Shares and the SPAC Class B Ordinary Shares (collectively, the “SPAC Ordinary Shares”) that is issued and outstanding immediately prior to the First Merger Effective Time (other than (w) the SPAC Ordinary Shares and the SPAC Warrants that are (or are required to be) forfeited pursuant to the Sponsor Support Agreement, as described below, (x) the SPAC Ordinary Shares that are held by a SPAC Shareholder who properly exercises in writing dissenters’ rights in accordance with Section 238 of the Cayman Companies Act, (y) the SPAC Ordinary Shares that the SPAC Shareholders have elected for the Company to redeem in connection with the Business Combination, and (z) the SPAC Ordinary Shares that are owned by the SPAC as treasury shares) shall automatically be converted into, and the holder of such SPAC Ordinary Share, shall be entitled to receive, one (1) newly issued, fully paid and non-assessable Company Ordinary Share, and such SPAC Ordinary Shares shall no longer be issued and outstanding and will automatically be cancelled and cease to exist at the First Merger Effective Time; and |
(iii) | each SPAC Warrant that is issued, outstanding and unexercised immediately prior to the First Merger Effective Time (but, for the avoidance of doubt, after the Unit Separation) shall be terminated in exchange for the right to receive a warrant to acquire one (1) Company Ordinary Share in accordance with the Business Combination Agreement. |
Description at June 30, 2026 | Quoted Price Prices in Active Markets (Level 1) | ||
Assets: | |||
Money market funds | $364,000 | ||
Description at December 31, 2025 | Quoted Price Prices in Active Markets (Level 1) | ||
Assets: | |||
Money market funds | $1,198,000 | ||
• | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. |
Dollars | Shares | |||||
Gross proceeds of Offering | $201,250,000 | 20,125,000 | ||||
Less: Offering proceeds allocated to Public Warrants | (1,509,000) | — | ||||
Offering costs | (11,538,000) | — | ||||
Plus: Accretion of carrying value to redemption value | 21,017,000 | — | ||||
Class A ordinary shares subject to possible redemption as of December 31, 2025 | $209,220,000 | 20,125,000 | ||||
Plus: Accretion of carrying value to redemption value | 3,714,000 | — | ||||
Class A ordinary shares subject to possible redemption as of June 30, 2026 (unaudited) | $212,934,000 | 20,125,000 | ||||
Three months ended June 30, 2026 | Six months ended June 30, 2026 | |||||||||||
Class A | Class B | Class A | Class B | |||||||||
Numerator: | ||||||||||||
Basic and diluted net loss per ordinary share: | ||||||||||||
Allocation of loss – basic and diluted | $(2,532,000) | $(813,000) | $(1,999,000) | $(642,000) | ||||||||
Denominator: | ||||||||||||
Basic and diluted weighted average ordinary shares: | 20,905,100 | 6,707,663 | 20,905,100 | 6,707,663 | ||||||||
Basic and diluted net loss per ordinary share | $(0.12) | $(0.12) | $(0.10) | $(0.10) | ||||||||
Three months ended June 30, 2025 | Six months ended June 30, 2025 | |||||||||||
Class A | Class B | Class A | Class B | |||||||||
Numerator: | ||||||||||||
Basic and diluted net income per ordinary shares: | ||||||||||||
Allocation of income – basic and diluted | $1,429,000 | $459,000 | $1,533,000 | $748,000 | ||||||||
Denominator: | ||||||||||||
Basic and diluted weighted average ordinary shares: | 20,905,100 | 6,707,663 | 13,744,000 | 6,707,663 | ||||||||
Basic and diluted net income per ordinary share | $0.07 | $0.07 | $0.11 | $0.11 | ||||||||
Share price | $9.945 | ||
Expected term (in years) | 6 | ||
Volatility | 4.0% | ||
Risk-free rate | 4.0% | ||
Description at June 30, 2026 | Quoted Price Prices in Active Markets (Level 1) | ||
Assets: | |||
Money market funds | $212,924,000 | ||
Description at December 31, 2025 | Quoted Price Prices in Active Markets (Level 1) | ||
Assets: | |||
Money market funds | $209,220,000 | ||
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); and |
• | if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days within a 30-trading day period commencing at least 30 days after completion of the initial Business Combination and ending three business days before NewHold sends the notice of redemption to the warrant holders. |
June 30, 2026 | December 31, 2025 | |||||
Cash and cash equivalents | $364,000 | $1,198,000 | ||||
Prepaid expenses | $176,000 | $136,000 | ||||
Investments held in Trust Account | $212,934,000 | $209,220,000 | ||||
Three months ended June 30, 2026 | Three months ended June 30, 2025 | |||||
General and administrative expenses | $(5,216,000) | $(269,000) | ||||
Other income (primarily income earned on the Trust Account) | $1,871,000 | $2,157,000 | ||||
Six months ended June 30, 2026 | Six months ended June 30, 2025 | |||||
General and administrative expenses | $(6,367,000) | $(536,000) | ||||
Other income (primarily income earned on the Trust Account) | $3,726,000 | $2,817,000 | ||||
December 31, | ||||||
2025 | 2024 | |||||
ASSETS | ||||||
Current assets: | ||||||
Cash and cash equivalents | $1,198,000 | $55,000 | ||||
Prepaid expenses | 136,000 | — | ||||
Deferred offering costs | — | 327,000 | ||||
Total current assets | 1,334,000 | 382,000 | ||||
Investments held in Trust Account | 209,220,000 | — | ||||
Total assets | $210,554,000 | $382,000 | ||||
LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT | ||||||
Current liabilities: | ||||||
Accounts payable (including approximately $75,000 and $0 of offering costs at December 31, 2025 and 2024, respectively) | $104,000 | $— | ||||
Accrued liabilities (including approximately $0 and $207,000 of offering costs at December 31, 2025 and 2024, respectively) | 694,000 | 207,000 | ||||
Deferred compensation – related parties | 453,000 | — | ||||
Promissory note – related party | — | 240,000 | ||||
Total current liabilities | 1,251,000 | 447,000 | ||||
Other liabilities: | ||||||
Deferred underwriting fee payable | 7,044,000 | — | ||||
Total liabilities | 8,295,000 | 447,000 | ||||
Commitments and contingencies | ||||||
Class A ordinary shares subject to possible redemption; 20,125,000 and 0 shares at $10.40 and $0.00 per share at December 31, 2025 and 2024, respectively | 209,220,000 | — | ||||
Shareholders’ deficit: | ||||||
Preference shares, $0.0001 par value; 1,000,000 authorized shares; none issued or outstanding at December 31, 2025 and 2024 | — | — | ||||
Class A ordinary shares, $0.0001 par value; 479,000,000 authorized shares; 780,100 and 0 shares issued and outstanding at December 31, 2025 and 2024 (excluding 20,125,000 shares subject to possible redemption), respectively | — | — | ||||
Class B ordinary shares, $0.0001 par value, 20,000,000 authorized shares; 6,707,663 shares issued and outstanding at December 31, 2025 and 2024(1) | 1,000 | 1,000 | ||||
Additional paid-in capital | — | 24,000 | ||||
Accumulated deficit | (6,962,000) | (90,000) | ||||
Total shareholders’ deficit | (6,961,000) | (65,000) | ||||
Total liabilities, Class A ordinary shares subject to possible redemption and shareholders’ deficit | $210,554,000 | $382,000 | ||||
(1) | Included, at December 31, 2024, 874,912 Class B ordinary shares that were subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters (see Note 8). |
For the year ended December 31, 2025 | For the period from August 13, 2024 (inception) through December 31, 2024(1) | |||||
General and administrative expenses | $2,090,000 | $90,000 | ||||
Loss from operations | (2,090,000) | (90,000) | ||||
Other income (expense): | ||||||
Interest income on Trust Account | 6,964,000 | — | ||||
Interest income on operating account | 44,000 | — | ||||
Other income | 7,008,000 | — | ||||
Net income (loss) | $4,918,000 | $(90,000) | ||||
Weighted average shares of Class A ordinary outstanding - basic and diluted | 17,354,000 | — | ||||
Class A ordinary shares – basic and diluted net income per share | $0.20 | $— | ||||
Weighted average Class B ordinary shares outstanding(1) – Basic and diluted | 6,707,663 | 5,833,000 | ||||
Class B ordinary shares – Basic and diluted net income (loss) per share | $0.20 | $(0.01) | ||||
(1) | For the period from August 13, 2024 (inception) to December 31, 2024 excludes 874,912 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 8). |
Ordinary Shares | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Deficit | ||||||||||||||||||
Class A Ordinary Shares | Amount | Class B Ordinary Shares | Amount | ||||||||||||||||||
Balances, December 31, 2024 | — | $— | 6,707,663 | $1,000 | $24,000 | $(90,000) | $(65,000) | ||||||||||||||
Issuance of 780,100 Private Placement Units to Sponsor and underwriters at $10.00 per unit | 780,100 | — | — | — | 7,801,000 | — | 7,801,000 | ||||||||||||||
Estimated fair value of 10,062,500 Public Warrants issued as part of Units sold in the Offering | — | — | — | — | 1,509,000 | — | 1,509,000 | ||||||||||||||
Allocated value of transaction costs to Public and Private Warrants | — | — | — | — | (107,000) | — | (107,000) | ||||||||||||||
Accretion in value of Class A ordinary shares | — | — | — | — | (9,227,000) | (11,790,000) | (21,017,000) | ||||||||||||||
Net income | — | — | — | — | — | 4,918,000 | 4,918,000 | ||||||||||||||
Balances, December 31, 2025 | 780,100 | $— | 6,707,663 | $1,000 | $— | $(6,962,000) | $(6,961,000) | ||||||||||||||
Class B Ordinary shares | Additional Paid-In Capital | Accumulated Deficit | Shareholder’s Deficit | ||||||||||||
Shares | Amount | ||||||||||||||
Balance as of August 13, 2024 (inception) | — | $— | $— | $— | $— | ||||||||||
Class B ordinary shares issued to Sponsor(1) | 6,707,663 | $1,000 | 24,000 | — | 25,000 | ||||||||||
Net loss | — | — | — | (90,000) | (90,000) | ||||||||||
Balance as of December 31, 2024 | 6,707,663 | $1,000 | $24,000 | $(90,000) | $(65,000) | ||||||||||
(1) | Includes 874,912 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 8). |
Cash flows from operating activities | For the year ended December 31, 2025 | For the period from August 13, 2024 (inception) through December 31, 2024 | ||||
Net income (loss) | $4,918,000 | $(90,000) | ||||
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||
Income earned on investments held in Trust Account | (6,964,000) | — | ||||
Payment of general and administrative expenses through promissory note – related party | — | 14,000 | ||||
Payment of general and administrative expenses through issuance of Class B ordinary shares | — | 9,000 | ||||
Changes in operating assets and liabilities: | ||||||
Increase in prepaid expenses | (136,000) | — | ||||
Increase in accounts payable | 29,000 | — | ||||
Increase in accrued expenses | 694,000 | — | ||||
Increase in deferred compensation – related parties | 453,000 | — | ||||
Net cash used in operating activities | (1,006,000) | (67,000) | ||||
Cash flows from investing activities | ||||||
Investment of cash into Trust Account | (202,256,000) | — | ||||
Net cash used in investing activities | (202,256,000) | — | ||||
Cash flows from financing activities | — | |||||
Proceeds from Sponsor Note | 2,000 | 225,000 | ||||
Repayment of Sponsor Note | (242,000) | — | ||||
Proceeds from sale of Units | 201,250,000 | — | ||||
Proceeds from sale of Private Placement Units | 7,801,000 | — | ||||
Payment of underwriting discounts and reimbursements | (4,075,000) | — | ||||
Payment of offering costs | (331,000) | (103,000) | ||||
Net cash provided by financing activities | 204,405,000 | 122,000 | ||||
Net change in cash | 1,143,000 | 55,000 | ||||
Cash and cash equivalents – beginning of period | 55,000 | — | ||||
Cash and cash equivalents – end of period | $1,198,000 | $55,000 | ||||
Supplemental disclosure of noncash activities: | ||||||
Deferred underwriting costs payable | $7,044,000 | $— | ||||
Deferred offering costs included in accounts payable | $75,000 | $— | ||||
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares | $— | 16,000 | ||||
Deferred offering costs included in accrued expenses | $— | 207,000 | ||||
• | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. |
Dollars | Shares | |||||
Gross proceeds of Offering | $201,250,000 | 20,125,000 | ||||
Less: Offering proceeds allocated to Public Warrants | (1,509,000) | — | ||||
Offering costs | (11,538,000) | — | ||||
Plus: Accretion of carrying value to redemption value | 21,017,000 | — | ||||
Class A ordinary shares subject to possible redemption as of December 31, 2025 | $209,220,000 | 20,125,000 | ||||
Year ended December 31, 2025 | Year ended December 31, 2024 | |||||||||||
Class A | Class B | Class A | Class B | |||||||||
Numerator: | ||||||||||||
Basic and diluted net income (loss) per share of ordinary shares: | ||||||||||||
Allocation of income (loss) – basic and diluted | $3,547,000 | $1,371,000 | $— | $(90,000) | ||||||||
Denominator: | ||||||||||||
Basic and diluted weighted average share of ordinary shares: | 17,354,000 | 6,707,663 | — | 5,833,000 | ||||||||
Basic and diluted net income (loss) per share of common share | $0.20 | $0.20 | $— | $0.01 | ||||||||
Share price | $9.945 | ||
Expected term (in years) | 6 | ||
Volatility | 4.0% | ||
Risk free rate | 4.0% | ||
Description at December 31, 2025 | Quoted Price Prices in Active Markets (Level 1) | ||
Assets: | |||
Money market funds | $209,220,000 | ||
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); and |
• | if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days within a 30-trading day period commencing at least 30 days after completion of the initial business combination and ending three business days before the Company sends the notice of redemption to the warrant holders. |
December 31, 2025 | December 31, 2024 | |||||
Cash and cash equivalents | $1,198,000 | $55,000 | ||||
Prepaid expenses | $136,000 | $— | ||||
Investments held in Trust Account | $209,220,000 | $— | ||||
Year ended December 31, 2025 | For the period from August 13, 2024 (inception) to December 31, 2024 | |||||
General, and administrative costs | $2,090,000 | $— | ||||
Investment income | $7,008,000 | $— | ||||

For the six months ended June 30, | For the six months ended June 30, 2026 | |||||||||||
Notes | 2026 | 2025 | ||||||||||
(in thousands of euros unless otherwise stated) | Convenience translation into US dollars* | |||||||||||
Revenue from Products and Services (2026: €788; 2025: nil from related party) | 3 | 19,429 | 13,347 | 22,149 | ||||||||
Cost of sales | (13,299) | (9,193) | (15,161) | |||||||||
Gross profit | 6,130 | 4,154 | 6,988 | |||||||||
Other income | 6,554 | 4,763 | 7,472 | |||||||||
Research and development expenses | (34,629) | (35,450) | (39,477) | |||||||||
Selling, General and Administrative expenses (2026: €170; 2025: €168 from related party) | 4 | (59,170) | (48,932) | (67,454) | ||||||||
Operating loss | (81,115) | (75,465) | (92,471) | |||||||||
Loss on disposal of assets | (9) | (3) | (10) | |||||||||
Finance income | 353 | 1,581 | 402 | |||||||||
Finance costs | (1,448) | (991) | (1,650) | |||||||||
Share of loss of associates | (83) | — | (95) | |||||||||
Loss before income tax | (82,302) | (74,878) | (93,824) | |||||||||
Income tax benefit | 5 | 321 | 585 | 366 | ||||||||
Net loss | (81,981) | (74,293) | (93,458) | |||||||||
Other comprehensive income (loss) | ||||||||||||
Items that may be subsequently reclassified to profit or loss | ||||||||||||
Currency translation differences | 198 | (144) | 226 | |||||||||
Other comprehensive income (loss), net of tax | 198 | (144) | 226 | |||||||||
Total comprehensive loss | (81,783) | (74,437) | (93,232) | |||||||||
Net loss attributable to: | ||||||||||||
Owners of newcleo plc | (81,981) | (74,293) | (93,458) | |||||||||
Non-controlling interest | — | — | — | |||||||||
Total comprehensive loss attributable to: | ||||||||||||
Owners of newcleo plc | (81,783) | (74,437) | (93,232) | |||||||||
Non-controlling interest | — | — | — | |||||||||
Net loss per share for loss attributable to the ordinary equity holders: | ||||||||||||
Basic and diluted loss per share | (0.16) | (0.16) | (0.18) | |||||||||
* | Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14). |

Notes | June 30, 2026 | December 31, 2025 | June 30, 2026 | |||||||||
(in thousands of euros unless otherwise stated) | Convenience translation into US dollars* | |||||||||||
ASSETS | ||||||||||||
NON-CURRENT ASSETS | ||||||||||||
Goodwill | 37,281 | 37,281 | 42,500 | |||||||||
Intangible assets, net | 42,760 | 43,054 | 48,746 | |||||||||
Property, plant and equipment, net | 6 | 115,999 | 93,436 | 132,239 | ||||||||
Right-of-use asset (2026: €416; 2025: €586 from related party) | 17,665 | 18,521 | 20,138 | |||||||||
Investments | 76 | 75 | 87 | |||||||||
Investments in associates | 31,553 | 31,635 | 35,970 | |||||||||
Other long-term receivables | 34,871 | 35,207 | 39,753 | |||||||||
Deferred tax assets | 5 | 3,059 | 2,176 | 3,487 | ||||||||
TOTAL NON-CURRENT ASSETS | 283,264 | 261,385 | 322,920 | |||||||||
CURRENT ASSETS | ||||||||||||
Inventories | 4,843 | 5,057 | 5,521 | |||||||||
Short-term investments | 2,335 | 2,291 | 2,662 | |||||||||
Trade receivable, contract and other assets, net (2026: €2,700; 2025: €1,200 from related party) | 8 | 77,768 | 62,314 | 88,656 | ||||||||
Cash and cash equivalents | 66,540 | 105,270 | 75,856 | |||||||||
TOTAL CURRENT ASSETS | 151,486 | 174,932 | 172,695 | |||||||||
TOTAL ASSETS | 434,750 | 436,317 | 495,615 | |||||||||
NON-CURRENT LIABILITIES | ||||||||||||
Provisions | 4,094 | 4,170 | 4,667 | |||||||||
Other liabilities | 8,932 | 9,305 | 10,182 | |||||||||
Lease liabilities (2026: €63; 2025: €252 from related party) | 14,667 | 15,537 | 16,720 | |||||||||
Borrowings | 10 | 15,929 | 16,306 | 18,159 | ||||||||
Deferred tax liabilities | 5 | 4,430 | 4,244 | 5,050 | ||||||||
TOTAL NON-CURRENT LIABILITIES | 48,052 | 49,562 | 54,778 | |||||||||
CURRENT LIABILITIES | ||||||||||||
Provisions | 378 | 186 | 431 | |||||||||
Trade and other payables | 9 | 60,055 | 83,808 | 68,463 | ||||||||
Lease liabilities (2026: €374; 2025: €369 from related party) | 3,545 | 3,250 | 4,041 | |||||||||
Borrowings | 10 | 2,497 | 2,583 | 2,847 | ||||||||
TOTAL CURRENT LIABILITIES | 66,475 | 89,827 | 75,782 | |||||||||
TOTAL LIABILITIES | 114,527 | 139,389 | 130,560 | |||||||||
EQUITY | ||||||||||||
Share capital | 7 | 5,046 | 4,739 | 5,752 | ||||||||
Share premium | 7 | 23,378 | 562,904 | 26,652 | ||||||||
Other reserves | 57,067 | 51,383 | 65,057 | |||||||||
Retained earnings (accumulated deficits) | 7 | 234,695 | (324,123) | 267,552 | ||||||||
Equity attributable to owners of newcleo plc | 320,186 | 294,903 | 365,013 | |||||||||
Non-controlling interests | 37 | 2,025 | 42 | |||||||||
TOTAL EQUITY | 320,223 | 296,928 | 365,055 | |||||||||
TOTAL EQUITY AND LIABILITIES | 434,750 | 436,317 | 495,615 | |||||||||
* | Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14). |

(in thousands of euros) | Notes | Share capital | Share premium | Other reserves | Retained earnings (accumulated deficits) | Attributable to owners of newcleo plc | Non- controlling interests | Total equity | ||||||||||||||||
Balance at December 31, 2025 | 4,739 | 562,904 | 51,383 | (324,123) | 294,903 | 2,025 | 296,928 | |||||||||||||||||
Net loss | — | — | — | (81,981) | (81,981) | — | (81,981) | |||||||||||||||||
Other comprehensive income | — | — | 198 | — | 198 | — | 198 | |||||||||||||||||
Total comprehensive loss | — | — | 198 | (81,981) | (81,783) | — | (81,783) | |||||||||||||||||
Transactions with owners in their capacity as owners: | ||||||||||||||||||||||||
Equity-settled share-based payments | 4 | — | — | 21,010 | — | 21,010 | — | 21,010 | ||||||||||||||||
Issue of share capital | 7 | 246 | 83,834 | — | — | 84,080 | — | 84,080 | ||||||||||||||||
Transfer of equity instruments issued in connection with the acquisition of Next-N Investment | 7 | 61 | 17,439 | (17,500) | — | — | — | — | ||||||||||||||||
NCI derecognized in connection with investment in Next-N | 7 | — | — | 1,988 | — | 1,988 | (1,988) | — | ||||||||||||||||
Share premium reduction | 7 | — | (640,799) | — | 640,799 | — | — | — | ||||||||||||||||
Other movements | — | — | (12) | — | (12) | — | (12) | |||||||||||||||||
Total transactions with owners | 307 | (539,526) | 5,486 | 640,799 | 107,066 | (1,988) | 105,078 | |||||||||||||||||
Balance at June 30, 2026 | 5,046 | 23,378 | 57,067 | 234,695 | 320,186 | 37 | 320,223 | |||||||||||||||||
(in thousands of euros) | Notes | Share capital | Share premium | Other reserves | Accumulated deficits | Attributable to owners of newcleo plc | Non- controlling interests | Total equity | ||||||||||||||||
Balance at December 31, 2024 | 4,620 | 530,911 | 11,473 | (185,782) | 361,222 | 21 | 361,243 | |||||||||||||||||
Net loss | — | — | — | (74,293) | (74,293) | — | (74,293) | |||||||||||||||||
Other comprehensive loss | — | — | (144) | — | (144) | — | (144) | |||||||||||||||||
Total comprehensive loss | — | — | (144) | (74,293) | (74,437) | — | (74,437) | |||||||||||||||||
Transactions with owners in their capacity as owners: | — | — | — | — | — | — | — | |||||||||||||||||
Equity-settled share-based payments | 4 | — | — | 4,975 | — | 4,975 | — | 4,975 | ||||||||||||||||
Capital increase in newcleo SA subscribed by non-controlling shareholders | 7 | — | — | 32,106 | — | 32,106 | — | 32,106 | ||||||||||||||||
Non-controlling interests recognized on the newcleo SA capital increase | 7 | — | — | (7,440) | — | (7,440) | 7,440 | — | ||||||||||||||||
Other movements | — | — | 3 | — | 3 | — | 3 | |||||||||||||||||
Total transactions with owners | — | — | 29,644 | — | 29,644 | 7,440 | 37,084 | |||||||||||||||||
Balance at June 30, 2025 | 4,620 | 530,911 | 40,973 | (260,075) | 316,429 | 7,461 | 323,890 | |||||||||||||||||

(in thousands of US dollars) | Notes | Share capital | Share premium | Other reserves | Retained earnings (accumulated deficits) | Attributable to owners of newcleo plc | Non- controlling interests | Total equity | ||||||||||||||||
Convenience translation into US dollars* | ||||||||||||||||||||||||
Balance at December 31, 2025 | 5,402 | 641,711 | 58,577 | (369,500) | 336,190 | 2,309 | 338,499 | |||||||||||||||||
Net loss | — | — | — | (93,458) | (93,458) | — | (93,458) | |||||||||||||||||
Other comprehensive income | — | — | 226 | — | 226 | — | 226 | |||||||||||||||||
Total comprehensive loss | — | — | 226 | (93,458) | (93,232) | — | (93,232) | |||||||||||||||||
Transactions with owners in their capacity as owners: | — | — | — | — | — | — | — | |||||||||||||||||
Equity-settled share-based payments | 4 | — | — | 23,951 | — | 23,951 | — | 23,951 | ||||||||||||||||
Issue of share capital | 7 | 280 | 95,571 | — | — | 95,851 | — | 95,851 | ||||||||||||||||
Transfer of equity instruments issued in connection with the acquisition of Next-N Investment | 7 | 70 | 19,880 | (19,950) | — | — | — | — | ||||||||||||||||
NCI derecognized in connection with investment in Next-N | 7 | — | — | 2,267 | — | 2,267 | (2,267) | — | ||||||||||||||||
Share premium reduction | 7 | — | (730,510) | — | 730,510 | — | — | — | ||||||||||||||||
Other movements | — | — | (14) | — | (14) | — | (14) | |||||||||||||||||
Total transactions with owners | 350 | (615,059) | 6,254 | 730,510 | 122,055 | (2,267) | 119,788 | |||||||||||||||||
Balance at June 30, 2026 | 5,752 | 26,652 | 65,057 | 267,552 | 365,013 | 42 | 365,055 | |||||||||||||||||
* | Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14) |

For the six months ended June 30 | For the six months ended June 30 2026 | |||||||||||
Notes | 2026 | 2025 | ||||||||||
(in thousands of euros) | Convenience translation into US$* | |||||||||||
Cash flows from operating activities | ||||||||||||
Net loss | (81,981) | (74,293) | (93,458) | |||||||||
Adjustments to reconcile net loss to net cash flows: | ||||||||||||
Loss from associates | 83 | — | 95 | |||||||||
Finance income | (30) | (1,476) | (34) | |||||||||
Finance costs | 1,131 | 830 | 1,289 | |||||||||
Income tax benefit | 5 | (321) | (585) | (366) | ||||||||
Depreciation of property, plant and equipment and right-of-use assets, amortization intangible assets and provisions | 6 | 8,286 | 7,397 | 9,446 | ||||||||
Share-based payment expense | 21,010 | 4,975 | 23,951 | |||||||||
Loss on disposals | 9 | 4 | 10 | |||||||||
Other revenues and expenses without effect on cash flow | 3 | 5 | 3 | |||||||||
Changes in working capital: | ||||||||||||
Decrease in inventory | 214 | 94 | 244 | |||||||||
(Increase) in trade receivables, contract and other assets | (15,217) | (6,781) | (17,347) | |||||||||
Increase (decrease) in trade and other payables | 13,077 | (2,428) | 14,908 | |||||||||
Income taxes received | 49 | 25 | 56 | |||||||||
Net cash flows used in operating activities | (53,687) | (72,233) | (61,203) | |||||||||
Cash flows from investing activities | ||||||||||||
Acquisition of intangible assets | (1,642) | (458) | (1,872) | |||||||||
Purchase of property, plant and equipment | (25,328) | (18,542) | (28,874) | |||||||||
Proceeds from maturities of short-term investments | — | 997 | — | |||||||||
Purchase of short-term investments | (41) | (160) | (47) | |||||||||
Interest received from short-term investments | 30 | 1,477 | 34 | |||||||||
Decrease (increase) in loans and deposits made | 4 | (2) | 5 | |||||||||
Proceeds from sale of tangible and intangible assets | 10 | 5 | 12 | |||||||||
Net cash flows used in investing activities | (26,967) | (16,683) | (30,742) | |||||||||
Cash flows from financing activities | ||||||||||||
Proceeds from issues of shares | 45,121 | — | 51,438 | |||||||||
Proceeds from issue of shares to non-controlling shareholders | — | 31,637 | — | |||||||||
Repayments of borrowings and lease liabilities (2026: €198; 2025: €464 from related party) | (2,129) | (2,535) | (2,427) | |||||||||
Interest expenses including interest on lease | (1,131) | (800) | (1,289) | |||||||||
Net cash flows from financing activities | 41,861 | 28,302 | 47,722 | |||||||||
Net decrease in cash and cash equivalents | (38,793) | (60,614) | (44,223) | |||||||||
Cash and cash equivalents at the beginning of the period | 105,270 | 192,714 | 120,008 | |||||||||
Effect of foreign exchange rate changes | 63 | (204) | 71 | |||||||||
Cash and cash equivalents at the end of the period | 66,540 | 131,896 | 75,856 | |||||||||
* | Convenience translation into US$ in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14) |

Ownership interest held by the Group | Ownership interest held by non-controlling interests | |||||||||||||||||
Name of entity | Place of business/country of incorporation | 2026 | 2025 | 2026 | 2025 | Principal activities | ||||||||||||
newcleo Spa | Italy | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo Generation (UK) Ltd | United Kingdom | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo SA | France | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo Operations | France | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo SA | Switzerland | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo Americas LLC | USA | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo Real Estate Srl | Italy | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
Fucina Italia Srl (“Fucina”) | Italy | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
Servizi Ricerche e Sviluppo Srl (“SRS”) | Italy | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
Proil Srl | Italy | 72% | 70.28% | 28% | 29.72% | Nuclear | ||||||||||||
CCR Internazionale Scrl | Italy | 90% | 87.85% | 10% | 12.15% | Nuclear | ||||||||||||
Consorzio SRS Scrl | Italy | 65% | 63.45% | 35% | 36.55% | Nuclear | ||||||||||||
newcleo Fuel Innovations | France | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo Lead Fast Reactors Innovations | France | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
NewCleo 1 | France | 100% | 97.61% | — | — | Nuclear | ||||||||||||
Newvys a.s.** | Slovakia | 49% | — | — | — | Nuclear | ||||||||||||
Next-N S.p.A.* | Italy | 40% | — | — | — | Nuclear | ||||||||||||
Pompes Rütschi SAS | France | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
Rütschi Fluid AG | Switzerland | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo SRO | Slovakia | 100% | 97.61% | 0% | 2.39% | Nuclear | ||||||||||||
newcleo SRL | Belgium | 100% | — | 0% | — | Nuclear | ||||||||||||
** | Joint-venture accounted for under equity method of accounting |
* | Associate accounted for under equity method of accounting |


• | Amendments to IFRS 9 and IFRS 7: Amendments to the Classification and Measurement of Financial Instruments |
• | Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7: Annual Improvements Volume 11 |
• | Amendments to IFRS 9 and IFRS 7: Contracts Referencing Nature dependent Electricity |
Standard | IASB effective date | ||
Amendments to IAS 21: Hyperinflationary presentation currency | January 1, 2027 | ||
IFRS 18: Presentation and Disclosure in Financial Statements (“IFRS 18”) | January 1, 2027 | ||
IFRS 19: Subsidiaries without Public Accountability: Disclosures | January 1, 2027 | ||

(in thousands of euros) | For the six-months ended June 30, | |||||
2026 | 2025 | |||||
External revenue by type: | ||||||
Manufacturing and installation of equipment and spare parts | 14,296 | 10,992 | ||||
Consultancy services | 5,133 | 2,355 | ||||
Total revenue | 19,429 | 13,347 | ||||
External revenue by country of sale: | ||||||
Italy | 7,814 | 3,044 | ||||
France | 7,298 | 7,512 | ||||
Switzerland | 3,529 | 2,791 | ||||
Slovakia | 788 | — | ||||
Total revenue | 19,429 | 13,347 | ||||

(in thousands of euros) | For the six-months ended June 30, | |||||
2026 | 2025 | |||||
External revenue by customer location: | ||||||
Europe | 14,841 | 9,424 | ||||
America | 2,436 | 2,206 | ||||
Asia | 2,067 | 1,625 | ||||
Africa | 59 | — | ||||
Middle East | 26 | 92 | ||||
Total revenue | 19,429 | 13,347 | ||||
External revenue by timing of revenue: | ||||||
Goods transferred over time | 8,865 | 5,680 | ||||
Consultancy services transferred over time | 5,133 | 2,355 | ||||
Goods transferred point in time | 5,431 | 5,312 | ||||
Total revenue | 19,429 | 13,347 | ||||
For the six monthsended June 30, | ||||||
(in thousands of euros) | 2026 | 2025 | ||||
Share-based payments recorded in: | ||||||
Selling, general and administrative expenses | 13,213 | 3,060 | ||||
Research and development expenses | 7,797 | 1,915 | ||||
Total share-based payments expense | 21,010 | 4,975 | ||||


As of June 30, | As of December 31, | |||||
(in thousands of euros) | 2026 | 2025 | ||||
Current | ||||||
Trade receivables | 10,946 | 9,559 | ||||
Contract assets | 24,277 | 20,938 | ||||
Loss allowance | (661) | (409) | ||||
Trade receivables and contract assets, net | 34,562 | 30,088 | ||||
Grants receivable | 7,319 | — | ||||
Prepayments | 8,222 | 6,852 | ||||
Advances | 3,910 | 4,567 | ||||
Accrued income | 163 | 1,459 | ||||
Other taxes | 20,582 | 17,350 | ||||
R&D tax credit | 2,733 | 1,779 | ||||
Other receivables | 277 | 219 | ||||
Total trade receivable, contract and other assets | 77,768 | 62,314 | ||||

As of June 30, | As of December 31, | |||||
(in thousands of euros) | 2026 | 2025 | ||||
Current | ||||||
Trade payables | 15,749 | 15,860 | ||||
Social security and other taxes | 2,331 | 5,487 | ||||
Accrued expenses | 8,415 | 6,655 | ||||
Payroll liabilities | 14,076 | 9,990 | ||||
Contract liabilities | 17,716 | 5,026 | ||||
Deferred redeemable bond obligation (Note 7) | — | 38,577 | ||||
Other payables | 1,768 | 2,213 | ||||
Total Trade and other payables | 60,055 | 83,808 | ||||
For the six months ended June 30, | ||||||
(In thousands of euros) | 2026 | 2025 | ||||
Customer A | 3,395 | — | ||||
Customer B | 3,213 | 2,912 | ||||
Customer C | 1,700 | 2,085 | ||||
Customer D | — | 645 | ||||

Year ended December 31, | |||||||||
(in thousands of euros unless otherwise stated) | Notes | 2025 | 2024 | ||||||
Revenue | 4 | 32,769 | 46,743 | ||||||
Cost of sales | 5 | (24,953) | (34,999) | ||||||
Gross profit | 7,816 | 11,744 | |||||||
Other income (2025: €24; 2024: €24 from related party) | 5 | 19,347 | 17,746 | ||||||
Research and development expenses | 5 | (68,544) | (58,473) | ||||||
Selling, General and Administrative expenses (2025: €9,744; 2024: €7,327 from related party) | 5 | (98,547) | (86,815) | ||||||
Operating loss | (139,928) | (115,798) | |||||||
(Loss) gain on disposal of assets | (1,630) | 180 | |||||||
Finance income | 7 | 1,937 | 5,232 | ||||||
Change in fair value of financial assets measured at fair value through profit or loss | 19 | — | 1,798 | ||||||
Finance costs | 7 | (2,120) | (1,977) | ||||||
Share of loss of associates | 25 | (48) | — | ||||||
Loss before income tax | (141,789) | (110,565) | |||||||
Income tax benefit | 8 | 1,824 | 402 | ||||||
Net loss | (139,965) | (110,163) | |||||||
Other comprehensive income (loss) | |||||||||
Items that may be subsequently reclassified to profit or loss | |||||||||
Currency translation differences | (809) | 105 | |||||||
Items that will not be reclassified to profit or loss | |||||||||
Remeasurements of defined benefit plans | 287 | 16 | |||||||
Income tax impact | — | — | |||||||
Other comprehensive income (loss), net of tax | (522) | 121 | |||||||
Total comprehensive loss | (140,487) | (110,042) | |||||||
Net loss attributable to: | |||||||||
Owners of newcleo Ltd. | (138,341) | (110,163) | |||||||
Non-controlling interest | (1,624) | — | |||||||
Total comprehensive loss attributable to: | |||||||||
Owners of newcleo Ltd. | (138,863) | (110,042) | |||||||
Non-controlling interest | (1,624) | — | |||||||
Net loss per share for loss attributable to the ordinary equity holders: | |||||||||
Basic and diluted loss per share | 17 | (0.30) | (0.25) | ||||||
Weighted-average ordinary shares outstanding – basic and diluted | 17 | 462,252,560 | 436,276,314 | ||||||
As of December 31, | |||||||||
(in thousands of euros) | Notes | 2025 | 2024 | ||||||
ASSETS | |||||||||
NON-CURRENT ASSETS | |||||||||
Goodwill | 9 | 37,281 | 37,281 | ||||||
Intangible assets, net | 9 | 43,054 | 46,436 | ||||||
Property, plant and equipment, net | 10 | 93,436 | 58,783 | ||||||
Right-of-use asset (2025: €586; 2024: €909 from related party) | 11 | 18,521 | 21,612 | ||||||
Investments | 75 | 1,027 | |||||||
Investments in associates | 25 | 31,635 | — | ||||||
Other non-current receivables | 12 | 35,207 | 15,820 | ||||||
Deferred tax assets | 8 | 2,176 | 1,169 | ||||||
TOTAL NON-CURRENT ASSETS | 261,385 | 182,128 | |||||||
CURRENT ASSETS | |||||||||
Inventories | 13 | 5,057 | 6,952 | ||||||
Short-term investments | 19 | 2,291 | 2,199 | ||||||
Trade receivable, contract and other assets, net (2025: €1,200; 2024: €0 from related party) | 14 | 62,314 | 64,018 | ||||||
Cash and cash equivalents | 15 | 105,270 | 192,714 | ||||||
TOTAL CURRENT ASSETS | 174,932 | 265,883 | |||||||
TOTAL ASSETS | 436,317 | 448,011 | |||||||
NON-CURRENT LIABILITIES | |||||||||
Provisions | 20 | 4,170 | 3,519 | ||||||
Other non-current liabilities | 21 | 9,305 | 1 | ||||||
Lease liabilities (2025: €252; 2024: €610 from related party) | 11 | 15,537 | 18,003 | ||||||
Borrowings | 19 | 16,306 | 2,283 | ||||||
Deferred tax liabilities | 8 | 4,244 | 5,781 | ||||||
TOTAL NON-CURRENT LIABILITIES | 49,562 | 29,587 | |||||||
CURRENT LIABILITIES | |||||||||
Provisions | 20 | 186 | 103 | ||||||
Trade and other payables | 23 | 83,808 | 52,116 | ||||||
Lease liabilities (2025: €369; 2024: €353 from related party) | 11 | 3,250 | 3,203 | ||||||
Borrowings | 19 | 2,583 | 1,759 | ||||||
TOTAL CURRENT LIABILITIES | 89,827 | 57,181 | |||||||
TOTAL LIABILITIES | 139,389 | 86,768 | |||||||
EQUITY | |||||||||
Share capital | 16 | 4,739 | 4,620 | ||||||
Share premium | 16 | 562,904 | 530,911 | ||||||
Other reserves | 51,383 | 11,473 | |||||||
Accumulated deficits | (324,123) | (185,782) | |||||||
Equity attributable to owners of newcleo Ltd. | 294,903 | 361,222 | |||||||
Non-controlling interests | 2,025 | 21 | |||||||
TOTAL EQUITY | 296,928 | 361,243 | |||||||
TOTAL EQUITY AND LIABILITIES | 436,317 | 448,011 | |||||||
(in thousands of euros) | Notes | Share capital | Share premium | Other reserves | Accumu- lated deficits | Attribu- table to owners of newcleo Ltd | Non- controlling interests | Total equity | ||||||||||||||||
Balance at December 31, 2023 | 4,127 | 396,078 | 1,868 | (75,619) | 326,454 | 21 | 326,475 | |||||||||||||||||
Net loss | — | — | (110,163) | (110,163) | — | (110,163) | ||||||||||||||||||
Other comprehensive income | — | — | 121 | — | 121 | — | 121 | |||||||||||||||||
Total comprehensive loss | — | — | 121 | (110,163) | (110,042) | — | (110,042) | |||||||||||||||||
Transactions with owners in their capacity as owners: | ||||||||||||||||||||||||
Equity-settled share-based payments | 18 | — | — | 8,316 | 8,316 | — | 8,316 | |||||||||||||||||
Issue of share capital | 16 | 493 | 134,833 | — | — | 135,326 | — | 135,326 | ||||||||||||||||
Other movements | — | — | 1,168 | — | 1,168 | — | 1,168 | |||||||||||||||||
Total transactions with owners | 493 | 134,833 | 9,484 | — | 144,810 | — | 144,810 | |||||||||||||||||
Balance at December 31, 2024 | 4,620 | 530,911 | 11,473 | (185,782) | 361,222 | 21 | 361,243 | |||||||||||||||||
Net loss | — | — | — | (138,341) | (138,341) | (1,624) | (139,965) | |||||||||||||||||
Other comprehensive income | — | — | (522) | (522) | — | (522) | ||||||||||||||||||
Total comprehensive loss | — | — | (522) | (138,341) | (138,863) | (1,624) | (140,487) | |||||||||||||||||
Transactions with owners in their capacity as owners: | ||||||||||||||||||||||||
Equity-settled share-based payments | 18 | — | — | 14,895 | — | 14,895 | — | 14,895 | ||||||||||||||||
Issue of share capital | 16 | 119 | 31,993 | — | — | 32,112 | — | 32,112 | ||||||||||||||||
Equity instruments issued in connection with the acquisition of Next-N Investment | 25 | — | — | 29,165 | — | 29,165 | — | 29,165 | ||||||||||||||||
NCI recognized in connection with investment in Next-N | 25 | — | — | (3,628) | — | (3,628) | 3,628 | — | ||||||||||||||||
Total transactions with owners | 119 | 31,993 | 40,432 | — | 72,544 | 3,628 | 76,172 | |||||||||||||||||
Balance at December 31, 2025 | 4,739 | 562,904 | 51,383 | (324,123) | 294,903 | 2,025 | 296,928 | |||||||||||||||||
Year ended December 31, | |||||||||
(in thousands of euros) | Notes | 2025 | 2024 | ||||||
Cash flows from operating activities | |||||||||
Net loss | (139,965) | (110,163) | |||||||
Adjustments to reconcile net loss to net cash flows: | |||||||||
Loss from associates | 48 | — | |||||||
Finance income | (1,734) | (4,941) | |||||||
Finance costs | 1,455 | 1,709 | |||||||
Income tax benefit | 8 | (1,824) | (402) | ||||||
Depreciation of property, plant and equipment and right-of-use assets, amortization intangible assets and provisions | 9, 10, 11, 20 | 16,931 | 13,121 | ||||||
Share-based payment expense | 18 | 14,895 | 8,316 | ||||||
Loss on disposals | 1,802 | 429 | |||||||
Change in fair value of financial assets measured at fair value through profit or loss | 19 | — | (1,798) | ||||||
Other revenues and expenses without effect on cash flow | (123) | (105) | |||||||
Changes in working capital: | |||||||||
Decrease in inventory | 13 | 1,895 | 3,301 | ||||||
Increase in trade receivables, contract and other assets (2025: €1,200; 2024: €0 from related party) | 14 | (16,787) | (21,046) | ||||||
Increase in trade and other payables | 23 | 3,469 | 8,448 | ||||||
Income taxes received (paid) | 260 | (1,346) | |||||||
Net cash flows used in operating activities | (119,678) | (104,477) | |||||||
Cash flows from investing activities | |||||||||
Investment in associate | 25 | (2,463) | — | ||||||
Acquisition of intangible assets | 9 | (2,861) | (11,751) | ||||||
Purchase of property, plant and equipment | 10 | (43,002) | (37,712) | ||||||
Proceeds from maturities of short-term investments | 859 | 358,804 | |||||||
Purchase of short-term investments | (2,615) | (186,082) | |||||||
Interest received from short-term investments | 1,735 | 3,944 | |||||||
Decrease (increase) in loans and deposits made | 50 | (970) | |||||||
Proceeds from sale of tangible and intangible assets | 13 | 33 | |||||||
Net cash flows (used in) / from investing activities | (48,284) | 126,266 | |||||||
Cash flows from financing activities | |||||||||
Proceeds from issues of shares | 31,637 | 61,985 | |||||||
Redeemable bond subscriptions | 23 | 38,577 | — | ||||||
Proceeds from borrowings | 16,664 | — | |||||||
Repayments of borrowings and lease liabilities (2025: €464; 2024: €544 from related party) | (4,749) | (4,412) | |||||||
Interest paid including interest on lease | (1,408) | (1,739) | |||||||
Other cash flows used in financing activities | — | (29) | |||||||
Net cash flows from financing activities | 80,721 | 55,805 | |||||||
Net increase in cash and cash equivalents | (87,241) | 77,594 | |||||||
Cash and cash equivalents at the beginning of the period | 192,714 | 114,797 | |||||||
Effect of foreign exchange rate changes | (203) | 323 | |||||||
Cash and cash equivalents at the end of the period | 105,270 | 192,714 | |||||||
Name of entity | Place of business/country of incorporation | Ownership interest held by the Group | Ownership interest held by non-controlling interests | Principal activities | ||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||||
newcleo Spa | Italy | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
newcleo Generation (UK) Ltd | United Kingdom | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
newcleo SA | France | 98.72% | 99.98% | 1.28% | 0.02% | Nuclear | ||||||||||||
newcleo Operations | France | 98.72% | 99.99% | 1.28% | 0.01% | Nuclear | ||||||||||||
newcleo SA | Switzerland | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
newcleo Americas LLC | USA | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
newcleo Real Estate Srl | Italy | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
Fucina Italia Srl (“Fucina”) | Italy | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
Servizi Ricerche e Sviluppo Srl (“SRS”) | Italy | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
Proil Srl | Italy | 71.08% | 72.00% | 28.92% | 28.00% | Nuclear | ||||||||||||
CCR Internazionale Scrl | Italy | 88.85% | 90.00% | 11.15% | 10.00% | Nuclear | ||||||||||||
Consorzio SRS Scrl | Italy | 64.17% | 65.00% | 35.83% | 35.00% | Nuclear | ||||||||||||
newcleo Fuel Innovations | France | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
newcleo Lead Fast Reactors Innovations | France | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
newcleo 1 | France | 98.72% | 0.00% | 1.28% | 0.00% | Nuclear | ||||||||||||
Newvys a.s. | Slovakia | 49.00% | 0.00% | 51.00% | 0.00% | Nuclear | ||||||||||||
Next-N S.p.A. | Italy | 40.00% | 0.00% | 60.00% | 0.00% | Nuclear | ||||||||||||
Pompes Rütschi SAS | France | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
Rütschi Fluid AG | Switzerland | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
newcleo SRO | Slovakia | 98.72% | 100% | 1.28% | 0.00% | Nuclear | ||||||||||||
• | Assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet; |
• | Income and expenses for each statement of profit or loss and other comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and |
• | All resulting exchange differences are recognized in other comprehensive income. |
i. | The customer simultaneously receives and consumes the benefits provided by the Group’s performance as the Group performs. |
ii. | The Group’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced. |
iii. | The Group’s performance does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date. |
• | Sales and manufacturing of complex pumps and components with quality documents associated that have a long lead time (over one year) and heavy implication of engineering, quality, purchase and production departments |
• | Sales of engineered pumps based on customer technical specifications with quality documents associated with small nuclear projects |
• | Sales of engineered pumps based on customer technical specifications for new nuclear power plants with quality documents associated |
• | Special projects of sales of militarized pumps for nuclear or conventional submarines with quality documents associated |
• | Fixed payments, including in-substance fixed payments, less any lease incentives receivable; |
• | Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date; |
• | The amount expected to be payable by the lessee under residual value guarantees; |
• | The exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and |
• | Payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate the lease. |
• | The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate; |
• | The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate, unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used; and |
• | A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification. |
• | Buildings: 25 to 30 years |
• | Computer equipment: 3 years |
• | Machinery and equipment: 5 to 20 years |
• | Leasehold improvements: shorter of the useful life or lease term |
• | Other tangible assets: the lesser of 5 to 7 years or the remaining useful life of the leased property |
• | Capitalized development costs: 5 years |
• | Software licenses: 5 years |
• | Patents: between 5 and 20 years |
• | Unpatented technology: 20 years |
• | Order backlog: 2 years |
• | Customer relationships: between 13 and 15 years |
• | it is technically feasible to complete the software product so that it will be available for use or sell; |
• | management intends to complete the software product and use or sell it; |
• | there is an ability to use or sell the software product; |
• | it can be demonstrated how the software product will generate probable future economic benefits; |
• | adequate technical, financial and other resources to complete the development and to use or sell the software product are available; and |
• | the expenditure attributable to the software product during its development can be reliably measured. |
• | the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and |
• | the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. |
• | The rights to receive cash flows from the asset have expired |
• | The Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a ‘pass-through’ arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset |
• | Classification of Liabilities as Current or Non-current and Non-current liabilities with covenants – Amendments to IAS 1; |
• | Lease Liability in Sale and Leaseback – Amendments to IFRS 16; and |
• | Supplier Finance Arrangements – Amendments to IAS 7 and IFRS 7. |
• | Lack of Exchangeability – Amendments to IAS 21 |
Standard | IASB effective date | ||
Amendments to IAS 21: Hyperinflationary presentation currency | January 1, 2027 | ||
Amendments to IFRS 9 and IFRS 7: Amendments to the Classification and Measurement of Financial Instruments | January 1, 2026 | ||
Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7: Annual Improvements Volume 11 | January 1, 2026 | ||
Amendments to IFRS 9 and IFRS 7: Contracts Referencing Nature dependent Electricity | January 1, 2026 | ||
IFRS 18: Presentation and Disclosure in Financial Statements (“IFRS 18”) | January 1, 2027 | ||
IFRS 19: Subsidiaries without Public Accountability: Disclosures | January 1, 2027 | ||
• | A pre-tax discount rate of 10.63% per cent per annum for PRM (France) and 8.46% per cent per annum for RFAG (Switzerland) was applied to future cashflows, applying the discounted cashflow method. A 1% increase in each discount rate would reduce the discounted cashflows by €9.2 million. |
• | Forecast sales are based on experience adjusted for factors such as sales/market trends, contracts in progress, and the strategic decisions made in respect of the Rütschi business plan. A 2% decrease in projected sales according to the business plan would reduce the discounted cash flows by 7.0 million. |
• | Profits are forecast based on historical experience of operating margins, adjusted for the impact of factors such as changes to product costs. Projections assume an average EBITDA margin of 24.3% for PRM and 32.8% for RFAG, in line with historic margins. A reduction of 15% of normative year EBITDA would reduce discounted cashflows by €9.1 million. |
• | Cash conversion is the ratio of operating cash flow to operating profit. Management forecasts cash conversion rates based on historical experience. Cash flows beyond that six-year period have been extrapolated using a steady 2% per annum for PRM (France) and 0.5% per annum for RFAG (Switzerland). Management estimates that a decrease in perpetual growth rate by 1% would reduce the headroom in Rütschi by €13.1 million. |
Change in estimated future costs | Effect on profit before tax | |||||
(in thousands of euros) | ||||||
Impact on change in the estimated future costs to be incurred in delivering partially unsatisfied performance obligations | +10% -10% | (3,633) 3,633 | ||||
2025 | |||
Weighted average expected term in years | 2.70 | ||
Weighted average expected ordinary price volatility | 46.37% | ||
Weighted average Risk-free interest rate | 2.47% | ||
Expected dividend yields | 0.0% | ||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
External revenue by type: | ||||||
Manufacturing and installation of equipment and spare parts | 27,883 | 40,739 | ||||
Consultancy services | 4,886 | 6,004 | ||||
Total revenue | 32,769 | 46,743 | ||||
External revenue by country of sale: | ||||||
Italy | 7,883 | 20,539 | ||||
France | 16,761 | 16,167 | ||||
Switzerland | 8,125 | 10,037 | ||||
Total revenue | 32,769 | 46,743 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
External revenue by customer location: | ||||||
Europe | 20,853 | 32,453 | ||||
America | 5,642 | 10,138 | ||||
Asia | 6,100 | 4,086 | ||||
Africa | 6 | — | ||||
Middle East | 168 | 66 | ||||
Total revenue | 32,769 | 46,743 | ||||
External revenue by timing of revenue: | ||||||
Goods transferred over time | 17,151 | 25,974 | ||||
Consultancy services transferred over time | 4,886 | 5,370 | ||||
Goods transferred point in time | 10,732 | 15,399 | ||||
Total revenue | 32,769 | 46,743 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Consultancy services | 2,168 | 2,702 | ||||
Manufacturing and installation of equipment and spare parts | 37,084 | 23,820 | ||||
Total | 39,252 | 26,522 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
R&D tax credits | 9,995 | 8,351 | ||||
Grant income | 8,619 | 7,006 | ||||
Other income | 733 | 2,389 | ||||
Total other income | 19,347 | 17,746 | ||||
Year ended December 31 | |||||||||
(in thousands of euros) | Notes | 2025 | 2024 | ||||||
Changes in inventories of finished goods and work in progress | (1,773) | (2,048) | |||||||
Raw materials and consumables | (6,042) | (9,444) | |||||||
Staff costs | 6 | (98,292) | (70,391) | ||||||
External services | (37,914) | (59,381) | |||||||
Legal and professional | (6,433) | (2,623) | |||||||
Depreciation and amortization | 9, 10, 11 | (15,880) | (13,155) | ||||||
Net change on provisions | (128) | 170 | |||||||
Office costs | (6,231) | (7,116) | |||||||
Recruitment costs | (232) | (963) | |||||||
Advertising and promotion | (1,348) | (1,604) | |||||||
Travel and subsistence | (5,836) | (5,926) | |||||||
IT costs | (7,662) | (6,045) | |||||||
Other costs | (4,273) | (1,761) | |||||||
Total cost of sales, selling and distribution, administrative and research and development expenses | (192,044) | (180,287) | |||||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Wages and salaries | (59,126) | (45,485) | ||||
Contributions to defined contribution plans | (1,443) | (2,026) | ||||
Expenses related to post-employment defined benefit plans | (878) | (29) | ||||
Social security costs | (17,176) | (11,221) | ||||
Share-based payment expense | (14,895) | (8,316) | ||||
Other costs | (4,774) | (3,314) | ||||
Total staff costs | (98,292) | (70,391) | ||||
Year ended December 31, | ||||||
2025 | 2024 | |||||
Monthly average number of employees (including executive directors) throughout the year | 966 | 777 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Short-term employee benefits | 4,632 | 3,847 | ||||
Consultancy fees | 370 | 203 | ||||
Post-employment benefits | — | 177 | ||||
Termination benefits | 71 | 385 | ||||
Other long-term employee benefits | 352 | — | ||||
Share-based payments | 3,486 | 1,751 | ||||
Total compensation to key management personnel | 8,911 | 6,363 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Aggregate emoluments | — | 56 | ||||
Other benefits | 57 | 44 | ||||
Share-based payments | 439 | 355 | ||||
Total remuneration | 496 | 455 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Interest income | 1,674 | 4,943 | ||||
Exchange rate gains | 263 | 289 | ||||
Total finance income | 1,937 | 5,232 | ||||
Lease interest expense | (1,323) | (1,413) | ||||
Exchange rate losses | (45) | (241) | ||||
Interest expense | (131) | (296) | ||||
Other finance expenses | (621) | (27) | ||||
Total finance costs | (2,120) | (1,977) | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Current income tax: | ||||||
Current income tax benefit | (724) | (1,434) | ||||
Deferred tax: | ||||||
Origination and reversal of temporary differences | 2,548 | 1,836 | ||||
Income tax expense reported in the consolidated statement of profit or loss and other comprehensive income | 1,824 | 402 | ||||
Year ended December 31, | ||||||||||||
(in thousands of euros) | 2025 | 2024 | ||||||||||
Loss before tax | (141,789) | (110,565) | ||||||||||
Tax credit at the UK corporation tax rate of 25% (2024: 25%) | 35,435 | 25% | 27,641 | 25% | ||||||||
Effect of tax rates of subsidiaries operating overseas | (791) | (0.6%) | (303) | (0.3%) | ||||||||
Non-taxable grants and other income | 2,724 | 1.9% | 1,845 | 1.7% | ||||||||
Tax effect of expenses that are not deductible in determining taxable profit | (3,059) | (2.2%) | (719) | (0.7%) | ||||||||
Adjustments relating to prior years | (298) | (0.2%) | — | — | ||||||||
Change in unrecognized timing differences | (2,332) | (1.6%) | (452) | (0.4%) | ||||||||
Change in unrecognized loss carry forward | (30,763) | (21.7%) | (27,547) | (24.9%) | ||||||||
Tax group relief | 929 | 0.7% | — | — | ||||||||
OCI reclassification | 255 | 0.2% | — | — | ||||||||
Other | (276) | (0.2%) | (63) | (0.1%) | ||||||||
Income tax credit & effective tax rate | 1,824 | 1.3% | 402 | 0.4% | ||||||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Deferred tax assets | ||||||
Deferred tax assets arising on business combinations | 1,322 | 1,405 | ||||
Temporary differences arising on long-term leases | 3,320 | 3,772 | ||||
Temporary differences arising on defined benefit plans | 71 | 95 | ||||
Other temporary differences | 1,895 | 327 | ||||
Offset against deferred tax liabilities | (4,432) | (4,430) | ||||
Total deferred tax assets | 2,176 | 1,169 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Deferred tax liabilities | ||||||
Deferred tax liabilities arising on business combinations | 5,228 | 6,195 | ||||
Temporary differences arising on long term leases | 3,216 | 3,712 | ||||
Other temporary differences | 232 | 304 | ||||
Offset against deferred tax assets | (4,432) | (4,430) | ||||
Total deferred tax liabilities | 4,244 | 5,781 | ||||
(in thousands of euros) | Balance at January 1, 2024 | Recognized in profit or loss | Acquired in business combinations | Balance at December 31, 2024 | Balance at December 31, 2024 | Balance at December 31, 2024 | ||||||||||||
Net | Net | Deferred tax assets | Deferred tax liabilities | |||||||||||||||
Deferred tax assets (liabilities) arising on business combinations | (6,536) | 1,746 | — | (4,790) | 1,405 | (6,195) | ||||||||||||
Temporary differences arising on long-term leases | — | 60 | — | 60 | 3,772 | (3,712) | ||||||||||||
Temporary differences arising on defined benefit plans | — | 5 | 90 | 95 | 95 | — | ||||||||||||
Other temporary differences | — | 22 | — | 22 | 326 | (304) | ||||||||||||
Tax assets (liabilities) before set-off | (6,536) | 1,833 | 90 | (4,613) | 5,598 | (10,211) | ||||||||||||
Offset against deferred tax liabilities | — | — | — | — | (4,429) | 4,430 | ||||||||||||
Net tax assets (liabilities) | (6,536) | 1,833 | 90 | (4,613) | 1,169 | (5,781) | ||||||||||||
(in thousands of euros) | Balance at January 1, 2025 | Recognized in profit or loss | Balance at December 31, 2025 | Balance at December 31, 2025 | Balance at December 31, 2025 | ||||||||||
Net | Net | Deferred tax assets | Deferred tax liabilities | ||||||||||||
Deferred tax assets (liabilities) arising on business combinations | (4,790) | 884 | (3,906) | 1,322 | (5,228) | ||||||||||
Temporary differences arising on long-term leases | 60 | 43 | 103 | 3,319 | (3,216) | ||||||||||
Temporary differences arising on defined benefit plans | 95 | (23) | 72 | 72 | — | ||||||||||
Other temporary differences | 22 | 1,641 | 1,663 | 1,895 | (232) | ||||||||||
Tax assets (liabilities) before set-off | (4,613) | 2,545 | (2,068) | 6,608 | (8,676) | ||||||||||
Offset against deferred tax liabilities | — | — | — | (4,432) | 4,432 | ||||||||||
Net tax assets (liabilities) | (4,613) | 2,545 | (2,068) | 2,176 | (4,244) | ||||||||||
(in thousands of euros) | Goodwill | Capitalized develop- ment costs | Software licenses | Patent and trademarks | Unpatented technology | Order backlog | Customer relation- ships | Assets under construc- tion | Total | ||||||||||||||||||
Cost: | |||||||||||||||||||||||||||
At January 1, 2024 | 37,870 | 1,460 | 3,578 | 7,424 | 8,597 | 4,198 | 16,568 | — | 79,695 | ||||||||||||||||||
Additions | — | — | 3,099 | 22 | — | — | — | 8,630 | 11,751 | ||||||||||||||||||
Disposals | — | — | (95) | (4) | — | — | — | — | (99) | ||||||||||||||||||
Transfer and others | (589) | (1,426) | (306) | (238) | — | — | — | 1,296 | (1,263) | ||||||||||||||||||
Effect of movement in exchange rates | — | (34) | 22 | — | — | — | — | 58 | 46 | ||||||||||||||||||
At December 31, 2024 | 37,281 | — | 6,298 | 7,204 | 8,597 | 4,198 | 16,568 | 9,984 | 90,130 | ||||||||||||||||||
Additions | — | — | 724 | 26 | — | — | 229 | 1,879 | 2,858 | ||||||||||||||||||
Disposals | — | — | (2,603) | (12) | — | — | — | (3) | (2,618) | ||||||||||||||||||
Transfer and others | — | — | 2,978 | — | — | — | — | (143) | 2,835 | ||||||||||||||||||
Effect of movement in exchange rates | — | — | (118) | — | — | — | — | (248) | (366) | ||||||||||||||||||
At December 31, 2025 | 37,281 | — | 7,279 | 7,218 | 8,597 | 4,198 | 16,797 | 11,469 | 92,839 | ||||||||||||||||||
Accumulation amortization: | |||||||||||||||||||||||||||
At January 1, 2024 | — | — | (723) | (845) | — | — | — | — | (1,568) | ||||||||||||||||||
Amortization charge | — | — | (1,293) | (365) | (430) | (2,098) | (1,171) | — | (5,357) | ||||||||||||||||||
Disposals | — | — | 109 | 4 | — | — | — | — | 113 | ||||||||||||||||||
Transfer and others | — | — | 142 | 254 | — | — | — | — | 396 | ||||||||||||||||||
Effect of movement in exchange rates | — | — | 3 | — | — | — | — | — | 3 | ||||||||||||||||||
At December 31, 2024 | — | — | (1,762) | (952) | (430) | (2,098) | (1,171) | — | (6,413) | ||||||||||||||||||
Amortization charge | — | — | (2,051) | (434) | (430) | (2,099) | (1,186) | — | (6,200) | ||||||||||||||||||
Disposals | — | — | 1,362 | — | — | — | — | — | 1,362 | ||||||||||||||||||
Transfer and others | — | — | (1,262) | — | — | — | — | — | (1,262) | ||||||||||||||||||
Effect of movement in exchange rates | — | — | 9 | — | — | — | — | — | 9 | ||||||||||||||||||
At December 31, 2025 | — | — | (3,704) | (1,386) | (860) | (4,197) | (2,357) | — | (12,504) | ||||||||||||||||||
Carrying amount: | |||||||||||||||||||||||||||
At December 31, 2024 | 37,281 | — | 4,536 | 6,252 | 8,167 | 2,100 | 15,397 | 9,984 | 83,717 | ||||||||||||||||||
At December 31, 2025 | 37,281 | — | 3,575 | 5,832 | 7,737 | 1 | 14,440 | 11,469 | 80,335 | ||||||||||||||||||
(in thousands of euros) | Land | Buildings | Computer equipment | Machinery and equipment | Leasehold improvements | Construction work in progress | Other tangible assets | Total | ||||||||||||||||
Cost: | ||||||||||||||||||||||||
At January 1, 2024 | 1,029 | 3,257 | 4,232 | 4,794 | 5,812 | 4,961 | 1,336 | 25,421 | ||||||||||||||||
Additions | — | 210 | 3,320 | 993 | 4,910 | 28,289 | 2,108 | 39,830 | ||||||||||||||||
Disposals | — | — | (93) | (162) | (48) | — | (30) | (333) | ||||||||||||||||
Transfer and others | — | (420) | (435) | 2,182 | (205) | (1,700) | 87 | (491) | ||||||||||||||||
Effect of movement in exchange rates | — | — | 26 | (25) | 14 | — | — | 15 | ||||||||||||||||
At December 31, 2024 | 1,029 | 3,047 | 7,050 | 7,782 | 10,483 | 31,550 | 3,501 | 64,442 | ||||||||||||||||
Additions | — | 3,678 | 782 | 4,971 | 432 | 32,748 | 330 | 42,941 | ||||||||||||||||
Disposals | — | — | (30) | (257) | (200) | — | (106) | (593) | ||||||||||||||||
Transfer and others | — | 424 | (3,024) | 8,447 | 1,770 | (10,651) | (60) | (3,094) | ||||||||||||||||
Effect of movement in exchange rates | — | — | (100) | 7 | (116) | 0 | (25) | (234) | ||||||||||||||||
At December 31, 2025 | 1,029 | 7,149 | 4,678 | 20,950 | 12,369 | 53,647 | 3,640 | 103,462 | ||||||||||||||||
Accumulation depreciation: | ||||||||||||||||||||||||
At January 1, 2024 | — | (11) | (857) | (322) | (302) | — | (188) | (1,680) | ||||||||||||||||
Amortization charge | — | (165) | (1,889) | (1,260) | (528) | — | (400) | (4,242) | ||||||||||||||||
Disposals | — | — | 89 | 157 | 17 | — | 17 | 280 | ||||||||||||||||
Transfer and others | — | — | (3) | 2 | (19) | — | (6) | (26) | ||||||||||||||||
Effect of movement in exchange rates | — | — | (2) | 12 | — | — | (1) | 9 | ||||||||||||||||
At December 31, 2024 | — | (176) | (2,662) | (1,411) | (832) | — | (578) | (5,659) | ||||||||||||||||
Amortization charge | — | (176) | (2,076) | (2,100) | (1,008) | — | (562) | (5,922) | ||||||||||||||||
Disposals | — | — | 5 | 10 | 45 | — | 76 | 136 | ||||||||||||||||
Transfer and others | — | (0) | 1,512 | (96) | (3) | — | (3) | 1,410 | ||||||||||||||||
Effect of movement in exchange rates | — | — | 13 | (13) | 5 | — | 4 | 9 | ||||||||||||||||
At December 31, 2025 | — | (352) | (3,208) | (3,610) | (1,793) | — | (1,063) | (10,026) | ||||||||||||||||
Carrying amount: | ||||||||||||||||||||||||
At December 31, 2024 | 1,029 | 2,871 | 4,388 | 6,371 | 9,651 | 31,550 | 2,923 | 58,783 | ||||||||||||||||
At December 31, 2025 | 1,029 | 6,797 | 1,470 | 17,340 | 10,576 | 53,647 | 2,577 | 93,436 | ||||||||||||||||
(in thousands of euros) | Buildings | Equipment | Motor vehicles | Total | ||||||||
Cost: | ||||||||||||
At January 1, 2024 | 21,006 | 216 | 279 | 21,501 | ||||||||
Additions | 5,775 | 251 | 7 | 6,033 | ||||||||
Disposals | (1,316) | — | (43) | (1,359) | ||||||||
Transfer and others | (475) | 27 | 76 | (372) | ||||||||
Effect of movement in exchange rates | 88 | — | — | 88 | ||||||||
At December 31, 2024 | 25,078 | 494 | 319 | 25,891 | ||||||||
Additions | 512 | 425 | 147 | 1,084 | ||||||||
Disposals | (455) | (29) | (115) | (599) | ||||||||
Transfer and others | 216 | — | 2 | 218 | ||||||||
Effect of movement in exchange rates | (332) | — | — | (332) | ||||||||
At December 31, 2025 | 25,019 | 890 | 353 | 26,262 | ||||||||
Accumulated depreciation: | ||||||||||||
At January 1, 2024 | (2,245) | (4) | (23) | (2,272) | ||||||||
Depreciation charge | (3,327) | (122) | (107) | (3,556) | ||||||||
Disposals | 1,476 | — | 27 | 1,503 | ||||||||
Transfer and others | 127 | (26) | (49) | 52 | ||||||||
Effect of movement in exchange rates | (6) | — | — | (6) | ||||||||
At December 31, 2024 | (3,975) | (152) | (152) | (4,279) | ||||||||
Depreciation charge | (3,459) | (191) | (108) | (3,758) | ||||||||
Disposals | 356 | 29 | 103 | 488 | ||||||||
Transfer and others | (210) | — | — | (210) | ||||||||
Effect of movement in exchange rates | 18 | — | — | 18 | ||||||||
At December 31, 2025 | (7,270) | (314) | (157) | (7,741) | ||||||||
Carrying amount: | ||||||||||||
At December 31, 2024 | 21,103 | 342 | 167 | 21,612 | ||||||||
At December 31, 2025 | 17,749 | 576 | 196 | 18,521 | ||||||||
(in thousands of euros) | 2025 | 2024 | ||||
Short-term leases, included in other operating expenses | ||||||
Office leases | 591 | 521 | ||||
Equipment | 382 | 32 | ||||
973 | 553 | |||||
Low value leases, rent included in other operating expenses | ||||||
Office leases | 24 | 157 | ||||
Equipment | 80 | 81 | ||||
104 | 238 | |||||
Total | 1,077 | 791 | ||||
(in thousands of euros) | |||
Cost: | |||
At January 1, 2024 | 18,593 | ||
Additions | 5,942 | ||
Translation differences | 75 | ||
Interest expense related to lease liabilities | 1,413 | ||
Repayment of lease liabilities (including interest) | (4,817) | ||
At December 31, 2024 | 21,206 | ||
Additions | 1,089 | ||
Translation differences | (272) | ||
Interest expense related to lease liabilities | 1,323 | ||
Repayment of lease liabilities (including interest) | (4,559) | ||
At December 31, 2025 | 18,787 | ||
Carrying amount: | |||
At December 31, 2024 | 21,206 | ||
At December 31, 2025 | 18,787 | ||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Lease Liabilities | ||||||
Current | 3,250 | 3,203 | ||||
Non-Current | 15,537 | 18,003 | ||||
Total | 18,787 | 21,206 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Maturity analysis: | ||||||
Long term leases | ||||||
0-1 year | 4,309 | 4,369 | ||||
2-5 years | 12,566 | 13,792 | ||||
More than 5 years | 6,939 | 9,307 | ||||
Total | 23,814 | 27,468 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Purchases on behalf of ENEA | 9,319 | 5,102 | ||||
R&D tax credit | 13,855 | 7,836 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Grant receivables-non-current | 9,273 | 1,418 | ||||
Other long-term assets | 2,760 | 1,464 | ||||
Total other non-current receivables | 35,207 | 15,820 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Raw materials | 637 | 743 | ||||
Work-in-progress | 427 | 1,362 | ||||
Finished goods | 3,993 | 4,847 | ||||
Total Inventories | 5,057 | 6,952 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Current | ||||||
Trade receivables | 9,559 | 15,871 | ||||
Contract assets | 20,938 | 14,835 | ||||
Loss allowance | (409) | (623) | ||||
Trade receivables and contract assets, net | 30,088 | 30,083 | ||||
Other receivables | 219 | 869 | ||||
Prepayments | 6,852 | 4,471 | ||||
Advances | 4,567 | 1,510 | ||||
Accrued income | 1,459 | 248 | ||||
Social security and other taxes | 17,350 | 25,319 | ||||
R&D tax credit | 1,779 | 1,518 | ||||
Total trade receivable, contract and other assets | 62,314 | 64,018 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Trade notes and accounts receivable | ||||||
Not due | 4,453 | 5,933 | ||||
0 to 30 days | 614 | 1,608 | ||||
30 to 60 | 758 | 531 | ||||
60 to 90 days | 87 | 58 | ||||
90 to 180 days | 1,238 | 476 | ||||
180 to 360 days | 20 | 1,394 | ||||
360+ days | 2,389 | 5,871 | ||||
Trade receivables | 9,559 | 15,871 | ||||
(in thousands of euros) | ||||||||||||||||||||||||
Trade receivables – days past due | ||||||||||||||||||||||||
At December 31, 2025 | Not past due | <30 | 31-60 | 61-90 | 91-180 | 180-360 | >360 | Total | ||||||||||||||||
ECL rate | 0.60% | 0.61% | 0.27% | 0.16% | 0.15% | 0.34% | 10.49% | |||||||||||||||||
Estimated total gross carrying amount at default | 4,453 | 614 | 758 | 87 | 1,238 | 20 | 2,389 | 9,559 | ||||||||||||||||
Lifetime ECL | 26 | 4 | 2 | 0 | 2 | 0 | 251 | 285 | ||||||||||||||||
Trade receivables – days past due | ||||||||||||||||||||||||
At December 31, 2024 | Not past due | <30 | 31-60 | 61-90 | 91-180 | 180-360 | >360 | Total | ||||||||||||||||
ECL rate | 0.85% | 0.80% | 1.18% | 0.34% | 1.60% | 1.26% | 6.83% | |||||||||||||||||
Estimated total gross carrying amount at default | 5,933 | 1,608 | 531 | 58 | 476 | 1,394 | 5,871 | 15,871 | ||||||||||||||||
Lifetime ECL | 50 | 13 | 6 | 0 | 8 | 18 | 401 | 496 | ||||||||||||||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Cash equivalents | 42 | 130,984 | ||||
Cash at bank | 105,228 | 61,593 | ||||
Accrued interest on cash | — | 137 | ||||
Total Cash and cash equivalents | 105,270 | 192,714 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Unrestricted cash | 105,166 | 189,666 | ||||
Restricted cash | 104 | 3,048 | ||||
Total Cash and cash equivalents | 105,270 | 192,714 | ||||
Number of Shares | Nominal Value €’000 | |||||
Authorized | ||||||
At January 1, 2022 | 212,659,000 | 2,127 | ||||
At December 31, 2022 | 412,659,000 | 4,127 | ||||
At December 31, 2023 | 412,659,000 | 4,127 | ||||
At December 31, 2024 | 462,007,424 | 4,620 | ||||
At December 31, 2025 | 473,910,109 | 4,739 | ||||
Issued, and fully paid and outstanding: | ||||||
At January 1, 2022 | 212,659,000 | 2,127 | ||||
Issued during the period | 200,000,000 | 2,000 | ||||
At December 31, 2022 | 412,659,000 | 4,127 | ||||
Issued during the year | — | — | ||||
At December 31, 2023 | 412,659,000 | 4,127 | ||||
Issued during the year | 49,348,424 | 493 | ||||
At December 31, 2024 | 462,007,424 | 4,620 | ||||
Issued during the year | 11,902,685 | 119 | ||||
At December 31, 2025 | 473,910,109 | 4,739 | ||||
Year ended December 31, | ||||||||||||
(in thousands of euros) | 2025 | 2024 | ||||||||||
Basic | Diluted | Basic | Diluted | |||||||||
Loss attributable to ordinary shareholders: | ||||||||||||
Loss of the year, attributable to equity holders of the parent | (138,341) | (138,341) | (110,163) | (110,163) | ||||||||
Year ended December 31, | ||||||||||||
2025 | 2024 | |||||||||||
Basic | Diluted | Basic | Diluted | |||||||||
Weighted-average number of ordinary shares: | ||||||||||||
Issued ordinary shares at January 1 | 462,007,424 | 462,007,424 | 412,659,000 | 412,659,000 | ||||||||
Effect of shares issued | 245,136 | 245,136 | 23,617,314 | 23,617,314 | ||||||||
Weighted-average number of ordinary shares | 462,252,560 | 462,252,560 | 436,276,314 | 436,276,314 | ||||||||
Basic | Diluted | Basic | Diluted | |||||||||
Loss per share: | ||||||||||||
Loss per share | (0.30) | (0.30) | (0.25) | (0.25) | ||||||||
Year ended December 31, | ||||||
2025 | 2024 | |||||
Options to purchase ordinary shares | 29,007,930 | 8,850,337 | ||||
2025 | ||||||
Number of share options | Weighted average exercise price (in €) | |||||
Outstanding at the beginning of year | 8,850,337 | 0.01 | ||||
Granted during the year | 20,879,221 | 0.01 | ||||
Forfeited during the year | (487,698) | 0.01 | ||||
Exercised during the year | (503,930) | 0.01 | ||||
Outstanding at the end of the year | 28,737,930 | 0.01 | ||||
Vested and exercisable at the end of the year | 4,213,844 | 0.01 | ||||
2025 | 2024 | |||||
Weighted average share price | €2.85 | €2.80 | ||||
Weighted average exercise price | €0.01 | €0.01 | ||||
Expected volatility | 36.7%-51.8% | 40%-47.5% | ||||
Expected life | 1- 4 Years | 1-4 Years | ||||
Risk-free rate | 3.55%-3.82% | 3.76%-4.40% | ||||
Expected dividend yields | 0.0% | 0.0% | ||||
Weighted average grant date fair value | €2.84 | €2.79 | ||||
2025 | 2024 | |||||
Number of RSUs | Number of RSUs | |||||
Nonvested balance at the beginning of year | — | — | ||||
Granted | 270,000 | — | ||||
Vested | (70,000) | — | ||||
Cancelled or expired | — | — | ||||
Nonvested balance at the end of the year | 200,000 | — | ||||
As of December 31, | |||||||||
(in thousands of euros) | Notes | 2025 | 2024 | ||||||
Financial assets | |||||||||
Financial assets measured at amortized cost | |||||||||
Short-term investments | 2,291 | 2,199 | |||||||
Trade receivables, contract and other assets ‘excluding non-financial assets’ | 14 | 13,381 | 16,365 | ||||||
Cash and cash equivalents | 15 | 105,270 | 192,714 | ||||||
Total financial assets | 120,942 | 211,278 | |||||||
Financial liabilities | |||||||||
Lease liabilities | 11 | 18,787 | 21,206 | ||||||
Trade and other payables ‘excluding non-financial liabilities’ | 23 | 61,092 | 33,140 | ||||||
Senior Secured Refinancing Facility | 16,733 | — | |||||||
State-guaranteed loans | 2,156 | 3,279 | |||||||
Unsecured bank loans | — | 763 | |||||||
Total financial liabilities | 98,768 | 58,388 | |||||||
(in thousands of euros) | At December 31, 2024 | Allowance | Reversal of unused provision | Translation adjustment | At December 31, 2025 | ||||||||||
Provisions for product warranty | 103 | 186 | (103) | — | 186 | ||||||||||
Current provisions | 103 | 186 | (103) | 186 | |||||||||||
Lawsuit contingency provision – non-current | — | 45 | — | — | 45 | ||||||||||
Pension plan provision | 2,564 | 1,132 | (517) | 4 | 3,183 | ||||||||||
Provision for site rehabilitation | 955 | — | — | (16) | 939 | ||||||||||
Provision for other expenses – non- current | — | 3 | — | — | 3 | ||||||||||
Non-current provisions | 3,519 | 1,180 | (517) | (12) | 4,170 | ||||||||||
Total provisions | 3,622 | 1,366 | (620) | (12) | 4,356 | ||||||||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Deferred income from grants | 9,305 | — | ||||
Other liabilities | — | 1 | ||||
Total Other long-term liabilities | 9,305 | 1 | ||||
As of December 31, | ||||||||||||||||||
Main actuarial assumptions used | 2025 | 2024 | ||||||||||||||||
Switzerland | France | Italy | Switzerland | France | Italy | |||||||||||||
Discount rate | 1.10% | 3.85% | 3.96% | 0.95% | 3.40% | 3.382% | ||||||||||||
Salary increase | 1.00% | 2.90% | 3.00% | 1.50% | 2.50% | 3% | ||||||||||||
Inflation | 0.50% | 2.00% | 2.00% | 1.00% | 2.00% | 2% | ||||||||||||
Mortality table | 100% x BVG 2020 | TH/TF 00-02 | ISTAT year 2000, - 25% | 100% x BVG 2020 | TH/TF 00-02 | ISTAT year 2000, - 25% | ||||||||||||
Average retirement age | 65 | 65 | n.d. | 65 | 65 | n.d. | ||||||||||||
Social charge | n/a | 40% | n.d. | n/a | 40% | n.d. | ||||||||||||
Weighted turnover | 8.90% | 3% | 6.50% | 100% x BVG 2020 | 2.51% | 6.5% | ||||||||||||
Lump sum payments at retirement | 35% | 100% | n.d. | 25% | 100% | n.d. | ||||||||||||
(in thousands of euros) | 2025 | 2024 | ||||
Changes in the Defined Benefit Obligation | ||||||
Opening defined benefit obligation | 7,105 | 4,695 | ||||
Current service cost | 1,048 | 2,207 | ||||
Past service cost | — | — | ||||
Plan participants’ contribution | 87 | 99 | ||||
Interest cost | 119 | 69 | ||||
Actuarial (gains) losses for the year | (167) | 310 | ||||
Benefits paid through pension assets | (638) | (171) | ||||
Benefits paid by employer | — | (25) | ||||
Plan amendments | — | (12) | ||||
Exchange rate differences | 57 | (67) | ||||
Closing defined benefit obligation | 7,611 | 7,105 | ||||
(in thousands of euros) | 2025 | 2024 | ||||
Changes in the Fair Value of Plan Assets | ||||||
Opening fair value of assets | 4,541 | 4,206 | ||||
Interest income | 43 | 61 | ||||
Return on plan assets excluding interest income | 122 | 326 | ||||
Plan participants’ contribution | 89 | 93 | ||||
Company contributions | 89 | 93 | ||||
Benefits paid through pension assets | (495) | (171) | ||||
Administration expense | (5) | (5) | ||||
Exchange rate differences | 45 | (62) | ||||
Closing fair value of assets | 4,429 | 4,541 | ||||
Actual return on plan assets | 159 | 387 | ||||
(in thousands of euros) | 2025 | 2024 | ||||
Present value of obligation | 7,611 | 7,105 | ||||
Fair value of plan assets | (4,428) | (4,541) | ||||
Total deficit of defined benefit pension plans | 3,183 | 2,564 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Current | ||||||
Trade payables | 15,860 | 20,999 | ||||
Social security and other taxes | 5,487 | 8,023 | ||||
Accrued expenses | 6,655 | 10,397 | ||||
Payroll liabilities | 9,990 | 7,647 | ||||
Contract liabilities | 5,026 | 3,305 | ||||
Deferred redeemable bond obligation | 38,577 | — | ||||
Other payables | 2,213 | 1,745 | ||||
Total Trade and other payables | 83,808 | 52,116 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Foreign exchange risk | ||||||
+5% Increase in British Pounds (GBP) | 208 | 974 | ||||
+5% increase in US Dollars (USD) | 3 | 50 | ||||
+5% increase in Swiss Franc (CHF) | 68 | 74 | ||||
-5% Decrease in British Pounds (GBP) | (208) | (974) | ||||
-5% Decrease in US Dollars (USD) | (3) | (50) | ||||
-5% increase in Swiss Franc (CHF) | (68) | (74) | ||||
Carrying amount | Total contractual cash flows | Contractual cashflows | ||||||||||||||||
(in thousands of euros) | Less than 1 year | Between 1 and 2 years | Between 2 and 5 years | Over 5 years | ||||||||||||||
December 31, 2025 | ||||||||||||||||||
Trade and other payables | 83,808 | 83,809 | 83,809 | — | — | — | ||||||||||||
Borrowings | 18,889 | 22,945 | 3,627 | 3,211 | 10,432 | 5,675 | ||||||||||||
Lease liability | 18,787 | 23,814 | 4,309 | 3,945 | 8,621 | 6,939 | ||||||||||||
Total | 121,484 | 130,568 | 91,745 | 7,156 | 19,053 | 12,614 | ||||||||||||
December 31, 2024 | ||||||||||||||||||
Trade and other payables | 52,116 | 52,115 | 52,115 | — | — | — | ||||||||||||
Borrowings | 4,042 | 4,008 | 1,569 | 842 | 1,346 | 251 | ||||||||||||
Lease liability | 21,206 | 27,468 | 4,369 | 4,092 | 9,700 | 9,307 | ||||||||||||
Total | 77,364 | 83,591 | 58,053 | 4,934 | 11,046 | 9,558 | ||||||||||||
2025 | |||
Weighted average expected term in years | 2.70 | ||
Weighted average expected ordinary price volatility | 46.37% | ||
Weighted average Risk-free interest rate | 2.47% | ||
Expected dividend yields | 0.0% | ||
Name of entity | Place of Business | % of ownership interest | Nature of relationship | Measurement method | Carrying amount | ||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||
% | % | ||||||||||||||||||||
NEXTN | Italy | 40 | — | Associate | Equity Method | 29,245 | — | ||||||||||||||
NEWVYS | Slovakia | 49 | — | Joint-Venture | Equity Method | 2,390 | — | ||||||||||||||
Total equity-method investments | 31,635 | — | |||||||||||||||||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Non-current assets by geographical region: | ||||||
France | 70,948 | 52,728 | ||||
Italy | 115,236 | 68,127 | ||||
United Kingdom | 8,104 | 24,555 | ||||
Switzerland | 30,451 | 33,059 | ||||
Total non-current assets | 224,739 | 178,469 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Customer A | 5,134 | 8,114 | ||||
Customer B | 5,065 | 6,181 | ||||
Customer C | 278 | 9,803 | ||||
Year ended December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Other Income | ||||||
Elysia Capital Srl | 24 | 24 | ||||
Lease depreciation | ||||||
Isola Srl | (337) | (334) | ||||
Planet Idea Srl | — | (175) | ||||
Total transactions with related parties | (313) | (485) | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Prepayments to related parties for service agreement: | ||||||
Next-N | 1,200 | — | ||||
Right of use assets for lease liabilities: | ||||||
Isola Srl | 586 | 909 | ||||
Amounts owed to related parties for lease liabilities: | ||||||
Isola Srl | 621 | 963 | ||||
As of December 31, | ||||||
(in thousands of euros) | 2025 | 2024 | ||||
Lease payments | ||||||
Isola Srl | 464 | 377 | ||||
Planet Idea Srl | — | 167 | ||||
Item 6. | Indemnification of Directors and Officers. |
Item 7. | Recent Sales of Unregistered Securities |
Item 8. | Exhibits and Financial Statement Schedules. |
Exhibit No. | Description | ||
Business Combination Agreement, dated as of May 26, 2026, by and among NewHold Investment Corp III, newcleo plc, newcleo1 Ltd. and newcleo2 Ltd. (incorporated by reference to Exhibit 2.1 to the Registration Statement on Form F-4 (File No. 333-297284) filed by the Company with the SEC on July 24, 2026). | |||
Amended and Restated Articles of Association of newcleo plc (incorporated by reference to Exhibit 99.1 to the Report on Form 6-K (File No. 001-43479) filed by the Company to the SEC on September 25, 2026). | |||
Specimen Ordinary Share Certificate of newcleo plc (incorporated by reference to Exhibit 4.7 to the Registration Statement on Form F-4 (File No. 333-297284) filed by the Company with the SEC on July 27, 2026). | |||
Specimen Warrant Certificate of newcleo plc (included in Exhibit 4.3). | |||
Warrant Termination, Adoption, Amendment and Novation Agreement, dated as of September 21, 2026, by and among the Company, SPAC, the SPAC Warrant Agent and the Company Warrant Agent (incorporated by reference to Exhibit 99.2 to the Report on Form 6-K (File No. 001-43479) filed by the Company to the SEC on September 25, 2026). | |||
Opinion of CMS Cameron McKenna Nabarro Olswang LLP. | |||
Exhibit No. | Description | ||
Amended and Restated Registration Rights Agreement, dated as of September 21, 2026, by and among the Company, SPAC, the Sponsor and the other holders party thereto (incorporated by reference to Exhibit 99.3 to the Report on Form 6-K (File No. 001-43479) filed by the Company to the SEC on September 25, 2026). | |||
Company Shareholder Support Agreement, dated May 26, 2026, by and among the Company, SPAC and the Company Shareholders party thereto (incorporated by reference to Exhibit 10.2 to SPAC’s Current Report on Form 8-K (File No. 001-42541) filed with the SEC on May 27, 2026). | |||
Sponsor Support Agreement, dated May 26, 2026, by and among the Company, SPAC and the Sponsor (incorporated by reference to Exhibit 10.1 to SPAC’s Current Report on Form 8-K (File No. 001-42541) filed with the SEC on May 27, 2026). | |||
Form of Subscription Agreement (incorporated by reference to Exhibit 10.3 to SPAC’s Current Report on Form 8-K (File No. 001-42541) filed with the SEC on May 27, 2026). | |||
Form of Non-Redemption Agreement (incorporated by reference to Exhibit 10.5 to SPAC’s Current Report on Form 8-K (File No. 001-42541) filed with the SEC on May 27, 2026). | |||
Framework Agreement, dated March 7, 2022, by and among ENEA and newcleo s.r.l. (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form F-4 (File No. 333-297284) filed by the Company with the SEC on July 6, 2026). | |||
Shareholders Agreement, dated June 3, 2025, by and among JAVYS and newcleo s.r.o. (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form F-4 (File No. 333-297284) filed by the Company with the SEC on July 6, 2026). | |||
English translation of the Unilateral Promise of Sale, dated November 5, 2025, by and between Département de l’Aube and newcleo Fuel Innovations SAS (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form F-4 (File No. 333-297284) filed by the Company with the SEC on July 6, 2026). | |||
Form of Deed of Indemnity (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form F-4 (File No. 333-297284) filed by the Company with the SEC on July 27, 2026). | |||
Prepaid Share Forward Confirmation, dated September 11, 2026, by and among newcleo plc and Tech Opportunities LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-42541) filed by NewHold Investment Corp III with the SEC on September 12, 2026). | |||
NewCleo Ltd Share Plan, adopted June 17, 2022 (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 (File No. 333-299063) filed by the Company with the SEC on September 22, 2026). | |||
NewCleo Ltd Non-Employee Share Plan, adopted June 17, 2022 (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-8(File No. 333-299063) filed by the Company with the SEC on September 22, 2026). | |||
newcleo 2026 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-8 (File No. 333-299063) filed by the Company with the SEC on September 22, 2026). | |||
newcleo 2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.4 to the Registration Statement on Form S-8 (File No. 333-299063) filed by the Company with the SEC on September 22, 2026). | |||
List of Subsidiaries of newcleo plc. | |||
Consent of Grant Thornton. | |||
Consent of WithumSmith+Brown, P.C. | |||
Consent of CMS Cameron McKenna Nabarro Olswang LLP (included in Exhibit 5.1). | |||
Powers of Attorney (included as part of the signature pages to the registration statement). | |||
Filing fee table. | |||
(1) | Certain schedules, exhibits and similar attachments have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of all omitted information to the SEC upon its request. |
† | Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. |
Item 9. | Undertakings. |
(a) (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i) | To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
(ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective registration statement; |
(iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; |
(2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; |
(3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; |
(4) | That, as a foreign private issuer, it will file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act of 1933 need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements; |
(5) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use; |
(6) | That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(b) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
newcleo plc | |||||||||
By: | /s/ Stefano Buono | ||||||||
Name: | Stefano Buono | ||||||||
Title: | Chief Executive Officer and Director | ||||||||
Signature | Title | Date | ||||
/s/ Stefano Buono | Chief Executive Officer and Director (Principal Executive Officer) | October 6, 2026 | ||||
Stefano Buono | ||||||
/s/ Jon Stranske | Group Chief Financial Officer (Principal Accounting and Financial Officer) | October 6, 2026 | ||||
Jon Stranske | ||||||
/s/ Elisabeth Rizzotti | Deputy Chief Executive Officer, Chief Operating Officer and Director | October 6, 2026 | ||||
Elisabeth Rizzotti | ||||||
/s/ Jeffrey J. Lyash | Chairman | October 6, 2026 | ||||
Jeffrey J. Lyash | ||||||
/s/ Raffaele Petrone | Director | October 6, 2026 | ||||
Raffaele Petrone | ||||||
/s/ Andrea Ruben Osvaldo Levi | Director | October 6, 2026 | ||||
Andrea Ruben Osvaldo Levi | ||||||
/s/ Manfredi Lefebvre d’Ovidio de Clunières di Balsorano | Director | October 6, 2026 | ||||
Manfredi Lefebvre d’Ovidio de Clunières di Balsorano | ||||||
Signature | Title | Date | ||||
/s/ Heinz Maeusli | Director | October 6, 2026 | ||||
Heinz Maeusli | ||||||
/s/ Anne-François de Bourdoncle de Saint Salvy | Director | October 6, 2026 | ||||
Anne-François de Bourdoncle de Saint Salvy | ||||||
/s/ Suzy Taherian | Director | October 6, 2026 | ||||
Suzy Taherian | ||||||
newcleo Americas LLC | |||||||||
By: | /s/ Stefano Buono | ||||||||
Name: | Stefano Buono | ||||||||
Title: | Chief Executive Officer | ||||||||